CISPLATIN IN YEAST: REPAIR OF DNA ADDUCTS AND BINDING OF HMG DOMAIN PROTEINS by Megan Moore McA'Nulty A.B.,Chemistry and Physics Harvard University 1989 Submitted to the Department of Chemistry in partial fulfillment of the requirements for the Degree of Doctor of Philosophy at the MASSACHUSETTS INSTITUTE OF TECHNOLOGY September, 1995 © Massachusetts Institute of Technology, 1995 all rights reserved Signature of Author Departi'ent of Chemistry August 17, 1995 t I Certified by , Stephen J. Lippard Thesis Advisor / / Accepted by Dietmar Seyferth Graduate Students admiecitee on j;Ba OF TECHNOL.OGY SEP 121995 LIBRARIES Scenie 2 This doctoral thesis has been examined by a Commitee of the Department of Chemistry as follows: L Profe~sr John M. Es 'nann, Chairman II '1/I' ProfessoPStepheJ. fa-i Thesis Supervisor \ I4 V Professor James R. Williamson 3 CISPLATIN IN YEAST: REPAIR OF DNA ADDUCTS AND BINDING OF HMG DOMAIN PROTEINS by Megan Moore McA'Nulty Submitted to the Department of Chemistry on August, 1995in partial fulfillment of the requirements for the Degree of Doctor of Philosophy in Chemistry, biochemistry subdivision ABSTRACT Cisplatin is a potent antitumor drug used to treat many different tumors. It is believed to kill cells by forming adducts on their DNA that block DNA and RNA polymerases. A class of transcription factors, HMG domain proteins, binds specifically to these cisplatin-DNA adducts. The effects of these proteins on cisplatin cytotoxicity were studied. Ixrl is one such protein from the yeast Saccharomycescerevisiae.When the IXR1 gene is deleted from yeast cells, the resulting ixrl strain is less sensitive to cisplatin treatment. The cisplatin cytotoxicity difference depended on the HMG domain of Ixrl, not its natural function. The decreased sensitivity of the ixrl strain was dependent upon several proteins (Rad) involved in the excision repair of cisplatin-DNA adducts. When the genes for the Rad proteins were deleted, the difference in sensitivity between the IXR1 and ixrl strains was substantially diminished. The IXR1 and ixrl strains are equally sensitive to ultraviolet light, which means that Ixrl does not affect excision repair of other forms of damage. Ixrl most likely shields cisplatin adducts from repair by binding to the them and blocking the access of the repair proteins. This theory was also supported by examination of the levels of the cisplatin-DNA adducts in the IXR1 and ixrl strains. Less cisplatin-DNA adducts were present in the ixrl strain, which supports the idea that the adducts were repaired more easily in this strain. The difference in adduct level was dependent on the presence of the Rad proteins. These data indicate that the level of repair was higher in the ixrl strain, probably because Ixrl blocks cisplatin adducts from excision repair. The binding of HMG domain proteins to cisplatin-DNA adducts could also affect binding to their natural sites, thus disrupting the transcription of the genes they regulate. This hypothesis was tested using Ixrl, which is a repressor of transcription from the Cox5b promoter. Treating cells with cisplatin did not affect the level of transcription from the Cox5b promoter, indicating that Ixrl is not titrated away from the promoter sufficiently to permit increased expression. The experiments presented in this thesis indicate that new cisplatin drugs or therapies could be designed by maximizing the level of HMG domain protein binding to the cisplatin DNA adducts so as to keep the adducts on the DNA and thus kill the tumor. Thesis Supervisor: Dr. Stephen J. Lippard 4 ACKNOWLEDGMENTS My first and loudest thanks belong to my husband, Peter, who helped me through the six years I worked on this thesis, first by courting me, then by wanting to marry me, and finally by cooking and cleaning for me so that all my attention could go to this all-consuming monster for the past six months or more. Naturally, the rest of my family was also wonderful--my parents got me started on science in the first place, and have helped ever since. Carol, Don, and John McA'Nulty made me feel truly welcome in their family; it's been really wonderful to have another family on this coast. I also want to thank my aunt Elizabeth for all the vacations in high school and college, and storing my stuff, and dinners, and everything. My 'little' brother Scott has loved me and argued with me for 24 years now, and even puts up with me calling him shrimp now that he's 6'5". No Lippard lab acknowledgments page is complete without the paragraph where you try to list all the people who have helped over the years. The boss himself, Steve, was indispensable, of course. Steve taught me a lot about being a scientist and how to organize your lab work. My early years were dominated by Steve Brown and Pieter Pil, and I want to thank Patti Kellett, Mike Keck, Steve Bellon, and Ken Comess who helped me remember that not all scientists are looney-tunes. Laura Pence and Joyce Whitehead were my first close friends in lab, and they helped make it a place I wanted to come to. Dave Coufal spent large portions of the last year saying "It will all be OK, Megan" to me before interviews and other horrible occasions, and talking computers and Star Wars games. Ann, and later Deb and Karen, came in and lightened up the upstairs bays, and generally made lab more fun and more hectic. Deb--good luck with the real human cells, and take more time off. Ann, thanks for letting me use your wet box, and not freaking when the top agar bottle broke and turned it into a large jello container. Young Douglas, I hope the nickname list is at an end, but I doubt it! Will you get rid of all those rubber bands before you graduate? Sonja arrived here having actually grown a yeast cell, which isn't true for anyone else as far as I know, and from there, has helped with so many different aspects of life that I can't list them all. Sonja, you come to Harvard Med every so often, how about snack time? Betsy, thanks for being so easy to teach and share space with, and actually being cheerful around me when I was wondering if I'd ever get it all done. Andy and Betsy, thanks for giving me the whole bay for a couple of weeks, you both know how much I needed it. 'Downstairs' platinum--thanks for letting me borrow equipment and radioactivity for those frantic weeks after the move. There are, of course, two other subgroups in the lab, and you can't be here for six years without getting to know some of the people in them. If I start listing all the past members, we'll be here all night, so I wont. Joanne, Maria, Susanna, I can't seem to pass your bays without hearing you guys laughing. Thank you (and Doug) for taking me to lunch before my defense. Andrew Feig provided an interesting competition to see who could get out first, and I figure that within two days of each other means we tied. Rene helped so much in the last stages of this thesis--at least in part by telling me how much worse her school's requirements for theses are. So, Joyce, Laura, I'll be a postdoc shortly, do I know everything now? The entire job search process was a living hell. Joyce, Laura, Kristin, and Paige were my companions for the on-campus interviews and afterwards commiserated about the miserable parts. Kitty in headquarters made that whole thing less stressful and has even managed to convince the Bursar's office that I don't owe them several thousand dollars--a true miracle. I've probably gotten more help from other professors both here and elsewhere than your run-of-the-mill graduate student, since my project was not exactly classical inorganic chemistry. Prof. John Essigmann also works on cisplatin, and I hope he knows how much I valued his input in those joint subgroup meetings those first years. The Essigmann lab in general also helped with advice and supplies, especially the tissue culture areas--I just hope I never have to clean one again. Prof. Fink provided a lot of much-needed yeast expertise, and lent me plasmids and yeast strains whenever I needed them. Prof. Guarente never really met me, but his lab also helped with the hunt to find a reasonable expression system for Ixrl. The gurus of yeast excision repair, Louise Prakash and Errol Friedberg (in the person of Wolfram Siede) made chapter 3 possible. Finally, thanks should go to Prof. Jamie Williamson for being willing to read what is, in essence, a biology thesis. Since I spent 4 years of college in the Boston area at that small liberal arts college up the river, I was lucky enough to have many friends in the area already. The members of the Society for Creative Anachronism helped by providing a complete distraction from the lab--I recommend such a thing to everyone. Dante, especially, kept telling me that it could be done, and her husband Mark told my husband that it could be done, so we just did it. My college friends Claire, Debbie, and Susan are all pursuing non-science Ph.D.'s right now, so, now it's my turn to say "See, it can be done", and maybe now I'll actually write letters more than once a year. Frank was the best man at our wedding and has since made it possible for me to finish my thesis by offering advice and a view point no one else could. Finally, I'd like to thank whoever decided on the yeast nomenclature system; whoever you are, I'd like to spell your name all in lower case. 6 TABLE OF CONTENTS Ab stract .......................................................................................................................... 3 Acknowledgments .......................................................................................................4 Table of Contents ..........................................................................................................6 List of Tables .................................................................................................................9 List of Figures .................................................... 10 Chapter 1. Cisplatin and cisplatin-DNA adduct binding proteins ......................15 Introduction .................................................... 16 Cisplatin cytotoxicity .................................................... Cisplatin adducts .................................................... 16 16 Cisplatin adducts block DNA and RNA polymerases ...................20 Resistance .................................................... 21 Oncogenes and tumor suppresser genes .......................................... 25 Cisplatin treatment causes changes in the cells ...............................25 Cell cycle and apoptosis ........................................ ............ 26 Other drugs affect cisplatin cytotoxicity ........................................... 27 Repair of cisplatin-DNA adducts ........................................ ............ 28 HMG domain proteins .................................................... 30 HMG1 binds to cisplatin-DNA adducts ........................................... 31 HMG domain proteins, a new class of DNA-binding proteins .................................................... 33 HMG1 binding to DNA .................................................... 36 The natural function of HMG1 .................................................... 38 HMG1 bends cisplatin-treated DNA ................................................. 40 HMG domain proteins and cisplatin antitumor activity................41 Yeast as a model system ....................................... ............................... 43 Summary and Conclusions ........................................................ .................... 45 References .................................................... ...... 47 Figures .................................................... 68 Chapter 2. Cisplatin and yeast cells.................................................... 93 Introduction .................................................... 94 Materials and methods .................................................... 97 Results .................................................... 102 Cytotoxicity difference between IXR1and ixrl strains ..................102 Ixrl binding to damaged DNA .................................................... 103 Roxl, an HMG domain protein .................................................... 103 Abf2, an HMG domain protein .................................................... 104 Ixrl overexpression studies .................................................... 104 Cytotoxicity assays on Ixrl mutants .................................................. 106 Cytotoxicity assays on cox5astrains .................................................. 108 Anaerobic cytotoxicity assays .................................................... 109 Cytotoxicity assay conditions ........................................ Discussion .................................................... ............ 109 111 7 The HMG domains of Ixrl cause the difference in cisplatin sensitivity ......................................................... 111 Different cellular conditions cause different responses .................113 Conclusions ......................................................... 115 References ......................................................... 116 Figures ........................................................................ 124 Chapter 3. The HMG domain protein Ixrl shields cisplatin-DNA adducts from excision repair in vivo ........................................................................................ 175 Introduction ......................................................... 176 Materials and methods ......................................................... 179 Results ................................................................................................................ 181 Construction of rad IXR1 and rad ixrl yeast strains ........................181 Cisplatin cytotoxicity in IXR1and ixrl strains ................................181 Excision repair mutants ......................................................... 182 Double-strand break repair mutant . ................................. Error-prone repair mutant ......................................................... Checkpoint mutant ......................................................... Discussion ......................................................... 183 184 184 184 Ixrl affects excision repair ........................................ ................. 184 Comparison to previous cisplatin yeast studies ..............................187 Double-strand break repair mutant . ................................. 188 Error-prone repair mutant ........................................ ................. 188 Cell-cycle checkpoint mutant ......................................................... 189 Conclusions ......................................................... References ......................................................... Figures ......................................................... 189 191 198 Chapter 4. Repair of cisplatin-DNA adducts ......................................................... 219 Introduction ......................................................... 220 Materials and methods ......................................................... 221 Results ......................................................... 228 Levels of cisplatin-DNA adducts on yeast genomic DNA............. 228 Levels of cisplatin-DNA adducts on a transcriptionally active yeast gene ......................................................... 228 Restriction enzyme cleavage of cisplatin- and trans-DDPDNA adducts ......................................................... 232 Restriction enzyme based DNA adduct repair assay ....................235 Discussion ......................................................... 236 Platinum levels on yeast DNA--general DNA .................................236 Platinum levels on actively transcribed DNA in yeast ...................238 Platinum levels on yeast DNA--Other types of repair ...................239 Comparison to mammalian and E. coli cell adduct levels .............. 240 Restriction enzyme digestion of platinum-treated DNA ...............241 Restriction enzyme based repair assay ............................................. 243 Conclusions ......................................................... 244 8 References ........................................................................................................ 246 Figures .................................................... 252 Chapter 5. HMG domain proteins binding to cisplatin-DNA adducts in vivo .................................................... 295............................. Introduction .................................................... 296 296 Titration Hypothesis .................................................... HMG1 binds cisplatin-DNA adducts in vivo .................................. 297 Materials and methods .................................................... 298 Results ................................................................................................................ 303 303 Titration Hypothesis experiments .................................................... Plasmid-based assay .................................................... 303 mRNA based assay .................................................... HMG1 binds to cisplatin-treated chicken erythrocyte DNA in 304 306 chromatin .................................................... Discussion .................................................... 307 Titration Hypothesis .................................................... 307 HM G1 binds cisplatin-DNA adducts in vivo .................................. 308 Conclusion .................................................... References .................................................... Figures .................................................... 309 ...... 311 314 9 LIST OF TABLES Chapter 2 Table I. Saccharomycescerevisiaestrains ........................................................ 119 Table II. Plasmids used in cytotoxicity experiments ..................................120 Table III. Cytotoxicity assay results .............................................................. 121 Table IV. Ixrl overexpression cytotoxicity assay........................................121 Table V. Ixrl-1 cytotoxicity assay ................................................................. 122 Table VI. Different growth conditions ......................................................... 122 Chapter 3 Table I. Plasmids used in construction of rad stains .................................. 196 Table II. Quantitation of cisplatin cytotoxicity in yeast ............................. 197 Chapter 4 Table I. (D/N)b levels measured by atomic absorption ............................249 Table II. Platinum-DNA adducts block restriction enzyme activity .......250 10 LIST OF FIGURES Chapter 1 Figure 1.1. Structure of various platinum compounds..............................68 Figure 1.2. Adducts formed by cisplatin adducts ...................................... 70 Figure 1.3. Types of cancer that cisplatin therapy is effective ag ainst ................................................................................................................ 72 Figure 1.4. Excision repair .............................................................................. 74 76 Figure 1.5. Excision repair proteins .............................................................. Figure 1.6. HMG1 and HMG domain protein DNA binding sites ..........78 Figure 1.7. Structure of HMG1 domain B .................................................... 80 82 Figure 1.8. Repair shielding theory .............................................................. 86 Figure 1.9. Titration hypothesis .................................................................... Figure 1.10. Interruption of genes in Saccharomycescerevisiae............... 90 Chapter 2 Figure 2.1. Ixrl domains ................................................................................. 124 Figure 2.2. Natural functions of Ixrl and related proteins ........................126 128 Figure 2.3. Ixrl expression plasmids ............................................................ Figure 2.4. Cytotoxicity assays performed on JM43 and JM43Aixrl 130 using standard conditions .............................................................................. Figure 2.5. Confirmation of construction of BWGAixrl strain ................. 132 Figure 2.6. Cytotoxicity assays performed on BWG and BWGAixrl 136 using standard conditions .............................................................................. Figure 2.7. Ixrl binds cisplatin damaged DNA but not other forms 138 of damaged DNA ............................................................................................. Figure 2.8. Cytotoxicity assays performed on JM43Aroxl, JM43, 142 and JM43Aixrl using standard conditions ................................................... 11 Figure 2.9. Southwestern blot of abf2 strains ....................................... 144 Figure 2.10. Southwestern blots of overexpression of Ixrl by using the GALl promoter ................................................... 148 Figure 2.11. Cytotoxicity assays performed on BWG and BWGAixrl cells with the control plasmid pCD43 and the Ixrl overexpression plasmid pCY .................................................... 152 Figure 2.12. Ixrl overexpression from the Met promoter ......................... 154 Figure 2.13. Cytotoxicity assays performed on JM43 and JM43Aixrl with the control plasmid pYes2 and the Ixrl overexpression plasm id pMM .................................................... 158 Figure 2.14. Cytotoxicity assays performed on mutant Ixrl and cox5a strains ....................................................................................................... 160 Figure 2.15. Cytotoxicity assays performed on Ixrl-1 strains ...................162 Figure 2.16. Cytotoxicity assays performed on JM45, F::5 ........................ 164 Figure 2.17. Cytotoxicity assays performed on JM43 and JM43Aixrl using anaerobic conditions ................................................... 166 Figure 2.18. Cytotoxicity assays performed on IXR1and ixrl grown on YPD and YPD with 10% dextrose .................................................... 168 Figure 2.19. Cytotoxicity assays performed on JM43 and JM43Aixrl grown on YPD with 10% dextrose ................................................... 170 Figure 2.20. Cytotoxicity assays performed on IXR1and ixrl grown in YPGE.................................................... 172 Chapter 3 Figure 3.1. Model for excision repair of cisplatin-DNA adducts ............. 198 Figure 3.2. Ultraviolet light sensitivity of various yeast strains ...............202 Figure 3.3. Cisplatin cytotoxicity assays performed on the excision repair deficient strains RAD IXR1, RAD ixrl, rad2 IXR1 and rad2 ixrl ...................................................... 206 12 Figure 3.4. Cisplatin cytotoxicity assays performed on the excision repair deficient strains rad4 IXR1, rad14IXR1, rad4ixrl, and radl4 ixrl ...................................................................... 208 Figure 3.5. Cisplatin cytotoxicity assays performed on the excision repair deficient strains radl IXR1, radlOIXR1, radl ixrl and radiO ixrl ................................................... 210 Figure 3.6. Cisplatin cytotoxicity assays performed on RAD IXR1 and the double strand break repair deficient lines rad52IXR1 and rad52 ixrl ................................................... 212 Figure 3.7. Cisplatin cytotoxicity assays performed on the errorprone repair deficient strains rad6 IXR1 and rad6 ixrl ................................214 Figure 3.8. Cisplatin cytotoxicity assays performed on RAD IXR1, RAD ixrl, and the cell cycle checkpoint deficient lines rad9 IXR1 and rad9ixrl ................................................... 216 Chapter 4 Figure 4.1. Gel of PCR product from PGK gene from yeast genomic DNA treated with various levels of cisplatin ............................................... 252 Figure 4.2. Analysis of PCR products from DNA extracted from IXR1and ixrl cells treated with increasing levels of cisplatin ..................256 Figure 4.3. Analysis of PCR products from DNA extracted from IXR1 and ixrl cells treated with cisplatin and permitted to recover in fresh media for various times ................................................... 258 Figure 4.4. Analysis of PCR products from DNA extracted from radl4 IXR1and radl4 ixrl cells treated with increasing levels of cisplatin ................................................... 260 Figure 4.5. Analysis of PCR products from DNA extracted from radl4 IXR1 and radl4 ixrl cells treated with cisplatin and permitted to recover in fresh media for various times .................................................. 262 Figure 4.6. Analysis of PCR products from DNA extracted from JM43 and JM43Aixrl cells treated with increasing levels of cisplatin ...... 264 Figure 4.7. Analysis of PCR products from DNA extracted from JM43 and JM43Aixrl cells treated with cisplatin and permitted to recover in fresh media for various times ...................................................266 13 Figure 4.8. Sac restriction enzyme digestion of trans-DDPtreated M13mpl8 virus DNA .................................................... 270 Figure 4.9. SmaI restriction enzyme digestion of cisplatin and transDDP treated pUC19 plasmid DNA ................................................... 274 Figure 4.10. EcoRI restriction enzyme digestion of cisplatin and trans-DDP treated pUC19 plasmid DNA ...................................................278 Figure 4.11. Construction of trans-DDP-M13-Xhol2C ............................... 282 Figure 4.12. Digestion of trans-DDP-M13-Xhol2C by XhoI ...................... 284 Figure 4.13. Test of repair assay substrates ................................................. 288 Figure 4.14. Restriction enzyme based repair assay performed in HeLa cell extracts ................................................... 292 Chapter 5 Figure 5.1. Titration hypothesis .................................................... 314 Figure 5.2. -galactosidase activity of JM43 and JM43Aixrl strains treated with cisplatin .................................................... 318 Figure 5.3. -galactosidase activity of JM43 and JM43Aixrl strains treated with cisplatin and permitted to recover in fresh media for 16 hours .................................................... 320 Figure 5.4. -galactosidase activity of JM43 and JM43Aixrl strains treated with cisplatin over time ................................................... 322 Figure 5.5. mRNA analysis of IXR1and ixrl strains treated with low levels of cisplatin ................................................... 324 Figure 5.6. mRNA analysis of IXR1 and ixrl strains treated with higher levels of cisplatin .................................................... 328 Figure 5.7. mRNA analysis of IXR1and ixrl strains treated with cisplatin and permitted to recover in fresh media for 16 hours ................330 Figure 5.8. mRNA analysis of IXR1and ixrl strains treated with 332 cisplatin after they were grown to saturation .............................................. Figure 5.9. mRNA analysis of IXR1and ixrl strains treated with cisplatin for various times ............................................. 334 14 Figure 5.10. HMG1 is present in the 0.35 M NaCl extract of chicken erythrocyte nuclei ............................................................................................. 336 Figure 5.11. HMG-1 was bound to DNA in cisplatin treated chicken erythrocyte nuclei ............................................................................................. 340 15 CHAPTER 1 Cisplatin and cisplatin-DNA adduct binding proteins 16 INTRODUCTION Cisplatin is a potent antitumor drug. It is especially effective against testicular tumors and is used in combination with other drugs against a number of other tumors. Cisplatin works by binding to the DNA, forming both intrastrand and interstrand adducts. These adducts are widely believed to kill the cells by blocking DNA and RNA polymerases. The HMG domain is a DNA binding motif that binds to cisplatin-DNA adducts. HMG domain proteins are primarily transcription factors. There are currently two main theories regarding how HMG domain proteins might affect cisplatin cytotoxicity. The proteins may block the repair of the adducts or the transcription of the genes the proteins regulate may be disrupted. Investigation of HMG domain proteins in general, and these theoretical models in particular, may lend insight into the design of better cisplatin-based antitumor drugs. The pursuit of these improved cisplatin analogs is important because cisplatin is not a perfect antitumor drug. The dose of cisplatin necessary to affect tumors causes many unpleasant and potentially fatal side effects. Ovarian tumors, which do not have effective alternative treatments, have a particular problem with intrinsic and acquired resistance. In order to treat such tumors, better cisplatin analogs or combination therapies need to be designed, taking into account the new knowledge of how cisplatin-DNA adducts affect cells. CISPLATIN CYTOTOXICITY Cisplatinadducts Cisplatin, or cis-diamminedichloroplatinum (II) (Fig. 1.la) can bind to DNA, RNA, and proteins. Many studies have demonstrated that the DNA adducts are the cytotoxic agent (reviewed in Lepre and Lippard, 1990). Studies with radioactive cisplatin have shown that the lethal dose was related to the binding of cisplatin to DNA, not to protein or RNA (Akaboshi et al., 1992). 17 Cisplatin forms both interstrand and intrastrand adducts on DNA (Fig. 1.2). The major cisplatin adduct has the platinum bound to the N7 of two adjacent guanine bases. Cisplatin d(GG) and d(AG) adducts comprise about 90% of the DNA adducts (Fig. 1.2a). The minor adducts consist of intrastrand cross-links between two guanines that are not adjacent (d(GXG))and interstrand cross-links between two guanines (Lepre and Lippard, 1990) (Fig 1.2 b,c). Cisplatin also forms a small number of adducts between DNA and proteins (Fig. 1.2d). Monofunctional adducts are formed at lone G residues (Fig 1.2e);diethyltriaminechloroplatinum(II) or [Pt(dien)C1]+ forms only monofunctional adducts (Fig. 1.le) (Lepre and Lippard, 1990). The cisplatin analog ethylenediaminedichloroplatinum(II) or [Pt(en)C12](Fig. 1.lb) forms the same adducts as cisplatin. trans-Diamminedichloroplatinum(II), or trans-DDP, the stereoisomer of cisplatin, is not an active antitumor drug (Fig. 1.ld). trans-DDPalso kills cells by forming DNA adducts (Akaboshi et al., 1993),but the DNA adduct spectrum formed by trans-DDPis substantially different from that of cisplatin. The 1,2intrastrand d(GG) and d(AG) adducts cannot be formed because the distance between the two Cl ligands on trans-DDPis too large. trans-DDPpredominantly forms 1,3-intrastrand adducts at d(GXG) and d(AXG) sites (Lepre and Lippard, 1990). Interstrand adducts are formed by trans-DDPbetween complementary guanine and cytosine residues at d(GC) sites (Brabec and Leng, 1993). Recently, it has been suggested that trans-DDPdoes not form bifunctional intrastrand adducts (Boudvillain et al., 1995). This result contradicts the findings of several different laboratories (for review see Lepre and Lippard, 1990). The recent results were based on digesting trans-DDPtreated DNA with the 3'-5' exonuclease activity of T4 DNA polymerase. The exonuclease was stopped by trans-d(GXG) adducts in studies on short oligonucleotides. When doublestranded DNA was treated with trans-DDP,no exonuclease stops were visible, so 18 the authors concluded that no trans-d(GXG)adducts were formed. There are several problems with this experiment. First, the DNA was only treated with trans-DDPfor 24 hours; formation of trans-DDPbifunctional adducts is not complete until 48 hours have past (Eastman and Barry, 1987). Furthermore, the DNA was treated with thiourea after the trans-DDPreaction, which is known to remove 80-85% of the adducts (Eastman and Barry, 1987;Boudvillain et al., 1995). Since the authors state that interstrand adducts comprise 15% of the pre-thiourea adducts, the thiourea treatment may be removing all non-interstrand adducts. In addition to these problems, the actual exonuclease gel figure shows a fairly dark, diffuse band of undigested material in the trans-DDPlanes; since the final digestion product (mononucleotides) was not shown in this picture, it is impossible to determine how complete the digestion actually was. The results from this paper are inconclusive since the authors did not treat the DNA in a manner similar to what would occur in cells, and the gels themselves were inadequate. The nature of the trans-DDPadducts is of interest because comparisons between the activities of cisplatin and trans-DDPhelp to identify which aspects of cisplatin activity are important to tumor cytotoxicity. The DNA adducts formed by cisplatin and trans-DDPdistort the normal DNA structure. The platinum-DNA adducts bend and unwind the DNA to varying degrees. The cisplatin d(GG) and d(AG) adducts bend the DNA by 3234° and unwind it by 13° according to gel electrophoretic studies (Fig. 1.2a). The cisplatin d(GTG) adduct bends the DNA similarly, but unwinds it by 23° (Bellon and Lippard, 1990;Bellon et al., 1991). X-ray crystallography and NMR studies confirmed that adducts distort the DNA (Sherman et al., 1985;van Garderen and van Houte, 1994). This distortion was also apparent in scanning tunneling microscopic studies of cisplatin treated DNA (Jeffrey et al., 1993). Studies with anti-nucleoside antibodies indicate that there is more single-stranded character in 19 cisplatin treated DNA than in normal DNA (Sundquist et al., 1986). DNAse I footprinting also indicated that the helix is distorted in the adduct region (Schwartz and Leng, 1994). T4 Endonuclease VII, which cleaves 4-way junction DNA, also cleaved cisplatin-DNA adducts but not normal DNA, indicating that the adducts form a structure more closely related to the 4-way junctions than to normal DNA (Murchie and Lilley, 1993). trans-DDP-DNA adducts do not distort the DNA in the same way as cisplatin. Gel electrophoretic studies indicated that the d(GXG) adducts caused a hinge joint in the DNA instead of a directed bend, and that the DNA was unwound by 6-13 degrees (Bellon and Lippard, 1990; Bellon et al., 1991). The anti-nucleoside antibody study and the T4 endonuclease VII study gave different results for trans-DDPDNA adducts (Sundquist et al., 1986;Murchie and Lilley, 1993). There was more single-stranded character in the trans-DDP treated DNA at a lower platination level, but trans-DDP-d(GTG)was not cleaved by T4 endonuclease VII. Cisplatin and trans-DDPinterstrand adducts are different from the intrastrand adducts. The cisplatin interstrand adduct enormously distorts the DNA, causing gel electrophoresis studies to give a bending angle of 45° and an unwinding angle of 79° (Malinge et al., 1994). trans-DDP interstrand adducts bend the DNA by 26° and unwind it by 12° (Brabec et al., 1993). DNAse I footprinting studies indicated that the distortions in the DNA extend over a greater area for the interstrand cross-links than for the cisplatin intrastrand adduct (Schwartz and Leng, 1994). Cisplatin adducts also disrupt chromatin structure. DNA in cells is wound around the histone core particle to form nucleosomes, which further organize into chromatin. Cisplatin treatment of cells altered the arrangement of nucleosomes, but neither trans-DDPnor [Pt(dien)Cl]+, which forms monofunctional adducts, affected chromatin structure (Houssier et al., 1983). Nucleosome placement is affected by other forms of damage, including 20 ultraviolet light induced adducts (Suquet and Smerdon, 1993). The mouse mammary tumor virus (MMTV) promoter is regulated by the glucocorticoid receptor, which alters the chromatin around the promoter. This alteration was reduced by cisplatin but not by trans-DDP (Mymryk et al., 1995). The location of nucleosomes affects transcription of genes by excluding transcription factor and polymerase binding (Levin, 1994). Cisplatin may affect transcription by changing the placement of nucleosomes on promoter regions. Cisplatinadducts blockDNA and RNA polymerases Early studies with cisplatin indicated that DNA synthesis was inhibited by cisplatin treatment of cells. It has also been shown that cisplatin-DNA adducts block DNA and RNA polymerases in vitro (Comess, 1991;Lemaire et al., 1991; Murray et al., 1992;Corda et al., 1993;Huang et al., 1993). Several studies using different DNA polymerases have shown that the cisplatin d(GG) adduct effectively blocks DNA synthesis in vitro (Comess et al., 1992;Murray et al., 1992; Corda et al., 1993;Huang et al., 1993). The cisplatin d(GXG) adduct does not form as effective a block, permitting up to 25% of the newly synthesized strands to extend past the adduct (Comess et al., 1992). Similar studies on trans-DDP adducts have led to conflicting results since some show that such adducts do not block polymerases as effectively as cisplatin DNA adducts, while others show that they block equally well (reviewed in Bruhn et al., 1990). The blocking of the DNA polymerase can also lead to misincorporation across from the lesion in those strands that are synthesized past the lesion. This phenomenon was investigated by examining the mutation rates of various adducts replicated on episomes in E. coli (Naser et al., 1988; Bradley et al., 1993; Yarema et al., 1994). These studies indicate that all the platinum adducts cause mutations in episomal DNA, although the rate and type of mutation vary from adduct to adduct. In 21 conclusion, cisplatin and trans-DDPadducts block DNA replication and thus probably prevent the cells from duplicating their DNA without errors. RESISTANCE Cisplatin and its analog carboplatin are used by themselves and in combination with other drugs against metastatic testicular tumors, metastatic ovarian tumors, advanced bladder cancer, small cell lung cancer, endometrial cancer, leukemia, head and neck cancers, and cervical carcinoma (Fig. 1.3) (McEvoy, 1994;Olin, 1994). Acquired or intrinsic resistance to chemotherapy in any of these diseases can prevent effective treatment resulting in death. Acquired resistance is a particular problem in ovarian cancer (Arky, 1994). In two large studies, the initial response rate to cisplatin therapy was about 60% in ovarian tumor patients. Approximately half of these patients remained tumor progression free after 2 years, and one third after 3 years. Seventy percent of the patients died within 3 years of cisplatin treatment. Either a new cisplatin analog that treats these patients, or a way to tell which patients are responding to therapy before the tumors grow back would be helpful in prolonging and improving their lives. The causes of resistance to cisplatin have been studied in many different systems. According to theory, the major causes of resistance will be ones which affect the formation or removal of cisplatin-DNA adducts, or the ability of those adducts to kill the cell. Changes in drug accumulation, removal, repair of the cisplatin-DNA adducts, and levels of sulfur-containing proteins that bind cisplatin have been investigated. One issue hampering these studies is the difficulty in acquiring matched normal and resistant cell lines from patients undergoing cisplatin chemotherapy. Many of the studies were performed by using cell lines that were selected for cisplatin resistance by in vitro growth in media containing cisplatin. Unfortunately, studies with other drugs indicate that 22 resistance mechanisms characterized in this manner are not necessarily the same as those in actual patients. One major cause of resistance is increased repair of cisplatin-DNA adducts. Many different cell lines have been tested for this increase in repair activity; almost all tested cell lines show some increase. Cisplatin resistant ovarian cell lines have an increased level of cisplatin-DNA adduct repair. This result has been demonstrated by comparing adduct levels in cells, by measuring the rate of adduct removal, by measuring the gene-specific repair of cisplatin interstrand cross-links, and by performing excision repair assays using cell extracts (Dempke et al., 1992;Zhen et al., 1992;Schmidt and Chaney, 1993; Johnson et al., 1994a; Johnson et al., 1994b; Jones et al., 1994; Mellish and Kelland, 1994). The increase in DNA repair has even been confirmed in vivo using lines acquired from a patient's original and secondary tumors (Ali-Osman et al., 1994). The in vivo experiment showed that a resistance difference of only 5.9 fold at 5 gM cisplatin could cause clinically important resistance. The difference in repair between the two strains was 2.8 fold, which indicates the importance of increased repair in real ovarian tumors. Differences in repair have also been found in resistant cell lines from colon carcinomas, HeLa, fibrosarcoma, and squamous cell carcinomas of the head and neck (Chao et al., 1991b; Parker et al., 1993; Schmidt and Chaney, 1993;Chao et al., 1994;Moorehead et al., 1994;Oldenburg et al., 1994). Multiple studies were performed by using both normal and resistant L1210 cell lines, which showed increases in repair of cisplatin-DNA adducts by several different methods (Sheibani et al., 1989;Gibbons et al., 1991;Olinski and Briggs, 1991; Calsou et al., 1993). Unfortunately, the "normal" L1210 cell line is not quite normal because it has a defect in a vital DNA excision repair gene, so none of these studies are necessarily related to real tumor situations since most people have functional excision repair systems (Vilpo et al., 1995). Platinum 23 DNA adduct levels have been associated with patient response in many different diseases (Blommaert et al., 1993;Reed et al., 1993). All of these data support the conclusion that increased DNA repair is an important method by which cells develop cisplatin resistance. Another widely studied resistance mechanism is increased levels of glutathione (GSH) and related enzymes. Theoretically, when the sulfhydryl groups on glutathione bind cisplatin, it is unable to form bifunctional adducts on DNA, so the cells can survive higher levels of cisplatin treatment. Increased levels of GSH have been found in head and neck carcinomas, ovarian carcinoma cell lines, testis cancer lines, mouse L1210lines, and colon carcinoma (Behrens et al., 1987;Hamaguchi et al., 1993;Ishikawa and Ali-Osman, 1993;Schmidt and Chaney, 1993; Timmer-Bosscha et al., 1993; Oldenburg et al., 1994; Yellin et al., 1994). Increases in GSH-related enzymes such as glutathione reductase have been found without any increase in GSH in small cell lung cancer lines (Twentyman et al., 1992;Hao et al., 1994). Naturally, not every study found such differences, including one study on ovarian carcinoma lines (Mellish and Kelland, 1994). The amount of GSH increase varied widely from cell line to cell line, and was not strictly correlated with cisplatin sensitivity. Overall, these data support the idea that raising the GSH levels increases cisplatin resistance, although it is clear that other changes within the cells have been made. Some studies measured the uptake and accumulation of cisplatin and how well the drug could make DNA adducts. Decreased uptake or accumulation of the drug was found in some resistant strains such as ovarian carcinoma cells, lung cancer cells, and colon carcinoma lines (Twentyman et al., 1992;Schmidt and Chaney, 1993;Jekunen et al., 1994;Mellish and Kelland, 1994;Oldenburg et al., 1994). Other strains, including a testis line, an ovarian cancer line, and a small cell lung cancer line show no such difference (Twentyman et al., 1992; 24 Timmer-Bosscha et al., 1993;Mellish and Kelland, 1994). Ovarian and testis resistant lines showed slower reaction of cisplatin with DNA (Timmer-Bosscha et al., 1993;Jekunen et al., 1994). These studies indicate that, whereas decreased uptake can be part of a resistant phenotype, it is not as frequent a mechanism as either increased DNA repair or increased GSH levels. Many other possible mechanisms of resistance have been theorized and investigated in one cell line or another, indicating the complexity of cisplatin resistance. One study demonstrated that resistant ovarian cells could alter the ability of their polymerases to bypass the cisplatin adducts and duplicate the DNA (Mamenta et al., 1994). Cisplatin resistant lung cancer cells increased phosphorylation of several nuclear proteins. Differential phosphorylation of proteins often modulates their activity in many different ways (Nishio et al., 1992). In another study, the level of ATP was increased in resistant human ovarian cells; such a change could affect many systems (Berghmans et al., 1992). The plasma and mitochondrial membrane potentials were decreased in a fibrosarcoma resistant line (Moorehead et al., 1994),while the activity of cytochrome c oxidase was increased in cisplatin resistant ovarian, breast, and squamous head and neck carcinomas (Ara et al., 1994). Differences in chromosome 12 distribution in the nucleus were found in a resistant testicular tumor cell line (Reilly et al., 1993). One study of bladder cancer suggested that increased levels of metallothionein may also cause tumors to become resistant (Wood et al., 1993). Nevertheless, metallothionein levels did not change in resistant human lung cells (Twentyman et al., 1992). Some potential mechanisms cause resistance when examined by changing the levels of expression of proteins, but do not appear in real resistant cell lines. Topoisomerase II expression affected repair of cisplatin interstrand cross-links (Ali-Osman et al., 1993). Treatment of cells with a topoisomerase I inhibitor does not sensitize the cells to 25 cisplatin, however (Teicher et al., 1993). Two studies showed no difference in the levels of topoisomerases, so this mechanism may not occur in resistant cells (AliOsman et al., 1993; Hamaguchi et al., 1993; Timmer-Bosscha et al., 1993). The mechanism of cisplatin resistance is apparently very complicated. In order to improve anticancer treatments, it is important to know which mechanism of resistance is the most important in each type of cancer, or to investigate only mechanisms that are common in all types of cancers. Oncogenesand tumor suppressergenes The formation of tumors often involves the activation of oncogenes and inactivation of tumor suppresser genes. The effect of several of the common oncogenes and tumor suppresser genes on cisplatin resistance has been studied. Increased levels of the ras oncoprotein lead to increased resistance, as did increased levels of c-myc (Isonishi et al., 1991;Sklar and Prochownik, 1991;Levy et al., 1994). Testis and small-cell lung cancer cell lines have an increased level of embryonic forms of myc, N-myc and L-myc (Saksela et al., 1989). These proteins may help cause the tumors since they are not normally expressed in nonembryonic tissues. A study of a resistant testicular strain found no increase in cmyc levels (Timmer-Bosscha et al., 1993). The tumor suppresser protein p53 was not mutated in testicular tumors (Peng et al., 1993), whereas levels of a different tumor suppresser, Rb, were lowered (Saksela et al., 1989). These results indicate that the effects of these proteins on cisplatin resistant cell lines are worth investigating, but they do not guarantee that altered levels of these proteins are an important determinant of resistance. Cisplatin treatment causes changes in the cells The effect of cisplatin on various proteins and cellular systems has been investigated. Some proteins, such as heat shock protein 25 (HSP25) and the growth arrest and DNA damage-inducible protein GADD153, were induced, but 26 others, such as CTP synthetase, were inhibited (Ganeva et al., 1991;Oesterreich et al., 1991;Gately et al., 1994). Cisplatin treatment inhibited parts of the ubiquitin system and the self-splicing activity of the self-splicing rRNA ribosyme (Danenberg et al., 1991; Isoe et al., 1992). The levels of poly(ADP-ribosyl)ation, cAMP, and the dNTPs were raised by cisplatin treatment (Just and Holler, 1991; Burkle et al., 1993). Cisplatin treatment also affected DNA processing enzymes, inhibiting DNA helicases and activating a magnesium-dependent nuclease (Hibino et al., 1994; Villiani et al., 1994). Not all alterations are necessarily related to the antitumor activity of cisplatin. For instance, the slowing of microtubule assembly by cisplatin treatment is probably related to the peripheral neuropathy that affects some patients (Boekelheide et al., 1992). Which of these and the many other alterations cisplatin causes in cells actually affect its ability to destroy tumors cannot be determined without many more studies. Cell cycle and apoptosis Cisplatin treatment also alters the progression of the cell cycle and sends cells into a form of apoptosis, or programmed cell death. The cell cycle proceeds from G1 to S (DNA synthesis) to G2 to M (mitosis) phases. Cisplatin arrested cells in G2 and at the G2/M border (Sorenson and Eastman, 1988b;Sorenson and Eastman, 1988a; Sorenson et al., 1990; Inoue et al., 1992). Cells synchronized in the same place in the cell cycle were more sensitive to cisplatin in the G1 phase than in the S phase (Krishnaswamy and Dewey, 1993). Cisplatin treatment in combination with another drug, pentoxifylline, caused accumulation in the S phase, but these cells were not actually synthesizing DNA (Perras et al., 1993). Cells that are treated differently show different cisplatin sensitivity and cell cycle characteristics. Apoptosis, or programmed cell death, occurs in many types of cells. Cisplatin seems to induce apoptosis normally in some cell types and oddly in other cell types. Thymocytes need to proceed through the cell cycle in order 27 for cisplatin to cause apoptosis (Evans and Dive, 1993;Evans et al., 1994). CHO cells arrest in G2, but then enter aberrant mitosis which leads to apoptosis after the cells lose contact with the extracellular matrix (Demarcq et al., 1994). Cisplatin causes apoptosis in ovarian carcinoma cells without the usual hallmark of apoptosis, DNA degradation (Ormerod et al., 1994). Cisplatin-induced apoptosis and cell cycle breaks vary from cell type to cell type. These studies need to be expanded to define the involvement of the various proteins involved in apoptosis and cell cycle arrest. Other drugs affectcisplatincytotoxicity The effects of other drugs on cisplatin cytotoxicity may give insight into the important determinants of that cytotoxicity. Many different drugs have been used in combination with cisplatin, either in human patients or in mouse or cell studies. Only those drugs which show substantial synergy with cisplatin will provide data indicating anything about their mechanisms of action. The reasons for synergy with most of those drugs are unknown. Tamoxifen helped cisplatin kill malignant melanomas in human patients. Tamoxifen had no effect on cisplatin uptake, intrastrand adduct formation or repair, or GSH or metallothionein levels, so the cause for this synergy is unknown (McClay et al., 1992). The antibiotic amphotericin B sensitized cell lines to cisplatin by increasing the intracellular accumulation and DNA adduct formation (Kikkawa et al., 1993; Morikage et al., 1993). Activation of protein kinase C (PKC) by TPA (12-O-tetradecanoyl-phorbol-13-acetate) caused cells to become more sensitive to cisplatin without affecting GSH or metallothionein levels and with only a small increase in adduct levels and decrease in DNA repair level (Isonishi et al., 1994). Other PKC activators such as epidermal growth factor (EGF) and transforming growth factor-ac(TGFa ) sensitized cells to cisplatin by increasing the uptake and accumulation but not the removal of cisplatin (Basu and Evans, 1994). The 28 increase in uptake caused by EGF was blocked by a PKC inhibitor, but the increases in accumulation and cisplatin sensitivity were not blocked. Contrary to these results, anti-EGF receptor antibodies sensitized carcinoma cells grafted into mice to cisplatin treatment by blocking the action of EGF (Fan et al., 1993). Presumably, the cells in the latter experiment had an alteration in the EGF induced pathways which caused the cells to proliferate abnormally. Another protein used as a drug, interleukin-l1t, caused cells to become more sensitive to cisplatin by increasing the cellular accumulation of cisplatin and decreasing the DNA repair in ovarian carcinoma cells (Benchekroun et al., 1993). The various drugs may all affect different aspects of the cisplatin chemotherapeutic process. Presumably, other drugs yet to be studied may help target the cisplatin to the tumor. These studies indicate that the some of the same factors causing resistance are also important in the drug-cisplatin synergy. REPAIR OF CISPLATIN-DNA ADDUCTS Cisplatin-DNA adducts are removed by excision repair (Fig. 1.4). This process excises a 29 nucleotide piece of single-stranded DNA, and requires 10 or more proteins (Hanawalt, 1995). These proteins are highly conserved from humans to yeast (Fig. 1.5). Many of the mammalian proteins were found by complementing UV-sensitive human xeroderma pigmentosum (XP) or rodent excision repair cross-complementing (ERCC)strains, which are deficient in excision repair. Cisplatin-DNA adducts were repaired by this system in cell extracts (Hansson and Wood, 1989;Sibghat-Ullah et al., 1989;Calsou et al., 1992). The excision repair system repairs primarily the cisplatin intrastrand adducts. The interstrand adducts are most likely repaired by a different system, which is also the case for psoralen interstrand adducts (Hang et al., 1993). Excision repair is related to transcription; transcribed areas of DNA are repaired more readily than the remainder (Hanawalt, 1995). 29 The first step of excision repair is recognition of the DNA adduct, which is predominantly performed by XPA in humans. XPA is a zinc finger protein that binds to DNA damaged with UV light, cisplatin, and other damaging agents (Guzder et al., 1993;Jones and Wood, 1993). XPA recruits much of the rest of the DNA repair complex to the damaged site (Park et al., 1995). There is another protein that may be a damage recognition protein, called UV-DRP, DDB, or XPE complementing factor. This protein complements the repair deficiency in some but not all XPE cell lines (Keeney et al., 1994). UV-DRP binds to UV adducts and cisplatin-DNA adducts, but not trans-DDPDNA adducts (Chu and Chang, 1988; Patterson and Chu, 1989;Chu and Chang, 1990;Chao et al., 1991a; Chao, 1992; Keeney et al., 1993;Reardon et al., 1993;Payne and Chu, 1994). It was induced by cisplatin treatment in ovarian and other carcinoma cells (Vaisman and Chaney, 1995). It may be part of the excision repair system, perhaps an unnecessary protein that assists with the repair of certain types of adducts. The human single-stranded DNA binding protein, which is involved in excision repair, is part of a complex of proteins that binds to cisplatin-DNA adducts (Clugston et al., 1992). Some of the excision repair proteins have been tested for their effect on cisplatin cytotoxicity. Raising the levels of the ERCC1 protein in ERCC1 deficient cells caused the cells to become more resistant to cisplatin, as would be expected (Lee et al., 1993). When ERCC1 was overexpressed in normal CHO cells, it caused them to become more sensitive to cisplatin; the authors theorized that it may be suppressing a pathway for the repair of cisplatin lesions (Bramson and Panasci, 1993). The expression of ERCC1 and ERCC2 was related in nonmalignant brain tissue, but not in malignant brain tumors, indicating that expression of one of these proteins was disturbed (Dabholkar et al., 1995). In a separate study, elevated ERCC1 levels were found in resistant testis teratoma cell 30 lines but not in resistant ovarian cell lines, whereas the levels of ERCC3/XPB were the same in all the lines (Taverna et al., 1994). Ovarian cancer patients that did not respond to cisplatin chemotherapy had raised levels of ERCC1 but not ERCC2 (Dabholkar et al., 1992). These studies indicate that ERCC1 may be particularly important in determining cisplatin cytotoxicity. Cisplatin adducts were repaired more readily in actively transcribed regions of DNA (Bohr, 1991;May et al., 1993). This phenomenon was dependent on active excision repair. Some excision repair proteins were not involved in this type of repair. XPC cells are sensitive to UV light but still performed repair on transcriptionally active regions of DNA (Venema et al., 1991;van Hoffen et al., 1993;Shivji et al., 1994). The yeast strains deficient in the repair proteins Rad7 and Radl6 also behaved in this manner; oddly, strains missing the XPC homolog, Rad4, did not (Verhage et al., 1994). At the other end of the spectrum, Cockayne's syndrome cells were deficient in this transcription specific repair, although they still had some repair capacity for general DNA (van Hoffen et al., 1993). XPA, XPD, and XPFwere required for gene specific repair (Evans et al., 1993;Zhen et al., 1993), as was the yeast homolog of ERCC3/XPB (Sweder and Hanawalt, 1994). The XPC cell line repair activity occurred more readily when the cells were not dividing (Kantor and Elking, 1988). In general, gene specific repair occurred particularly rapidly in early G1 phase (Rampino and Bohr, 1994). Gene specific repair does not require exactly the same proteins as general DNA repair, nor does it seem to occur with the same timing in the cell cycle. It is unclear how important gene specific repair may be in determining which tumors will be more sensitive to cisplatin. HMG DOMAIN PROTEINS The search for proteins that bind to cisplatin-DNA adducts started when researchers realized that these proteins might have a large effect on cisplatin 31 cytotoxicity. Initially, such proteins were identified by Southwestern blot and bandshift assays, which detect proteins that bind to cisplatin-treated radiolabelled DNA. Human cell extracts examined by Southwestern blotting and bandshift assay contained several such proteins (Chu and Chang, 1988;Toney et al., 1989; Donahue et al., 1990), some in the 87-100 kDa range and two in the 25-28 kDa range. To identify these proteins, a human cDNA expression library was screened with cisplatin-modified DNA. The screen yielded the gene for a protein of unknown function, structure specific recognition protein 1, SSRP-1,which had an HMG domain (Bruhn et al., 1992). This finding suggested that the 25-28 kDa band might contain HMG1, another HMG domain protein. The UV-DRP protein was also initially identified in the bandshift assay. HMG1 binds to cisplatinDNA adducts more tightly than either UV-DRP or XPA (Pil and Lippard, 1992; Jones and Wood, 1993;Payne and Chu, 1994). Finding a class of cisplatin-DNA adduct binding proteins led to the study of these proteins and their potential effects on cisplatin cytotoxicity and resistance. HMG1 binds to cisplatin-DNA adducts The 25-28 kDa bands were shown to be HMG1 and HMG2 by selective immunoprecipitation with anti-HMG1 antibody and by performing parallel Southwestern and Western blots (Pil and Lippard, 1992). HMG1 contains 2 HMG domains and an acidic tail (Fig. 1.6a). HMG2 is highly homologous to HMG1; in the mouse, HMG1 and HMG2 genes are 73% identical (Stolzenburg et al., 1992); Rat HMG1, expressed in Escherichiacoli, bound selectively to platinated DNA in a bandshift assay (Pil and Lippard, 1992). HMG1 bound specifically to cisplatin-DNA 1,2-(GpG) and -(ApG) adducts, but not to 1,3(GpTpG) adducts or to monofunctional [Pt(dien)Cl]+-d(G) adducts. Moreover, HMG1 bound to a site-specific 1,2-(GpG) adduct with a dissociation constant of 3.7x10-7 M, and to the corresponding unplatinated sequence with a Kd of 32 3.4x10-5 M. Another group independently demonstrated that HMG1 and HMG2 bound to cisplatin-modified DNA cellulose, providing further evidence for the specificity of this interaction (Billings et al., 1992; Hughes et al., 1992). The fact that HMG1 binds to DNA containing cisplatin adducts is consistent with its interactions with other types of structurally modified DNA, such as 4-way junctions (Fig. 1.6b). As described previously, cisplatin 1,2-intrastrand cross-links cause the DNA to bend and unwind. Binding of HMG1 was sensitive to the specific type of bending and the degree of unwinding that occurs for these different adducts, interacting most selectively with the 1,2-intrastrand crosslinks. HMG1 contacted at least a 15 nucleotide region of DNA in DNAse I footprinting assays (Locker et al., 1995). The region of HMG1 responsible for the cisplatin-DNA adduct binding activity has been investigated. Proteolytically digested HMG1 was used to determine that HMG domain B, or the combined HMG domains A and B, will both bind selectively to cisplatin-treated DNA in a Southwestern blot (Chow et al., 1995). A fragment containing all of domain B plus the acidic tail did not bind cisplatin-modified DNA, probably because of its negative charge (pI - 4.5). HMG domain B was separately cloned and found to bind to cisplatin-treated DNA with the same affinity as HMG1 itself; however, its binding to unmodified DNA was substantially higher, so the selectivity of domain B for cisplatinmodified DNA was diminished. Similar studies were performed with HMG2 (Lawrence et al., 1993). In this case the amino terminus was found to be essential, because a fragment containing all but 51 amino terminal residues did not bind to cisplatin-damaged DNA cellulose. Domain B of HMG2 was also necessary; removing as few as 30 amino acids from a fragment containing both HMG domains decreased its binding affinity compared to that of either HMG2 or an HMG2 fragment lacking only the acidic tail. Both HMG2 domains A and B 33 bound separately, but with very low affinity. These results differ from those for HMG1, either because of differences in the proteins or in the assay conditions employed. HMG domain proteins, a new class of DNA-binding proteins When a new DNA-binding motif is first announced, it is not unusual to find it in a large number of related proteins. Such is the case for HMG domain (Landsman and Bustin, 1993), which has recently joined the list of previously identified DNA-binding motifs, the zinc finger, helix-turn-helix, and leucine zipper. The first HMG domain to be identified in a protein other than HMG1 occurred in hUBF, a transcription factor for rRNA (Jantzen et al., 1990). Proteins containing the HMG domain bend DNA and many of them are transcription factors. HMG domain proteins have been divided into two subfamilies based upon their ability to bind DNA in a sequence-specific versus a structure-specific manner (Grosschedl et al., 1994). HMG1 itself typifies the latter category, recognizing structures such as four-way junctions (Fig. 1.6b) and cisplatin-DNA adducts rather than a specific DNA sequence. LEF-1, lymphoid enhancer binding protein 1, contains one HMG domain, binds to the T-cell antigen receptor (TCRa) enhancer, and participates in gene expression and differentiation (Travis et al., 1991). The protein bent DNA by 130° when bound to its target site, as revealed by the circular permutation assay (Giese et al., 1992). LEF-1 contacts AT base pairs primarily in the minor groove; replacement of AT with IC base pairs, which are identical in the minor groove but differ in the major groove, had no affect on binding (Giese et al., 1992). Giese et al. hypothesized that LEF-1might not be a traditional transcription factor. Instead of activating transcription by interacting with other proteins, LEF-1 might play an architectural role. The bend in DNA induced by LEF-1may bring distant elements of the promoter into closer contact, permitting proteins bound 34 to those elements to interact and activate transcription. Further experiments demonstrated that the HMG domain of LEF-1could not substitute for the entire protein in activating transcription at the TCRocenhancer (Giese and Grosschedl, 1993). In addition, replacement of the HMG domain by the LexA DNA binding domain and of the LEF-1binding site by the LexA binding site diminished but did not abolish TCRLoenhancer activity. Since LexA does not bend DNA, the non-HMG domains of LEF-1 must participate in activating transcription. Thus, LEF-1 activates transcription both by bending DNA, a property of its HMG domain, and by interacting with other proteins. Another extensively studied HMG domain protein is hSRY,the sex determining factor in humans. When the mouse analogue, mSRY,was expressed in a female embryo it developed into a male mouse (Koopman et al., 1991). hSRY bound to four-way junctions (Fig. 1.6b) as well as to AACAAAG and related sequences (Ferrari et al., 1992;Giese et al., 1994). Human SRYbound predominantly in the minor groove, as shown by methylation interference experiments and by replacing AT with IC base pairs (van de Wetering and Clevers, 1992). Mouse SRYhas a significantly different amino acid sequence and formed more extensive major groove contacts than hSRY (Giese et al., 1994). Two dimensional NMR studies of hSRY revealed partial intercalation of an isoleucine residue between two AT base pairs in the minor groove (King and Weiss, 1993). SRY bends DNA by 83-85° when it binds to its recognition sites (Ferrari et al., 1992; Giese et al., 1992;Giese et al., 1994). Binding of the HMG domains of mSRY and hSRY to two different sequences was compared, the former bending DNA by 2030° more than the latter (Giese et al., 1994). A family of proteins related to SRY called Sox bound the same sequence and, in one case, activated transcription (Denny et al., 1992;van de Wetering et al., 1993). Sox5 bends DNA by about 75° (Connor et al., 1994). SRYitself bound to upstream elements in the promoters of 35 two sex-specific genes (Haqq et al., 1993). Mutations in SRY that cause sex reversal affect the ability of SRY to bind DNA properly (Pontiggia et al., 1994; Werner et al., 1995). One of these mutant SRYproteins could still bind to 4-way junction DNA, so only the site-specific binding activity was abolished (Peters et al., 1995). Thus, much like LEF-1, SRY binds DNA in the minor groove, bends it, and activates transcription. In addition to SRY, there is another testis-specific HMG domain protein in mice, tsHMG1 (Boissonneault and Lau, 1993). tsHMG1 was isolated by screening a testis library with the testis-specific promoter from PGK-2. It contains two HMG domains and binds to 5'-AGGTTTTTACAT-3'.This protein was expressed in postpuberal testis, whereas SRYwas expressed only in early development. tsHMG1 binds to cisplatin-DNA adducts (Raju, NL, Whitehead, JP, unpublished data). hUBF is a transcription factor for rRNA production which consists of five HMG domains and an acidic tail (Jantzen et al., 1990). As found in other HMG domain proteins, one or more of the boxes was necessary for DNA binding (Maeda et al., 1992). hUBF interacted with a specific subunit of RNA polymerase I (Schnapp et al., 1994),and the second HMG domain affected the role of hUBF in activating transcription and counteracting histone H-mediated repression (Kuhn et al., 1994). hUBF also bends DNA, possibly blocking H1 repression because DNA is wrapped around hUBF in the opposite direction from the way it is wrapped around the histones (Putnam et al., 1994). The HMG domain protein SSRP-1(structure specific recognition protein 1), originally cloned because it binds to cisplatin-modified DNA (Bruhn et al., 1992), interacts with a variety of different sequences. The mouse SSRP-1(also known as T160) bound to recombination signal sequences used when cells are performing V-D-J recombination (Shirakata et al., 1991). The chick and rat homo- 36 logues of SSRP-1 bound to the collagen II gene promoter (Wang et al., 1993). The true function of SSRP-1is uncertain. Not only was SSRP-1present at significant levels in all tissue types that were screened (Bruhn et al., 1992),but it was also well conserved across the species; the Drosophila homologue is 54% identical to the human protein (Bruhn et al., 1993;Hsu et al., 1993). Thus it seems unlikely that SSRP-1 is a specific factor for collagen II gene transcription or for V-D-J recombination, since these functions are specific to certain cell types. SSRP-1 also binds to the c-Myc oncoprotein, further complicating its potential function (Bunker and Kingston, 1995). A variety of other HMG domain proteins bind and bend DNA (Diffley and Stillman, 1992;Fisher et al., 1992;Dooijes et al., 1993). The bending seems to be a property of the HMG domain, irrespective of whether it occurs in a sequence- or a structure-specific recognition protein. Any differences between these various proteins must result either from the exact degree of the bending or from other domains. HMG1 binding to DNA HMG1 is a 25 kDa protein with two HMG domains (A and B) and an acidic tail (Bustin et al., 1990) (Fig. 1.6). The structure of HMG1 domain B (Fig. 1.7), determined by two dimensional NMR spectroscopy (Read et al., 1993;Weir et al., 1993), is comprised of three helices folded into the shape of the letter L. The DNA-binding properties of HMG1 have been extensively investigated (Landsman and Bustin, 1993; Grosschedl et al., 1994). Briefly, HMG1 bound to single-stranded DNA, mono- and di-nucleosomes, cruciforms, 4-way junctions, and cisplatin intrastrand cross-links (Fig. 1.6). The common element among these varieties of structurally deformed DNA is unclear, in part because many of the DNA-binding experiments were carried out under different conditions. Most 37 of the DNA motifs that bind HMG1 have single-stranded character, regions where the DNA is somewhat underwound, or bent double-stranded structures. Several experiments have revealed that HMG1 alters the structure of DNA. HMG1 binding changed the linking number of negatively supercoiled DNA and prevented its relaxation by topoisomerase I (Sheflin and Spaulding, 1989). A proteolytic fragment of HMG1, missing only the acidic tail, supercoiled DNA in the presence of topoisomerase; this fragment was more active than HMG1 itself at high ionic strength (Stros et al., 1994). Electron microscopic experiments confirmed this result and demonstrated that high levels of the HMG domains alone compact DNA in much the same manner as histones (Stros et al., 1994). The acidic tail of HMG1 decreased the ability of the protein to bend DNA, or at least its ability to bind to the DNA. Sheflin et al. (Sheflin et al., 1993)determined that HMG1 unwinds DNA by 58°, whereas the proteolytic fragment lacking the acidic tail unwound it by only 10°. The DNA binding sites of the two proteins were estimated by increasing their concentrations to the point above which they failed to increase the superhelicity. At this amount of bound protein, which corresponds to saturation binding, HMG1 covered approximately 20 base pairs whereas the proteolytic fragment only spanned 4 base pairs. In these experiments, the acidic tail interfered with binding to DNA. Modifying the cysteine sulfhydryl groups of HMG1 with N-ethylmaleimide prevented HMG1 from binding as effectively to negatively supercoiled DNA (Sheflin et al., 1993). Since there are no cysteines in the acidic domain, this result indicated that cysteine residues in the HMG domains are involved in the interaction of HMG1 with negatively supercoiled DNA. Binding of HMG1 to single-stranded DNA, and of the proteolytic fragment to any form of DNA, were unaffected by cysteine modification, so the acidic domain must 38 influence whatever change is created by modifying the cysteine sulfhydryl residues within the HMG domain. The naturalfunction of HMG1 The possible functions of HMG1 have been extensively debated in the literature. One hypothesis is that HMG1 affects the location of nucleosomes on DNA, thus regulating the regions accessible to transcription. Several experiments support this theory. HMG1 suppressed nucleosome assembly at physiological ionic strength, probably due to its binding the DNA (Waga et al., 1989). HMG1 also bound to histone H1, as monitored by the quenching of HMG1 tryptophan fluorescence (Kohlstaedt and Cole, 1994). Histone H1 interacted with the nucleosome core to compact the DNA. The exact state of the HMG1 substantially affected its binding to H1, as did pH changes. At pH 6.0, HMG1 bound as a tetramer with a dissociation constant of 3.4x10-8 M , whereas at pH 7.5 monomeric HMG1 bound with a dissociation constant less than 10-9 M. Histone H1 inhibited the transcription but not the replication of DNA (Halmer and Gruss, 1995). HMG1 and HMG2 competed with histone H1 for binding to 4-way junctions. Four-way junction DNA is a reasonable model for the crossover of DNA at the entry and exit of nucleosomes. This result indicates that HMG1 may replace H1 to activate transcription (Varga-Weisz et al., 1994). In early Drosophila embryogenesis, the HMG1 analogue, HMG-D, was expressed instead of histone H1 (Ner and Travers, 1994). As the embryo developed, the volume of the nucleus decreased and the length of the nuclear cycle increased. This alteration in chromatin occurred concomitantly with increased expression of H1 and with a decrease in HMG-D expression. The less dense chromatin structure associated with HMG-D expression may be required for the rapid nuclear cycles in early development. These experiments reveal the ability of HMG1 to modulate chromatin structure. 39 HMG1 has also been implicated as a regulator of gene transcription. Since other HMG domain proteins are transcription factors, HMG1 might affect transcription by preventing their binding to DNA (Landsman and Bustin, 1993). It has also been proposed that HMG1 itself activates transcription. In an attempt to evaluate this hypothesis, the ability of the protein to function in one of the standard transcriptional activation assays was investigated. An HMG1-LexA binding domain fusion protein could not activate transcription from the lexA operator (Landsman and Bustin, 1991). This result does not prove that HMG1 is not a transcriptional activator. The fusion protein interacted non-specifically with DNA through its HMG domain, so it was impossible to ascertain whether the construct bound correctly to its promoter. Other evidence suggests that HMG1 is required for transcription of a number of genes. Incubation of HeLa nuclear cell extracts with antibodies to HMG1 inhibited run-off transcription of four different promoters (Singh and Dixon, 1990). A related study indicated that the protein was required for initiation of transcription rather than elongation of the RNA (Tremethick and Molloy, 1988). HMG1 may promote transcription by helping other factors to bind DNA and activate RNA polymerase. HMG1 increased the rate of binding of MLTF to its site on the adenovirus major late promoter (Watt and Molloy, 1988). It also increased the ability of the progesterone receptor (PR) to bind DNA and activate transcription (Onate et al., 1994). Addition of HMG1 increased the DNA affinity of PR by at least an order of magnitude for perfectly palindromic binding sites and by much more for imperfect sites. PR and HMG1 co-immunoprecipitated from the binding complex, although HMG1 was not apparent in gel mobility shift assays. Onate et al. (1994)also tested various domains of HMG1 and other HMG domain proteins for similar activity. The B HMG domain of HMG1 was nearly as effective as HMG1 itself, whereas the A domain only weakly enhanced 40 PR binding. A construct including both the A and B domains but not the acidic tail failed to enhance binding. LEF-1and SRYsimilarly did not enhance PR binding, even though they did bind to the DNA. Thus, HMG1 facilitated the binding of PR by inducing a structural change in the target DNA, and this activity was specific to HMG domain B of the protein. HMG1 stimulated transcription in COS-1 cells, but only if the acidic tail was intact (Aizawa et al., 1994). The closely related HMG2 protein interacts with the octamer transcription factors Octl and Oct2 to assist in their sequence-specific binding, which results in increased transcription (Zwilling et al., 1995). These data indicate that HMG1 and HMG2 may activate transcription by assisting other proteins. In summary, these experiments are consistent with the notion that HMG1 is a kind of nuclear chaperone protein which, perhaps by bending and unwinding the duplex, creates an enhanced site for transcription-factor binding and activation of gene expression (Ner et al., 1994). HMG1 bendscisplatin-treatedDNA Since HMG1 bends unplatinated DNA, it is no surprise that it also bends cisplatin-modified DNA. This behavior was first measured by the ligasemediated circularization assay (Pil et al., 1993), an experiment in which it is not feasible to quantitate the bend angle. In order to obtain this information, it was necessary to study HMG1 binding to single, site-specific cisplatin-DNA adduct. Experiments examining the bend angle induced by HMG1 and other HMG domain proteins binding to a single cisplatin-1,2-(GpG) adduct were performed by using the circular permutation assay (Chow et al., 1994). Site-specific probes were successfully employed to calculate the bend angles for HMG1 and several HMG domain containing proteins bound to the cisplatin-modified DNA. The bend angles ranged from 70° to 85°;most of the HMG domain proteins had values closer to 70°, whereas HMG1 itself bent the platinated DNA by 85°. HMG 41 domain B bent the DNA to a degree similar to that of the HMG domain proteins. These bend angles are of the same magnitude as that found previously for SRY (Ferrari et al., 1992; Giese et al., 1992; Giese et al., 1994). HMG domainproteinsand cisplatinantitumor activity There are several ways in which the binding of HMG1 and other HMG domain proteins to cisplatin-DNA adducts might affect the biological activity of cisplatin (Donahue et al., 1990;Lippard, 1994). First, the HMG domain proteins may themselves be part of the excision repair apparatus of the cell. In order for excision repair to occur, some protein or other cellular component must recognize the damage created by the cisplatin adducts. None of the excision repair proteins which have been sequenced to date have an HMG domain. A second possibility is that the HMG domain protein may block the cisplatin-DNA adducts from recognition by the repair apparatus (Fig. 1.8). If the HMG domain protein does prevent repair of the adduct, then cells could become resistant to cisplatin by lowering the levels of the protein. A third possibility is that the cisplatin titrates or "hijacks" the protein away from its natural binding sites (Fig. 1.9). Assuming that the hijacked protein is in some manner vital to the tumor cell, its diversion could sensitize the cells to cisplatin. Alternatively, the hijacked protein may cause transcriptional activation or repression in the area of the cisplatin binding sites, thus disrupting normal gene regulation of the genes in their vicinity. A few studies have reported that the levels of cisplatin-DNA adduct-binding proteins increase or decrease when cells become more resistant to cisplatin treatment. No such effect has yet been observed in actual tumor cells, however, and the results reported by different laboratories are inconsistent (Chao, 1991; Bissett et al., 1993; McLaughlin et al., 1993). These hypotheses, which are not mutually exclusive, have been subjected to a number of experimental tests. Treiber et al. (Treiber et al., 1994) evaluated 42 the hijacking hypothesis in vitro by using the HMG domain protein hUBF. The dissociation constant for hUBF binding to a site-specific cisplatin intrastrand 1,2(GpG) cross-link was measured to be 60 pM by analysis of a DNAse I footprint assay. The Kd for the binding of hUBF to its normal site on DNA, the rRNA promoter, was of the same order of magnitude, 18 pM. Additional footprinting experiments revealed that hUBF binds cooperatively to the rRNA promoter. Any decrease in hUBF levels could have a significant effect on rRNA gene transcription. Footprinting analysis was performed on the rRNA promoter element in the presence of increasing amounts of cisplatin-treated DNA. At concentrations of cisplatin substantially lower than those in treated cells, the binding of hUBF to its promoter site was abolished. In cells treated with cisplatin, hUBF may be diverted from its natural target sites. Since rRNA is a vital element for cell survival, down-regulation created by cisplatin treatment might contribute to the toxic effects of cisplatin. Such a conclusion assumes, of course, that the cell does not respond by increasing the levels of hUBF expression. Experiments to test the hijacking hypothesis in vivo are required to evaluate further these possibilities. The repair shielding hypothesis has been tested in two sets of experiments, one employing cell extracts and the other, yeast cells. The in vitro studies were performed with HeLa and other human whole cell extracts (Huang et al., 1994). A 156-bp linear piece of DNA radiolabeled near a site-specific platinum intrastrand 1,2-(GpG)or 1,3-(GpTpG) adduct was incubated with the cell extracts and the resulting mixture was resolved on a polyacrylamide gel. Bands of approximately 29 bp form for both adducts only when the cell extracts had all the components of the excision repair excinuclease system. When relatively high levels of HMG1 were added to the extracts, less repair of the cisplatin 1,2-(GpG) adduct occurred, presumably because the protein bound to the platinated DNA and blocked repair. HMG1 had no effect on repair of the 1,3- 43 (GpTpG) adduct, which is reasonable since HMG1 does not bind this adduct. Previous in vitro excision repair studies employing the repair synthesis assay did not reveal the ability of the system to excise the 1,2-(GpG) adducts (Szymkowski et al., 1992). The repair synthesis assay measures the incorporation of radiolabelled nucleotides into repair patches on the damaged strand of sitespecifically platinated plasmid DNA. The background in this assay can be higher due to random nicking events which may have obscured the signal. In addition, the difference may reflect some difference in the cell extracts. In any event, it is clear from the excision assay that the major adducts of cisplatin on DNA are effectively removed by the human excinuclease system. More importantly, this work established the feasibility of the repair shielding hypothesis in a defined in vitro investigation. Yeast as a model system Perhaps the best system yet discovered for revealing how HMG domain proteins might affect the activity of cisplatin is in yeast. Several yeast HMG domain proteins have been identified, one by using the same expression library screening methodology previously employed to identify human SSRP-1(Brown et al., 1993). The yeast protein, designated Ixrl for intrastrand cross-link recognition, was identified in Saccharomycescerevisiaecell extracts by a Southwestern blot using cisplatin-modified DNA as the probe (Brown et al., 1993). Ixrl binds to both globally platinated DNA and site-specific cisplatin 1,2-(GpG) cross-links in gel mobility shift assays (Whitehead and Lippard, 1995). It bent DNA containing a site-specific cisplatin adduct to the same extent as other HMG domain proteins, as determined by the circular permutation assay (Chow et al., 1994). Experiments were performed to determine exactly how Ixr might have altered the response of yeast cells to cisplatin. S. cerevisiaeis a useful eukaryote because it is relatively easy to delete its genes (Fig. 1.10). When the IXR1 gene 44 was interrupted, the resulting ixrl strain was significantly less sensitive to cisplatin than the wild type, IXR1, strain (Brown et al., 1993). This finding is inconsistent with the theory that Ixrl might be an adduct-recognition component of the excision repair apparatus since removing an component of DNA repair would make the cells more sensitive to cisplatin. The result could be explained if Ixrl regulates repair proteins and its absence lead to an increase in their expression, but this is unlikely since the UV sensitivity of the two lines was the same. The result supports the theory that Ixrl may block the access of repair proteins to the platinum adducts on DNA. In such a case, deletion of the gene encoding the Ixrl protein would lead to greater repair and enhance the survival of cells treated with cisplatin. Saccharomycescerevisiaehas several different HMG domain proteins. It has structure specific proteins like HMG1 in both the mitochondria (ABF2)and the nucleus (NHP6a/b) (Kolodrubetz and Burgum, 1990;Diffley and Stillman, 1992). These proteins can substitute for each other if they are expressed in the correct location (Kao et al., 1993). Additionally, the bacterial HU and human mtTFA proteins can substitute for ABF2,indicating that ABF2does not function as a sitespecific DNA binding protein (Megraw and Chae, 1993;Parisi et al., 1993). NHP6a/b have been shown to bend DNA in the same way HMG1 does (Paull and Jonson, 1995). NHP6a/b act in the MAPK pathway which responds to extracellular signals; they may help activate transcription in a manner similar to HMG1 (Costigan et al., 1994). Yeast contain other nonspecific DNA binding proteins with HMG domains, such as SIN1, which is involved in regulation of HO transcription, (Kruger and Herskowitz, 1991). Roxl is a site-specific DNA binding HMG domain protein. It binds to the sequence ATTGTTCTCand represses transcription of hypoxic genes in an oxygen and heme dependent manner (Balasubramanian et al., 1993). It is not clear whether Ixrl is a sequence 45 or structure specific protein; it binds to the Cox5b promoter region, but the exact site of binding has not yet been determined (Lambert et al., 1994). Ixrl, also known as ORD1, represses transcription of COX5b from the Cox5b promoter region. SUMMARY AND CONCLUSIONS The HMG domain is a DNA binding motif that bends DNA. Many of the proteins that harbor this domain are transcription factors whereas others are thought to regulate structural properties of DNA in the nucleus. The HMG domain proteins also bind to cisplatin-modified DNA and, as a class, may affect the cytotoxicity of the drug. Cisplatin-DNA adducts at therapeutic levels can titrate hUBF away from its normal binding site in vitro. HMG1 blocks excision repair in human cell extracts. Removal of the gene encoding Ixrl desensitizes the yeast to cisplatin. These results and the results detailed in the following chapters suggest that one strategy for improving the antitumor activity of platinum drugs would be to synthesize cisplatin derivatives that can form DNA adducts which would bind HMG domain proteins with greater affinity. These compounds should be more toxic because of the diminished capacity of the cells to repair the adducts. It is not yet clear that this approach would selectively sensitize cancer cells. Since one of the main diseases treated by cisplatin is testicular cancer, it is interesting that the testis-determining factor SRYis an HMG domain protein. Perhaps the state of SRY or other HMG domain proteins in solid tumors of the testes differs from that in normal cells. Investigation of the various HMG domain proteins and their ability to influence excision repair in testis and other tissues should lead to better and broader cisplatin based chemotherapy. Before any of the complicated mammalian cell culture and tumor tissue experiments are performed, it is important to check the various hypothesis in a simpler system. S. cerevisiaeis one of the simplest eukaryotes, and its genetics have been well 46 defined. Many of its vital systems contain proteins with homologous mammalian counterparts, including the excision repair system. The yeast HMG domain protein Ixrl affects cisplatin cytotoxicity. The use of this system to investigate models for how HMG domain proteins affect cisplatin cytotoxicity is described in subsequent chapters. 47 REFERENCES Parts of this chapter were originally published in M.M. McA'Nulty and S.J.Lippard (1995)Consequences of HMG-domain proteins binding to cisplatinmodified DNA. Nucleic Acids and Molecular Biology 9, 264-284. Aizawa, S., H. Nishino, K. Saito, K. Kimura, H. Shirakawa and M. Yoshida (1994) Stimulation of transcription in cultured cells by high mobility group protein 1: essential role of the acidic carboxyl-terminal region. Biochemistry 33, 14690- 14695. Akaboshi, M., K. Kawai, H. Maki, K. Akuta, Y. Ujeno and T. Miyahara (1992) The number of platinum atoms binding to DNA, RNA and protein molecules of HeLa cells treated with cisplatin at its mean lethal concentration. Jpn J. Cancer Res. 83, 522-526. Akaboshi, M., K. Kawai, H. Maki, K. Akuta, Y. Ujeno, K. Ono and T. Miyahara (1993)Determination of the target volume of HeLa cells treated with platinum195m radiolabeled trans-diamminedichloroplatinum(II): a comparison with cisdiamminedichloroplatinum(II). Nucl. Med. Biol. 20, 389-393. Ali-Osman, F., M.S. Berger, A. Rairkar and D.E. Stein (1994) Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases cxand 3,and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy. J. Cellular Biochem. 54, 11-19. Ali-Osman, F., M.S. Berger, S. Rajagopal, A. Spence and R.B. Livingston (1993) Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res. 53, 5663-5668. Ara, G., T. Kusumoto, T.T. Korbut, F. Cullere-Luengo and B.A. Teicher (1994) cis- Diamminedichloroplatinum(II) resistant human tumor cell lines are collaterally sensitive to PtC14 (Rh-123)2: evidence for mitochondrial involvement. Cancer Res. 54, 1497-1502. Arky, R. (1994).Physicians' Desk Reference. New Jersey, Medical Economics Data Production Company. Balasubramanian, B., C.V. Lowry and R.S. Zitomer (1993)The Roxl repressor of the Saccharomycescerevisiaehypoxic genes is a specific DNA-binding protein with a high-mobility-group motif. Mol. Cell. Biol. 13, 6071-6078. 48 Basu, A. and R.W. Evans (1994) Comparison of effects of growth factors and protein kinase C activators on cellular sensitivity to cis-diamminedichloroplatinum(II). Int J Cancer 58, 587-591. Behrens, B.C., T.C. Hamilton, H. Masuda, K.R. Grotzinger, J. Whang-Peng, K. Louie, T. Knutsen, W.M. McKoy, R.C. Young and R.F. Ozols (1987) Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47, 414-418. Bellon, S.F., J.H. Coleman and S.J.Lippard (1991)DNA unwinding produced by site-specific intrastrand crosslinks of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry 30, 8026-8035. Bellon, S.F. and S.J.Lippard (1990)Bending studies of DNA site-specifically modified by cisplatin, trans-diamminedichloroplatinum(II) and cis[Pt(NH 3 )2 (N3-cytosine)Cl]+ . Biophysical Chemistry 35, 179-188. Benchekroun, M.N., R. Parker, E. Reed and B.K. Sinha (1993) Inhibition of DNA repair and sensitization of cisplatin in human ovarian carcinoma cells by interleukin-la. Biochem Biophys Res Comm 195, 294-300. Berghmans, K., J. Ruiz-Cabello, H. Simpkins, P.A. Andrews and J.S. Cohen (1992) Increase in the ATP signal after treatment with cisplatin in two different cell lines studied by 31p NMR spectroscopy. Biochem Biophys Res Comm 183, 114- 120. Billings, P.C., R.J. Davis, B.N. Engelsberg, K.A. Skov and E.N. Hughes (1992) Characterization of High Mobility Group protein binding to cisplatin-damaged DNA. Biochem Biophys Res Comm 188, 1286-1294. Bissett, D., K. McLaughlin, L.R. Kelland and R. Brown (1993) Cisplatin-DNA damage recognition proteins in human tumour extracts. Br. J. Cancer 67, 742-748. Blommaert, F.A., C. Michael, P.M.A.B. Terheggen, F.M. Muggia, V. Kortes, J.H. Schornagel, A.A.M. Hart and L. den Engelse (1993)Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: Interindividual variation and correlation with disease response. Cancer Res. 53, 5669-5675. Boekelheide, K., M.E. Arcila and J. Eveleth (1992) cis- Diamminedichloroplatinum(II) (Cisplatin) alters microtubule assembly dynamics. Toxicol. Appl. Pharmacol. 116, 146-151. 49 Bohr, V. (1991) Gene specific DNA repair. Carcinogenesis 12, 1983-1992. Boissonneault, G. and Y.F.C. Lau (1993) A testis-specific gene encoding a nuclear high-mobility-group box protein located in elongating spermatids. Mol. Cell. Biol. 13, 4323-4330. Boudvillain, M., R. Dalbies, C. Aussourd and M. Leng (1995) Intrastrand cross- links are not formed in the reaction between transplatin and native DNA: relation with the clinical inefficiency of transplatin. Nucleic Acids Res. 23, 23812388. Brabec, V. and M. Leng (1993)DNA interstrand cross-links of transdiamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. Proc. Natl. Acad. Sci. (U.S.A.) 90, 5345-5349. Brabec, V., M. Sip and M. Leng (1993) DNA conformational change produced by the site-specific interstrand cross-link of trans-diamminedichloroplatinum(II). Biochemistry 32, 11676-11681. Bradley, L.J.N., K.J. Yarema, S.J. Lippard and J.M. Essigmann (1993) Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry 32, 982-988. Bramson, J. and L.C. Panasci (1993) Effect of ERCC-1 overexpression of sensitivity of chinese hamster ovary cells to DNA damaging agents. Cancer Res. 53, 3237-3240. Brown, S.J.,P.J. Kellett and S.J.Lippard (1993)Ixrl, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science 261,603-605. Bruhn, S.L., D.E. Housman and S.J.Lippard (1993)Isolation and characterization of cDNA clones encoding the Drosophilahomolog of the HMG-box SSRP family that recognizes specific DNA structures. Nucleic Acids Res. 21, 1643-1646. Bruhn, S.L., P.M. Pil, J.M. Essigmann, D.E. Housman and S.J. Lippard (1992) Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc. Natl. Acad. Sci. (U.S.A.) 89, 23072311. Bruhn, S.L.,J.H. Toney and S.J.Lippard (1990)Biological processing of DNA modified by platinum compounds. Progress in Inorganic Chemistry 38, 477-516. Bunker, C.A. and R.E. Kingston (1995) Identification of a cDNA for SSRP1, an HMG-box protein, by interaction with the c-Myc oncoprotein in a novel bacterial expression screen. Nucleic Acids Res. 23, 269-276. 50 Burkle, A., G. Chen, J.H. Kupper, K. Grobe and W.J. Zeller (1993) Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment. Carcinogenesis 14, 559-561. Bustin, M., D.A. Lehn and D. Landsman (1990)Structural features of the HMG chromosomal proteins and their genes. Biochim. Biophy. Acta 1049, 231-243. Calsou, P., J.M. Barret, S. Cros and B. Salles (1993) DNA excision repair synthesis is enhanced in a murine leukemia L1210 cell line resistant to cisplatin. Eur. J. Biochem. 211, 403-409. Calsou, P., P. Frit and B. Salles (1992) Repair synthesis by human cell extracts in cisplatin-damaged DNA is preferentially determined by minor adducts. Nucleic Acids Res. 20, 6363-6368. Chao, C.C.K. (1991)Potential negative regulation of damage-recognition proteins in cisplatin-resistant 59-66. HeLa cells in response to DNA damage. Mutation Res. 264, Chao, C.C.K. (1992) Damage-recognition proteins as a potential indicator of DNA-damage-mediated sensitivity or resistance of human cells to ultraviolet radiation. Biochem J. 282, 203-207. Chao, C.C.K., S.L. Huang, L.Y. Lee and S. Lin-Chao (1991a) Identification of inducible damage-recognition proteins that are overexpressed in HeLa cells resistant to cis-diamminedichloroplatinum (II). Biochem. J. 277, 875-878. Chao, C.C.K., Y.L. Lee, P.W. Cheng and S. Lin-Chao (1991b) Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells resistant to cis-diamminedichloroplatinum(II). Cancer Res. 51, 601-605. Chao, C.C.K., T.C. Shieh and H. Huang (1994) Use of a monoclonal antibody to detect DNA damage caused by the anticancer drug cis-diamminedichloroplatinum (II) in vivo and in vitro. FEBS Lett 354, 103-109. Chow, C.S., C.M. Barnes and S.J.Lippard (1995)A single HMG domain in HighMobility Group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct. Biochemistry 34, 2956-2964. Chow, C.S., J.P. Whitehead and S.J.Lippard (1994)HMG-domain proteins induce sharp bends in cisplatin-modified DNA. Biochemistry 33, 15124-15130. Chu, G. and E. Chang (1988) Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA. Science 242, 564-567. 51 Chu, G. and E. Chang (1990)Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc. Natl. Acad. Sci. (U.S.A.) 87, 33243327. Clugston, C.K., K. McLaughlin, M.K. Kenny and R. Brown (1992) Binding of human single-stranded DNA binding protein to DNA damaged by the anticancer drug cis-diamminedichloroplatinum (II). Cancer Res. 52, 6375-6379. Comess, K.M. (1991) M.I.T. Thesis Comess, K.M., J.N. Burstyn, J.M. Essigmann and S.J.Lippard (1992)Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-Diamminedichloroplatinum(II) DNA adducts. Biochemistry 31, 39753990. Connor, F., P.D. Cary, C.M. Read, N.S. Preston, P.C. Driscoll, P. Denny, C. Crane- Robinson and A. Ashworth (1994)DNA binding and bending properties of the post-meiotically expressed Sry-related protein Sox-5. Nucleic Acids Res. 22, 33393346. Corda, Y., C. Job, M. Anin, M. Leng and D. Job (1993) Spectrum of DNA- platinum adduct recognition by prokaryotic and eukaryotic DNA-dependent RNA polymerases. Biochemistry 32, 8582-8588. Costigan, C., I). Kolodrubetz and M. Snyder (1994)NHP6A and NHP6B, which encode HMG1-like proteins, are candidates for downstream components of the yeast SLT2 mitogen-activated 2403. protein kinase pathway. Mol. Cell. Biol. 14, 2391- Dabholkar, M., F. Bostick-Bruton, C. Weber, V.A. Bohr, C. Egwuagu and E. Reed (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. JNCI 84, 1512-1517. Dabholkar, M.D., M.S. Berger, J.A. Vionnet, C. Egwuagu, J.R. Silber, J.J. Yu and E. Reed (1995)Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2. Cancer Res. 55, 1261-1266. Danenberg, P.V., L.C.C. Shea, K.O. Danenberg and T. Horikoshi (1991) Inactivation of tetrahymena rRNA self-splicing by cisplatin proceeds through dissociable complexes. Nucleic Acids Res. 19, 3123-3128. Demarcq, C., R.T. Bunch, D. Creswell and A. Eastman (1994) The role of cell cycle progression in cisplatin-induced apoptosis in chinese hamster ovary cells. Cell growth and differentiation 5, 983-993. 52 Dempke, W.C.M., S.A. Shellard, L.L. Hosking, A.M.J. Fichtinger-Schepmann and B.T. Hill (1992)Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated Xirradiation in vitro. Carcinogenesis 13, 1209-1215. Denny, P., S. Swift, F. Connor and A. Ashworth (1992) An SRY-related gene expressed during spermatogenesis in the mouse encodes a sequence-specific DNA-binding protein. EMBO J. 11, 3705-3712. Diffley, J.F.X.and B. Stillman (1992)DNA binding properties of an HMG1related protein from yeast mitochondria. J. Biol.Chem. 267, 3368-3374. Donahue, B.A., M. Augot, S.F. Bellon, D.K. Treiber, J.H. Toney, S.J. Lippard and J.M. Essigmann (1990)Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry 29, 5872-5880. Dooijes, D., M. van de Wetering, L. Knippels and H. Clevers (1993) The Schizosaccharomyces pombemating-type gene mat-Mc encodes a sequence-specific DNA-binding high mobility group box protein. J. Biol.Chem. 268, 24813-24817. Eastman, A. and M.A. Barry (1987)Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione. Biochemistry 26, 3303-3307. Evans, D.L. and C. Dive (1993)Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res. 53, 2133-2139. Evans, D.L., M. Tilby and C. Dive (1994)Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. Cancer Res. 54, 1596-1603. Evans, M.K., J.H. Robbins, M.B. Ganges, R.E. Tarone, R.S. Naim and V.A. Bohr (1993)Gene-specific DNA repair in Xeroderma Pigmentosum complementation groups A, C, D, F. J. Biol. Chem. 268, 4839-4847. Fan, Z., J. Baselga, H. Masui and J. Mendelsohn (1993) Antitumor effect of anti- epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum(II) on well established A431 cell xenografts. Cancer Res. 53, 4637-4642. Ferrari, S., V.R. Harley, A. Pontiggia, P.N. Goodfellow, R. Lovell-Badge and M.E. Bianchi (1992) SRY, like HMG1, recognizes sharp angles in DNA. EMBO J. 11, 4497-4506. 53 Fisher, R.P., T. Lisowsky, M.A. Parisi and D.A. Clayton (1992)DNA wrapping and bending by a mitochondrial high mobility group-like transcriptional activator protein. J. Biol. Chem. 267, 3358-3367. Ganeva, R.L., N.C. Spassovska and D.D. Genchev (1991) The effect of some platinum compounds on the activity of the CTP synthetase of Ehrlich Ascites tumor cells: in vitro and in vivo studies. J. Inorganic Biochem. 43, 717-722. Gately, D.P., J.A. Jones, R. Christen, R.M. Barton, G. Los and S.B. Howell (1994) Induction of the growth arrest and DNA damage-inducible gene GADD153 by cisplatin in vitro and in vivo. Br. J. Cancer 70, 1102-1106. Gibbons, G.R., W.K. Kaufmann and S.G. Chaney (1991) Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells. Carcinogenesis 12, 2253-2257. Giese, K., J. Cox and R. Grosschedl (1992) The HMG domain of Lymphoid Enhancer Factor 1 bends DNA and facilitates assembly of functional nucleoprotein structures. Cell 69, 185-195. Giese, K. and R. Grosschedl (1993)LEF-1 contains an activation domain that stimulates transcription only in a specific context of factor-binding sites. EMBO J. 12, 4667-4676. Giese, K., J. Pagel and R. Grosschedl (1994)Distinct DNA-binding properties of the high mobility group domain of murine and human SRYsex-determining factors. Proc. Natl. Acad. Sci. (U.S.A.) 91, 3368-3372. Grosschedl, R., K. Giese and J. Pagel (1994)HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet. 10, 94-100. Guzder, S.N., P. Sung, L. Prakash and S. Prakash (1993)Yeast DNA-repair gene RAD14 encodes a zinc metalloprotein with affinity for ultraviolet-damaged DNA. Proc. Natl. Acad. Sci. (U.S.A.) 90, 5433-5437. Halmer, L. and C. Gruss (1995)Influence of histone H1 on the in vitro replication of DNA and chromatin. Nucleic Acids Res. 23, 773-778. Hamaguchi, K., A.K. Godwin, M. Yakushiji, P.J. O'Dwyer, R.F. Ozols and T.C. Hamilton (1993)Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 53, 5225-5232. Hanawalt, P.C. (1995) DNA repair comes of age. Mutation Res. 366, 101-113. 54 Hang, B., A.T. Yeung and M.W. Lambert (1993)A damage-recognition protein which binds to DNA containing interstrand cross-links is absent or defective in Fanconi anemia, complementation group A, cells. Nucleic Acids Res. 21, 41874192. Hansson, J. and R.D. Wood (1989)Repair synthesis by human cell extracts in DNA damaged by cis- and trans- diamminedichloroplatinum(II). Nucleic Acids Res. 17, 8073-8091. Hao, X.Y., J. Bergh, O. Brodin, U. Hellman and B. Mannervik (1994) Acquired resistance to cisplatin and doxorubicin in a small cell lung cancer cell line is correlated to elevated expression of glutathione-linked detoxification enzymes. Carcinogenesis 15, 1167-1173. Haqq, C.M., C.Y. King, P.K. Donahoe and M.A. Weiss (1993) SRY recognizes conserved DNA sites in sex-specific promoters. Proc. Natl. Acad. Sci. (U.S.A.) 90, 1097-1101. Hibino, Y., E. Kusashio, T. Terakawa and N. Sugano (1994)Enhancement of an Mg 2 +-dependent nuclease activity in rat liver cells exposed to cisplatin. Biochem Biophys Res Comm 202, 749-756. Houssier, C., M.C. Depauw-Gillet, R. Hacha and E. Fredericq (1983)Alteration in the nucleosome and chromatin structures upon interaction with platinum coordination complexes. Biochim. Biophy. Acta 739, 317-325. Hsu, T., D.L. King, C. LaBonne and F.C. Kafatos (1993) A Drosophila single-strand DNA/RNA-binding factor contains a high-mobility-group box and is enriched in the nucleolus. Proc. Natl. Acad. Sci. (U.S.A.) 90, 6488-6492. Huang, J.-C., D.B. Zamble, J.T. Reardon, S.J. Lippard and A. Sancar (1994) HMG- domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin. Proc. Natl. Acad. Sci. (U.S.A.) 91, 10394-10398. Huang, L., J. Turchi, A.F. Wahl and R.A. Bambara (1993)Effects of the anticancer drug cis-diamminedichloroplatinum(II) on the activities of calf thymus DNA polymerase e. Biochemistry 32, 841-848. Hughes, E.N., B.N. Engelsberg and P.C. Billings (1992) Purification of nuclear proteins that bind to cisplatin damaged DNA: identity with high mobility group proteins 1 and 2. J. Biol. Chem. 267, 13520-13527. Inoue, S., S. Mizuno, M. Ito and T. Ohnuma (1992) Flow cytometric analyses of the characteristics of tumor cells treated with two platinum compounds: 1,1- 55 cyclobutanedicarboxylato(2-aminomethylpyrrolidine)-platinum(II) and cisplatin. Jpn. J. Cancer Res. 83, 1231-1240. Ishikawa, T. and F. Ali-Osman (1993) Glutathione-associated cis- Diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. J. Biol. Chem. 268, 20116-20125. Isoe, T., M. Naito, A. Shirai, R. Hirai and T. Tsuruo (1992) Inhibition of different steps of the ubiquitin system by cisplatin and aclarubicin. Biochim. Biophys. Acta 1117, 131-135. Isonishi, S., D.K. Hom, A. Eastman and S.B. Howell (1994)Enhancement of sensitivity to platinum(II)-containing drugs by 12-O-tetradecanlyl-phorbol-13acetate in a human ovarian carcinoma cell line. Br J Cancer 69, 217-221. Isonishi, S., D.K. Hom, F.B. Thiebaut, S.C. Mann, P.A. Andrews, A. Basu, J.S. Lazo, A. Eastman and S.B. Howell (1991)Expression of the c-Ha-ras oncogene in mouse NIH3T3 cells induces resistance to cisplatin. Cancer Res. 51, 5903-5909. Jantzen, H.M., A. Admon, S.P. Bell and R. Tjian (1990) Nucleolar transcription factor hUBF contains a DNA-binding motif with homology to HMG proteins. Nature (London) 344, 830-836. Jeffrey, A.M., T.W. Jing, J.A. DeRose, A. Vaught, D. Rekesh, F.X. Lu and S.M. Lindsay (1993)Identification of DNA-cisplatin adducts in a blind trial of in situ scanning tunneling microscopy. Nucleic Acids Res. 21, 5896-5900. Jekunen, A.P., D.K. Hom, J.E. Alcaraz, A. Eastman and S.B. Howell (1994) Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatinsensitive and resistant human ovarian carcinoma cells. Cancer Res. 54, 2680-2687. Johnson, S.W., R.P. Perez, A.K. Godwin, A.T. Yeung, L.M. Handel, R.F. Ozols and T.C. Hamilton (1994a) Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 47, 689-697. Johnson, S.W., P.A. Swiggard, L.M. Handel, J.M. Brennan, A.K. Godwin, R.F. Ozols and T.C. Hamilton (1994b)Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res. 54, 5911-5916. Jones, C.J. and R.D. Wood (1993)Preferential binding of the Xeroderma pigmentosum Group A complementing protein to damaged DNA. Biochemistry 32, 12096-12104. 56 Jones, S.L., I.D. Hickson, A.L. Harris and P.R. Harnett (1994)Repair of cisplatinDNA adducts by protein extracts from human ovarian carcinoma. Int. J. Cancer 59, 388-393. Just, G. and E. Holler (1991) Enhanced levels of cyclic AMP, adenosine- (5')tetraphospho(5')adenosine and nucleoside 5'-triphosphates in mouse leukemia P388/D1 after treatment with cis-diamminedichloroplatinum(II). Biochemical pharmacology 42, 285-294. Kantor, G.J. and C.F. Elking (1988) Biological significance of domain-oriented DNA repair in Xeroderma Pigmentosum cells. Cancer Res. 48, 844-849. Kao, L.R., T.V. Megraw and C.B. Chae (1993) Essential role of the HMG domain in the function of yeast mitochondrial histone HM: functional complementation of HM by the nuclear nonhistone protein NHP6A. Proc. Natl. Acad. Sci. (U.S.A.) 90, 5598-5602. Keeney, S., G.J. Chang and S. Linn (1993)Characterization of a human DNA damage binding protein implicated in Xeroderma Pigmentosum E. J. Biol. Chem. 268, 21293-21300. Keeney, S., A.P.M. Eker, T. Brody, W. Vermeulen, D. Bootsma, J.H.J. Hoeijmakers and S. Linn (1994)Correction of the DNA repair defect in xeroderma pigmentosum group E by injection of a DNA damage-binding protein. Proc. Natl. Acad. Sci. (U.S.A.) 91, 4053-4056. Kikkawa, F., M. Kojima, H. Oguchi, O. Maeda, H. Ishikawa, K. Tamatoshi, K. Mizuno, M. Kawai, N. Suganuma and Y. Tomoda (1993) Potentiating effect of amphotericin B on five platinum anticancer drugs in human cis-diamminedichloroplatinum(II) sensitive and resistant ovarian carcinoma cells. Anticancer research 13, 891-896. King, C.Y. and M.A. Weiss (1993) The SRY high-mobility-group box recognizes DNA by partial intercalation in the minor groove: A topological mechanism of sequence specificity. Proc. Natl. Acad. Sci. (U.S.A.) 90, 11990-11994. Kohlstaedt, L.A. and R.D. Cole (1994) Specific interaction between H1 histone and High Mobility Protein HMG1. Biochemistry 33, 570-575. Kolodrubetz, D. and A. Burgum (1990)Duplicated NHP6 genes of Saccharomyces cerevisiaeencode proteins homologous to bovine high mobility group protein 1. J. Biol. Chem. 265, 3234-3239. Koopman, P., J. Gubbay, N. Vivian, P. Goodfellow and R. Lovell-Badge (1991) Male development of chromosomally female mice transgenic for Sry. Nature (London) 351, 117-127. 57 Kraulis, P.J. (1991)Molscript: a program to produce both detailed and schematic plots of protein structures. J Appl Cryst 24, 946-950. Krishnaswamy, G. and W.C. Dewey (1993)Cisplatin induced cell killing and chromosomal aberrations in CHO cells: treated during G1 or S phase. Mutation Research, DNA Repair 293, 161-172. Kruger, W. and I. Herskowitz (1991)A negative regulator of HO transcription, SIN1 (SPT2), is a nonspecific DNA-binding protein related to HMG1. Mol. Cell. Biol. 11, 4135-4146. Kuhn, A., R. Voit, V. Stefanovsky, R. Evers, M. Bianchi and I. Grummt (1994) Functional differences between the two splice variants of the nucleolar transcription factor UBF: the second HMG box determines specificity of DNA binding and transcriptional activity. EMBO J. 13, 416-424. Lambert, J.R., V.W. Bilanchone and M.G. Cumsky (1994) The ORD1 gene encodes a transcription factor involved in oxygen regulation and is identical to IXR1,a gene that confers cisplatin sensitivity to Saccharomycescerevisiae.Proc. Natl. Acad. Sci. (U.S.A.) 91, 7345-7349. Landsman, D. and M. Bustin (1991)Assessment of the transcriptional activation potential of the HMG chromosomal proteins. Mol. Cell. Biol. 11, 4483-4489. Landsman, D. and M. Bustin (1993)A signature for the HMG-1 box DNAbinding proteins. Bioessays 15, 539-546. Lawrence, D.L., B.N. Engelsberg, R.S. Farid, E.N. Hughes and P.C. Billings (1993) Localization of the binding region of High Mobility Group protein 2 to cisplatindamaged DNA. J. Biol. Chem. 268, 23940-23945. Lee, K., R. Parker, V. Bohr, T. Comelison and E. Reed (1993) Cisplatin sensitivity/resistance in UV repair-deficient chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 14, 2177-2180. Lemaire, M., A. Schwartz, A. Rahmouni and M. Leng (1991) Interstrand cross- links are preferentially formed at the d(GC) sites in the reaction between cisdiamminedichloroplatinum(II) and DNA. Proc. Natl. Acad. Sci. (U.S.A.) 88, 1982- 1985. Lepre, C.A. and S.J.Lippard (1990).Interaction of platinum antitumor compounds with DNA. Nucleic Acids and Molecular Biology Eds. F. Eckstein and D. M. J. Lilley. Heidelberg, Springer-Verlag. 58 Levin, B. (1994)Chromatin and gene expression: constant questions, but changing answers. Cell 79, 397-406. Levy, E., C. Baroche, J.M. Barret, C. Alapetite, B. Salles, D. Averbeck and E. Moustacchi (1994)Activated ras oncogene and specifically acquired resistance to cisplatin in human mammary epithelial cells: induction of DNA cross-links and their repair. Carcinogenesis 15, 845-850. Lippard, S.J. (1994).Structural and biological consequences of platinum anticancer drug binding to DNA. Proceedings of the Robert A. Welch Foundation 37th conference on chemical research, 40 years of the DNA double helix, October 1993 . 49-60. Locker, D., M. Decoville, J.C. Maurizot, M.E. Bianchi and M. Leng (1995) Interaction between cisplatin-modified DNA and the HMG boxes of HMG1: DNAse I footprinting and circular dichroism. J Mol Biol 246, 243-247. Maeda, Y., K. Hisatake, T. Kondo, K. Hanada, C.Z. Song, T. Nishimura and M. Muramatsu (1992)Mouse rRNA gene transcription factor mUBF requires both HMG-box 1 and an acidic tail for nucleolar accumulation: molecular analysis of the nucleolar targeting mechanism. EMBO J. 11, 3695-3704. Malinge, J.M., C. Perez and M. Leng (1994) Base sequence-independent distortions induced by interstrand cross-links in cis-diamminedichloroplatinum(II)-modified DNA. Nucleic Acids Res. 22, 3834-3839. Mamenta, E.L.,E.E. Poma, W.K. Kaufmann, D.A. Delmastro, H.L. Grady and S.G. Chaney (1994)Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 54, 3500-3505. May, A., R.S. Nairn, D.S. Okumoto, K. Wassermann, T. Stevnsner, J.C. Jones and V.A. Bohr (1993)Repair of individual DNA strands in the hamster dihydrofolate reductase gene after treatment with ultraviolet light, alkylating agents, and cisplatin. J. Biol. Chem. 268, 1650-1657. McClay, E.F., K.D. Albright, J.A. Jones, A. Eastman, R. Christen and S.B. Howell (1992)Modulation of cisplatin resistance in human malignant melanoma cells. Cancer Res. 52, 6790-6796. McEvoy, G.K., Ed. (1994). AHFS Drug Information. Bethesda, MD, American Society of Hospital Pharmacists, Inc. McLaughlin, K., G. Coren, J. Masters and R. Brown (1993)Binding activities of cisplatin-damage recognition proteins in human tumour cell lines. Int. J. Cancer 53, 662-666. 59 Megraw, T.V. and C.-B. Chae (1993)Functional complementarity between the HMG1-like yeast mitochondrial histone HM and the bacterial histone-like protein HU. J. Biol. Chem. 268, 12758-12763. Mellish, K.J. and L.R. Kelland (1994)Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichlorocyclohexylamine platinum (IV) (JM216)in two human ovarian carcinoma cell lines. Cancer Res. 54, 6194-6200. Moorehead, R.A., S.G. Armstrong, B.C.Wilson and G. Singh (1994)Crossresistance to cisplatin in cells resistant to photofrin-mediated photodynamic therapy. Cancer Res. 54, 2556-2559. Morikage, T., T. Ohmori, K. Nishio, Y. Fujiwara, Y. Takeda and N. Saijo (1993) Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines. Cancer Res. 53, 3302-3307. Murchie, A.I.H. and D.M.J. Lilley (1993) T4 endonuclease VII cleaves DNA containing a cisplatin adduct. J Mol Biol 233, 77-85. Murray, V., H. Motyka, P.R. England, G. Wickham, H.H. Lee, W.A. Denny and W.D. McFadyen (1992)The use of Taq DNA polymerase to determine the sequence specificity of DNA damage caused by cis-diamminedichloroplatinum(II), Acridine-tethered platinum(II) diammine complexes or two analogues. J. Biol. Chem. 267, 18805-18809. Mymryk, J.S., E. Zaniewski and T.K. Archer (1995)Cisplatin inhibits chromatin remodeling, transcription factor binding, and transcription from the mouse mammary tumor virus promoter in vivo. Proc. Natl. Acad. Sci. (U.S.A.)92, 20762080. Naser, L.J., A.L. Pinto, S.J. Lippard and J.M. Essigmann (1988)Chemical and biological studies of the major DNA adduct of cis-diamminedichloroplatinum(II), cis[Pt(NH 3 )2 (d(GpG)}], built into a specific site in a viral genome. Biochemistry 27, 4357-4367. Ner, S.S. and A.A. Travers (1994) HMG-D, the Drosophila melanogaster homologue of HMG 1 protein, is associated with early embryonic chromatin in the absence of histone H1. EMBO J. 13, 1817-1822. Ner, S.S., A.A. Travers and M.E.A. Churchill (1994)Harnessing the writhe: a role for DNA chaperones in nucleoprotein-complex formation. TIBS 19, 185-187. Nishio, K., Y. Sugimoto, K. Kasahara, Y. Fujiwara, S. Nishiwaki, H. Fujiki, M. Ohata and N. Saijo (1992)Increased phosphorylation of nuclear phosphoproteins 60 in human lung-cancer cells resistant to cis-diamminedichloroplatinum(II). Cancer 50, 438-442. Int. J. Oesterreich, S., H. Schunck, R. Benndorf and H. Bielka (1991) Cisplatin induces the small heat shock protein Hsp25 and thermotolerance in Ehrlich Acites tumor cells. Biochem Biophys Res Comm 180, 243-248. Oldenburg, J., A.C. Begg, M.J.H. van Vugt, M. Ruevekamp, J.H. Schornagel, H.M. Pinedo and G. Los (1994) Characterization of resistance mechanisms to cis- Diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro. Cancer Res. 54, 487-493. Olin, B.R., Ed. (1994). Drug facts and comparisons. St. Louis, Wolters Kluwer. Olinski, R. and R. Briggs (1991) DNA-protein cross-linking in L1210 cells sensitive and resistant to cis-diamminedichloroplatinum(II). Molecular Biology Reports 15, 81-86. Onate, S.A., P. Prendergast, J.P. Wagner, M. Nissen, R. Reeves, D.E. Pettijohn and D.P. Edwards (1994)The DNA-bending protein HMG-1 enhances progesterone receptor binding to its target DNA sequences. Mol. Cell. Biol. 14, 3376-3391. Ormerod, M.G., C.F. O'Neill, D. Robertson and K.R. Harrap (1994)Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exp Cell Res 211, 231-237. Parisi, M.A., B. Xu and D.A. Clayton (1993) A human mitochondrial transcriptional activator can functionally replace a yeast mitochondrial HMGbox protein both in vivo and in vitro. Mol. Cell. Biol. 13, 1951-1961. Park, C.H., D. Mu, J.T. Reardon and A. Sancar (1995)The general transcriptionrepair factor TFIIH is recruited to the excision repair complex by the XPA protein independent of the TFIIE transcription factor. J. Biol. Chem. 270, 4896-4902. Parker, R.J., I.W. Dimery, M. Dabholkar, J. Vionnet and E. Reed (1993) Platinum- DNA adduct in head and neck cancer patients receiving cisplatin and carboplatin chemotherapy. Int J Oncol 3, 331-335. Patterson, M. and G. Chu (1989)Evidence that Xeroderma Pigmentosum cells from complementation group E are deficient in a homolog of yeast photolyase. Mol. Cell. Biol. 9, 5105-5112. Paull, T.T. and R.C. Jonson (1995)DNA looping by Saccharomycescerevisiaehigh mobility group proteins NHP6A/B. J. Biol. Chem. 270, 8744-8754. 61 Payne, A. and G. Chu (1994)Xeroderma pigmentosum group E binding factor recognizes a broad spectrum of DNA damage. Mutation Res. 310, 89-102. Peng, H.Q., D. Hogg, D. Malkin, D. Bailey, B.L. Gallie, M. Bulbul, M. Jewett, J. Buchanan and P.E. Goss (1993)Mutations of the p53 gene do not occur in testis cancer. Cancer Res. 53, 3574-3578. Perras, J.P., R. Ramos and B.U. Sevin (1993) Demonstration of an S phase population of cells without DNA synthesis generated by cisplatin and pentoxifylline. Cytometry 14, 441-448. Peters, R., C.Y. King, E. Ukiyama, S. Falsafi, P.K. Donahoe and M.A. Weiss (1995) An SRY mutation causing human sex reversal resolves a general mechanism of structure-specific DNA recognition: application to the four-way DNA junction. Biochemistry 34, 4569-4576. Pil, P.M., C.S. Chow and S.J. Lippard (1993) High-mobility-group 1 protein mediates DNA bending as determined by ring closures. Proc. Natl. Acad. Sci. (U.S.A.) 90, 9465-9469. Pil, P.M. and S.J. Lippard (1992) Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 256, 234-237. Pontiggia, A., R. Rimini, V.R. Harley, P.N. Goodfellow, R. Lovell-Badge and M.E. Bianchi (1994)Sex reversing mutations affect the architecture of SRY-DNA complexes. EMBO J. 13, 6115-6124. Putnam, C.D., G.P. Copenhaver, M.L. Denton and C.S. Pikaard (1994) The RNA polymerase I transactivator upstream binding factor requires its dimerization domain and high-mobility-group (HMG) box 1 to bend, wrap, and positively supercoil enhancer DNA. Mol. Cell. Biol. 14, 6476-6488. Rampino, N.J. and V.A. Bohr (1994)Rapid gene-specific repair of cisplatin lesions at the human DUG/DHFR locus comprising the divergent upstream gene and dihydrofolate reductase gene during early G1 phase of the cell cycle assayed by using the exonucleolytic activity of T4 DNA polymerase. Proc. Natl. Acad. Sci. (U.S.A.) 91, 10977-10981. Read, C.M., P.D. Cary, C. Crane-Robinson, P.C. Driscoll and D.G. Norman (1993) Solution structure of a DNA-binding domain from HMG1. Nucleic Acids Res. 21, 3427-3436. Reardon, J.T., A.F. Nichols, S. Keeney, C.A. Smith, J.S. Taylor, S. Linn and A. Sancar (1993)Comparative analysis of binding of human damaged DNA-binding protein (XPE) and Escherichiacoli damage recognition protein (UvrA) to the major ultraviolet photoproducts. J. Biol. Chem. 268, 21301-21308. 62 Reed, E., R.J. Parker, I. Gill, A. Bicher, M. Dabholkar, J.A. Vionnet, F. Bostick- Bruton, R. Tarone and F.M. Muggia (1993)Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res. 53, 3694-3699. Reilly, P.A., N.A. Heerema, G.W. Sledge and C.G. Palmer (1993) Unusual distribution of chromosome 12 in a testicular germ-cell tumor cell line (833K) and its cisplatin-resistant derivative (64CP9).Cancer Genet Cytogenet 68, 114-121. Saksela, K., T. Makela and K. Alitalo (1989) Oncogene expression in small-cell lung cancer cell lines and a testicular germ- cell tumor: activation of the n-myc gene and decreased Rb mRNA. Int. J. Cancer 44, 182-185. Schmidt, W. and S.G. Chaney (1993)Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res. 53, 799-805. Schnapp, G., F. Santori, C. Carles, M. Riva and I. Grummt (1994) The HMG box- containing nucleolar transcription factor UBF interacts with a specific subunit of RNA polymerase I. EMBO J. 13, 190-199. Schwartz, A. and M. Leng (1994) DNase I footprinting of cis- or transDNA. J Mol Biol 236, 969-974. diamminedichloroplatinum(II)-modified Sheflin, L.G., N.W. Fucile and S.W. Spaulding (1993) The specific interactions of HMG1 and 2 with negatively supercoiled DNA are modulated by their acidic Cterminal domains and involve cysteine residues in their HMG1/2 boxes. Biochemistry 32, 3238-3248. Sheflin, L.G. and S.W. Spaulding (1989)High Mobility Group protein 1 preferentially conserves torsion in negatively supercoiled DNA. Biochemistry 28, 5658-5664. Sheibani, N., M.M. Jennerwein and A. Eastman (1989)DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. Biochemistry 28, 3120-3124. Sherman, S.E., D. Gibson, A.H.J. Wang and S.J. Lippard (1985) X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis[Pt(NH 3 ) 2 1d(pGpG)}]. Science 230, 412-417. Shirakata, M., K. Huppi, S. Usuda, K. Okazaki, K. Yoshida and H. Sakano (1991) HMG1-related DNA-binding protein isolated with V-(D)-Jrecombination signal probes. Mol. Cell. Biol. 11, 4528-4536. 63 Shivji, M.K.K., A.P.M. Eker and R.D. Wood (1994) DNA repair defect in Xeroderma pigmentosum group C and complementing factor from HeLa cells. J. Biol. Chem. 269, 22749-22757. Sibghat-Ullah, I. Husain, W. Carlton and A. Sancar (1989)Human nucleotide excision repair in vitro: repair of pyrimidine dimers, psoralen and cisplatin adducts by HeLa cell-free extract. Nucleic Acids Res. 17, 4471-4484. Singh, J. and G.-H.Dixon (1990)High Mobility Group proteins 1 and 2 function as general class II transcription factors. Biochemistry 29, 6295-6302. Sklar, M.D. and E.V. Prochownik (1991)Modulation of cis-platinum resistance in friend erythroleukemia cells by c-myc. Cancer Res. 51, 2118-2123. Sorenson, C.M., M.A. Barry and A. Eastman (1990)Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst. 82, 749-754. Sorenson, C.M. and A. Eastman (1988a)Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res. 48, 6703-6707. Sorenson, C.M. and A. Eastman (1988b) Mechanism of cis- diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res. 48, 4484-4488. Stolzenburg, F., E. Dinkl and F. Grummt (1992)Nucleotide sequence of a mouse cDNA encoding the non-histone chromosomal high mobility group protein-2 (HMG-2). Nucleic Acids Res. 20, 4927. Stros, M., J. Stokrova and J.O. Thomas (1994)DNA looping by the HMG-box domains of HMG1 and modulation of DNA binding by the acidic C-terminal domain. Nucleic Acids Res. 22, 1044-1051. Sundquist, W.I., S.J.Lippard and B.D. Stollar (1986)Binding of cis- and transdiamminedichloroplatinum (II) to deoxyribonucleic acid exposes nucleosides as measured immunochemically with anti-nucleoside antibodies. Biochemistry 25, 1520-1524. Suquet, C. and M.J. Smerdon (1993)UV damage to DNA strongly influences its rotational setting on the histone surface of reconstituted nucleosomes. J. Biol. Chem. 268, 23755-23757. Sweder, K.S. and P.C. Hanawalt (1994)The COOH terminus of suppresser of stem loop (SSL2/RAD25) in yeast is essential for overall genomic excision repair and transcription-coupled repair. J. Biol. Chem. 269, 1852-1857. 64 Szymkowski, D.E., K. Yarema, J.M. Essigmann, S.J. Lippard and R.D. Wood (1992)An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proc. Natl. Acad. Sci. (U.S.A.) 89, 10772-10776. Taverna, P., J. Hansson, K.J. Scanlon and B.T. Hill (1994) Gene expression in X- irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity. Carcinogenesis 15, 2053-2056. Teicher, B.A., S.A. Holden, V. Khandakar and T.S. Herman (1993) Addition of a topoisomerase I inhibitor to trimodality therapy (cis-diamminedichloroplatinum(II)/heat/radiation) in a murine tumor. J Cancer Res Clin Oncol 119, 645-651. Timmer-Bosscha, H., A. Timmer, C. Meijer, E.G.E. de Vries, B. de Jong, J.W. Oosterhuis and N.H. Mulder (1993)cis-Diamminedichloroplatinum(II) resistance in vitro and in vivo in human embryonal carcinoma cells. Cancer Res. 53, 57075713. Toney, J.H., B.A. Donahue, P.J. Kellett, S.L. Bruhn, J.M. Essigmann and S.J. Lippard (1989)Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II). Proc. Natl. Acad. Sci. (U.S.A.) 86, 8328-8332. Travis, A., A. Amsterdam, C. Belanger and R. Grosschedl (1991) LEF-1, a gene encoding a lymphoid-specific with protein, an HMG domain, regulates T-cell receptor ccenhancer function. Genes Dev. 5, 880-894. Treiber, D.K., X. Zhai, H.M. Jantzen and J.M. Essigmann (1994)Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc. Natl. Acad. Sci. (U.S.A.) 91, 5672-5676. Tremethick, D.J. and P.L. Molloy (1988)Effects of high mobility group proteins 1 and 2 on initiation and elongation of specific transcription by RNA polymerase II in vitro. Nucleic Acids Res. 16, 11107-11123. Twentyman, P.R., K.A. Wright, P. Mistry, L.R. Kelland and B.A. Murrer (1992) Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res. 52, 56745680. Vaisman, A. and S.G. Chaney (1995)Induction of UV-damage recognition protein by cisplatin treatment. Biochemistry 34, 105-114. 65 van de Wetering, M. and H. Clevers (1992)Sequence-specific interaction of the HMG box proteins TCF-1 and SRYoccurs within the minor groove of a WatsonCrick double helix. EMBO J. 11, 3039-3044. van de Wetering, M., M. Oosterwegel, K. van Norren and H. Clevers (1993)Sox4, an Sry-like HMG box protein, is a transcriptional activator in lymphocytes. EMBO J. 12, 3847-3854. van Garderen, C.J. and L.P.A. van Houte (1994)The solution structure of a DNA duplex containing the cis-Pt(NH3) 2 [d(-GTG-)-N7(G),N7(G)]adduct, as determined with high-field NMR and molecular mechanics/dynamics. Eur. J. Biochem. 225, 1169-1179. van Hoffen, A., A.T. Natarajan, L.V. Mayne, A.A. van Zeeland, L.H.F. Mullenders and J. Venema (1993)Deficient repair of the transcribed strand of active genes in Cockayne's syndrome cells. Nucleic Acids Res. 21, 5890-5895. Varga-Weisz, P., K. van Holde and J. Zlatanova (1994)Competition between linker histones and HMG1 for binding to four-way junction DNA: implications for transcription. Biochem Biophys Res Comm 203, 1904-1911. Venema, J., A. van Hoffen, V. Karcagi, A. Natarajan, A. van Zeeland and L. Mullenders (1991)Xeroderma pigmentosum complementation group C cells remove pyrimidine dimers selectively from the transcribed strand of active genes. Mol Cell Biol 11, 4128-4134. Verhage, R., A.-M. Zeeman, N. de Groot, F. Gleig, D.D. Bang, P. van de Putte and J. Brouwer (1994)The RAD7 and RAD16 genes, which are essential for pyrimidine dimer removal from the silent mating type loci, are also required for repair of the nontranscribed strand of an active gene in Saccharomycescerevisiae. Mol. Cell. Biol. 14, 6135-6142. Villiani, G., M.J. Pillaire and P.E. Boehmer (1994)Effect of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum(II) of the activity of a helicase essential for DNA replication, the Herpes Simplex Virus Type-i origin binding protein. J. Biol. Chem. 269, 21676-21681. Vilpo, J.A., L.M. Vilpo, D.E. Szymkowski, A. O'Donovan and R.D. Wood (1995) An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells. Mol. Cell. Biol. 15, 290-297. Waga, S., S. Mizuno and M. Yoshida (1989)Nonhistone proteins HMG1 and HMG2 suppress the nucleosome assembly at physiological ionic strength. Biochim. Biophy. Acta 1007, 209-214. 66 Wang, L., P. Precht, R. Balakir and W.E. Horton Jr. (1993) Rat and chick cDNA clones encoding HMG-like proteins. Nucleic Acids Res. 21, 1493. Watt, F. and P.L. Molloy (1988)High mobility group proteins 1 and 2 stimulate binding of a specific transcription factor to the adenovirus major late promoter. Nucleic Acids Res. 16, 1471-1486. Weir, H.M., P.J. Kraulis, C.S. Hill, A.R.C. Raine, E.D. Laue and J.O. Thomas (1993) Structure of the HMG box motif in the B-domain of HMG1. EMBO J. 12, 1311-1319. Werner, M.H., J.R. Huth, A.M. Gronenborn and G.M. Clore (1995)Molecular basis of human 46X,Ysex reversal revealed from the three-dimensional solution structure of the human SRY-DNA complex. Cell 81, 705-714. Whitehead, J.P. and S.J. Lippard (1995)Purification of the yeast protein, Ixrl(Ordl), and characterization of its specific binding to a cisplatin intrastrand d(GpG) cross-link in DNA. in preparation. Wood, D.P., E. Klein, W.R. Fair and R.J.K. Chaganti (1993) Metallothionein gene expression in bladder cancer exposed to cisplatin. Modern Pathology 6, 33-35. Yarema, K.J.,J.M. Wilson, S.J.Lippard and J.M. Essigmann (1994)Effects of DNA adduct structure and distribution on the mutagenicity and genotoxicity of two platinum anticancer drugs. J Mol Biol 236, 1034-1048. Yellin, S.A., B.J. Davidson, J.T. Pinto, P.G. Sacks, C. Qiao and S.P. Schantz (1994) Relationship of glutathione and glutathione-S-transferase to cisplatin sensitivity in human head and neck squamous carcinoma cell lines. Cancer Lett 85, 223-232. Zhen, W., M.K. Evans, C.M. Haggerty and V.A. Bohr (1993)Deficient gene specific repair of cisplatin-induced lesions in xeroderma pigmentosum and Fanconi's anemia cell lines. Carcinogenesis 14, 919-924. Zhen, W., C.J. Link, P.M. O'Connor, E. Reed, R. Parker, S.B. Howell and V.A. Bohr (1992)Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin- resistant human ovarian cancer cell lines. Mol. Cell. Biol. 12, 3689-3698. Zwilling, S., H. Konig and T. Wirth (1995)High mobility group protein 2 functionally interacts with the POU domains of octamer transcription factors. EMBO J. 14, 1198-1208. 67 68 Figure 1.1. Structure of various platinum compounds. a) Cisplatin or cisdiamminedichloroplatinum(II). b) [Pt(en)C12]or ethylenediaminedichloroplatinum(II). c) Carboplatin. d) trans-DDPor trans-diamminedichloroplatinum(II). e) [Pt(dien)C1]+or diethylenetriaminechloroplatinum(II) 69 Active antitumor complexes a) b) H3 N C1 /-7 H2N NH2 Pt H3N Pt C1 C1 C1 Cisplatin Pt(en)C1 2 O c) H3N Pt H3N O O 0 Carboplatin Inactive complexes d) + C1 H3N e) H2 N Pt C1 NH Pt NH3 trans-DDP C1 NH 2 Pt(dien)Cl+ 70 Figure 1.2. Adducts formed by cisplatin adducts. a) GG and AG intrastrand adducts. Structure was adapted from Sherman et al. (1985)and represents cisplatin bound to single-stranded d(pGpG). b) GXG intrastrand adducts. c) Interstrand adducts. d) DNA-protein cross-links. e) Monofunctional adducts. 71 a) GG, AG crosslinks G GI G A )NA 32-34° 130 _NH 3 Pt N NH K / 3 /NH 3 Pt NH3 b) GXG crosslinks Intrastrand adducts (90-95%) c) Interstrand adducts (1-5%) N [H3 /NH 3 Pt NH 3 G, G I G NH 3 Pt-NH 3 I G Pt ili:2.> ,.,.,,,::,,.-... NH3 . -. d) DNA-protein crosslinks (< 1%) H20 e) Monofunctional adducts (<1%) 72 Figure 1.3. Types of cancer that cisplatin therapy is effective against. Cisplatin is used on its own or in combination with other drugs to treat all the marked types of cancer. 73 and Cancer reast 7ancer Small Cell Lung Cance Ovarian Cancer Advan( Bladdel Cancer Cer Carcinoma dometrial .ncer sticular ncer Leukemia 74 Figure 1.4. Excision repair. The excision repair process begins with adduct recognition and incision of the DNA; these steps are performed by the proteins detailed in Fig. 1.5. The resulting gap is filled by DNA polymerases and closed by DNA ligase. 75 -~-~ Cisplatin GG .0- GG dduct is recognized air proteins -4 > Adduct is excised by repair proteins d Gap is filled in by polyl and closed with GG 76 Figure 1.5. Excision repair proteins. Human, rodent and yeast proteins are highly similar; not all proteins in each species have been cloned. The picture at the bottom gives some indication about the interaction of the yeast excision repair proteins. These interactions are described in more detail in chapter 3. 77 Human Rodent Yeast Radl4 XP-A (XPAC) Comments XPACbinds cisplatin and uv damaged DNA. Rad 14 binds uv damaged DNA. XP-B (XPBC) ERCC3 Rad 4 XP-C (XPCC) XP-D (XPDC) Rad25 ERCC2 Rad3 Bandshifts cisplatin damaged DNA. XP-E (XPEC) XP-F XP-G (XPGC) ERCC5 Rad2 CS-A CS-B ERCC6 ERCC1 Rad 10 Removing ERCC1 affects cisplatin adduct repair. Rad 1 Proteins for yeast DNA excision repair 'Components of transcription factor TFIIH 78 Figure 1.6. HMG1 and HMG domain protein DNA binding sites. A) a schematic view of the three domains of HMG1. B. The various types of DNA bound by HMG domain proteins. Not all types of DNA are bound equally well. 79 A. HMG domains A acidic tail B E'//////////7//17/I// B. four-way junction single-stranded DNA AA CAAAG TT specific sequence Pt H3 N small circular DNA NH 3 cisplatin-DNA adducts 80 Figure 1.7. Structure of HMG1 domain B as determined in a two-dimensional NMR spectroscopic study. The amino terminus is in the upper right-hand corner. The drawing was made with Molscript (Kraulis 1991) from coordinates kindly supplied by C. Read and C. Crane-Robinson. 81 \ .:: U~ 82 Figure 1.8. Repair shielding theory. HMG domain proteins may bind the cisplatin-DNA adduct and shield the adduct from the repair protein complex. 83 Repair --------P- 1 Repair Complex I HMG domain protein Repair Blocked 85 86 Figure 1.9. Titration hypothesis. HMG domain proteins bind to their normal site and activate or repress the transcription of gene X. When cells are treated with cisplatin, HMG domain proteins may be titrated away from their natural binding sites and the transcription of gene X is not properly regulated. 87 ,. HMG domain protein -10 4 addu per cell Small number of normal binding sites Transcription activation or repression of gene X Protein not bound to normal site so the transcription of gene X is not properly regulated 89 90 Figure 1.10. Interruption of genes in Saccharomycescerevisiae.The yeast cell used lacks a particular selectable marker, in this case the gene for Leu2, a protein involved in leucine biosynthesis. These cells require leucine to grow. An interrupted copy of the IXR1 (or any other) gene was constructed on a plasmid, which was cut to give a piece of DNA that the yeast cells could not replicate. The plasmid fragment was transformed into the yeast strain. Recombination between the plasmid fragment and the yeast genomic DNA occurred at a low level. Yeast strains where recombination has occurred have a viable copy of the LEU2 gene. These cells are selected by growth on media lacking leucine. 91 Yeast cell (leu2) / 7- x IXR -IXR1 "4,24 Plasmid fragment ixrl Transform with plasm ' IXR1 LEU2 occurs LE U2 Select for yeast cells with LEU2 gene by growing on media lacking leucine 3' IXR1 92 93 CHAPTER 2 Cisplatin and yeast cells 94 INTRODUCTION The difference in cisplatin sensitivity between yeast cells with the gene for HMG domain protein Ixrl (IXR1) and those without (ixrl) indicates that Ixrl mediates cisplatin cytotoxicity (Brown et al., 1993). Further investigation of Ixrl (Fig. 2.1a) and other HMG domain proteins may help in designing better cisplatin-related antitumor drugs. A series of experiments was performed to determine what aspect of Ixrl causes the difference in cisplatin sensitivity. The lack of sensitivity of the ixrl strain could be due to the cisplatin-DNA adduct binding properties of Ixrl or it could be related to the actual function of Ixrl. Yeast HMG domain proteins The ability of two other SaccharomycescerevisiaeHMG domain proteins to bind to cisplatin-DNA adducts was investigated. ABF2is made in the mitochondria, but it is present in both nucleus and mitochondria (Diffley and Stillman, 1992;Megraw and Chae, 1993). Roxl (Fig. 2.1b) belongs to the other class of HMG domain proteins, those that bind specific sequences and activate or repress transcription (Balasubramanian et al., 1993). Roxl represses transcription from the sequence YYYATTGTTCTCon a number of proteins used for respiration under hypoxic conditions (Lowry and Zitomer, 1988;Lowry et al., 1990). Naturalfunction of Ixrl Ixrl and Roxl both regulate the transcription of cytochrome c oxidase subunit V (CoxV) (Zitomer and Lowry, 1992;Lambert et al., 1994). There are two isoforms of CoxV, CoxVa, which is used under aerobic conditions, and CoxVb, which is used under hypoxic conditions (Hodge et al., 1989). The genes encoding the CoxV proteins are called COX5a and COX5b. Expression of the CoxV isoforms is regulated by several different proteins (Fig. 2.2). Ixrl represses the expression of the COX5b gene but does not affect the 95 expression of COX5a (Lambert et al., 1994). The conditions which relieve the Ixrl repression are unknown. Roxl represses the expression of COX5b in an oxygendependent manner (Zitomer and Lowry, 1992). Both ixrl and roxl mutants express COX5b. Both genes are repressed by glucose, COX5a by HAP2/3/4 and COX5b directly by MIG1 (Zitomer and Lowry, 1992;de Winde and Grivell, 1993). TUP1 and SSN6 are involved in both oxygen and glucose regulation of proteins; they activate different proteins based on which stimuli are present (Williams and Trumbly, 1990;Zhang et al., 1991;Trietel and Carlson, 1995). There are other proteins used under hypoxic conditions in the respiration pathway, which indicates how important such proteins are to the cells. Cytochrome c is encoded by two isoforms, CYC1 and CYC7 (Laz et al., 1984). CYC1 is used under normal conditions whereas CYC7 is used under hypoxic conditions. These proteins are regulated by using some of the same systems as COX5a and COX5b (Zitomer and Lowry, 1992). Neither these two nor any of the other hypoxic or aerobic respiration genes investigated were regulated by Ixrl (Lambert et al., 1994). The cell seems to need different isoforms of some proteins when the oxygen level is low. This phenomenon is also present in mammalian cells (Wang and Semenza, 1993). Yeast CoxVb stimulated both higher turnover rates and higher rates of heme oxidation by cytochrome c oxidase (Waterland et al., 1991), probably because subunit V affects ligand binding at the oxygen site and alters the heme a environment (Allen et al., 1995). When the pairs of cytochrome c-cytochrome c oxidase proteins used under aerobic and hypoxic conditions were compared, they had very similar activities (Allen et al., 1995). The changes that Cyc7 caused counterbalanced the changes that CoxVb caused. It is possible that the cell only wants to make small, subtle changes in this pathway under hypoxic conditions. 96 Growthof yeast S. cerevisiaecan grow in several different manners (Ausubel et al., 1994), and such differences may affect the cisplatin cytotoxicity assay. Yeast can be either haploid or diploid; all of the strains examined in this thesis were haploid strains. Yeast can either ferment carbon sources such as glucose, or it can aerobically respire by using its mitochondria. When there is glucose (dextrose) in the media, many genes are repressed, including the COX5 genes (Fig. 2.2). Ixrl is present in cells grown on dextrose. Yeast can also ferment other carbon sources such as galactose, but they prefer glucose. Aerobic respiration only occurs if the yeast are grown on non-fermentable substrates such as lactate, glycerol, and ethanol. Cytochrome c oxidase is required for aerobic respiration. When yeast are grown in liquid media with dextrose, they enter and go through exponential growth by fermenting the dextrose. When the dextrose is exhausted, they undergo a diauxic shift to aerobic respiration. The postdiauxic phase then lasts for several days during which time the cells grow substantially more slowly. After 7-8 days, the yeast cells enter stationary phase, which is characterized by cell cycle arrest (Werner-Washburne et al., 1993). The difference in cisplatin sensitivity between IXR1 and ixrl strains was seen only when cells were grown past exponential phase (S. Brown, personal communication and data presented here). The cells were not grown long enough to have entered into stationary phase. Therefore, it is important to consider what changes may have occurred between exponential growth and the time when the assay is conducted. The conditions under which the difference in cisplatin sensitivity is measurable may give some important indications as to how Ixrl affects cisplatin cytotoxicity. Even if no such information is found, it is important to understand under what conditions this assay functions so that other studies can be appropriately designed. 97 Ixrl experiments Experiments were performed to investigate what features of Ixrl and the yeast cells are involved in the making ixrl cells less sensitive to cisplatin than IXR1 cells. The effect of interrupting IXR1 on the cisplatin sensitivity of yeast cells was confirmed in two different backgrounds of yeast. Other yeast HMGdomain proteins were investigated for cisplatin binding. Ixrl was overexpressed in ixrl cells to show that it is actually the lack of Ixrl that is causing the difference. Cytotoxicity assays were performed on cells with mutant forms of Ixrl, Cox5a interruptions, and Roxl interruptions, demonstrating that the difference in cisplatin cytotoxicity is not due to the ixrl cells having higher levels of CoxVb. Finally, cytotoxicity assays were performed under a number of different growth conditions to determine what effect the state of the yeast cells might have on the cisplatin sensitivity of IXR1 and ixrl strains. These experiments indicate that it is the HMG domain of Ixrl that is crucial, not its function in repressing COX5b expression. MATERIALS AND METHODS Yeast Strains and Plasmids The yeast strains in Table I were obtained or constructed. Plasmid pMet is an Escherichiacoli plasmid that includes the Met promoter in the polylinker and was obtained from the laboratory of G. Fink, M.I.T.. The ABF2 knockout plasmid, pAMI::Trpl, was obtained from the laboratoryof B. Stillman, Cold Spring Harbor. The IXR1 interruption plasmid pSB5 and pSB4, the E. Coli plasmid containing the IXR1 gene were described in Brown, et al. (1993). pCD43, obtained from the laboratory of L. Guarente, M.I.T., and pYes2 (Invitrogen) were yeast expression plasmids. Plasmid pSL301 (Invitrogen) was a plasmid with a superlinker containing 50 restriction enzyme sites. pCox5a was a yeast 98 expression plasmid containing the COX5a gene linked to its genomic promoter, and was obtained from the laboratory of M. Cumsky, U.C. Irvine. Constructionof IXRl Aabf2and BWGAixrl strains The two genes were disrupted by transforming the wild type strains with plasmid fragments containing the gene interrupted by a selectable marker (Ausubel et al., 1994). Cells with the gene disruptions were selected by growing the transformed cells on synthetic media lacking either leucine or tryptophan such that only the presence of the interrupting gene permitted cell growth. The construction of the BWGAixrl strain was confirmed by Southwestern blot (Pil and Lippard, 1992), which examines the level of protein present by running an SDS-PAGE gel, transferring the proteins to nitrocellulose and probing the nitrocellulose with radiolabelled DNA modified by cisplatin. The strain was also examined by Southern blot (Ausubel et al., 1994). The blot was probed with a fragment of IXR1 that is present in both the interrupted and wild-type genes. The construction of IXRlAabf2was confirmed by Southwestern blotting. Bandshift assay Bandshift assays were performed with a 123 bp probe treated with various DNA damaging agents in the presence and absence of Ixrl. The 123 bp probe was treated with cisplatin to an (Drug/Nucleotide)bound ((D/N)b) of 0.022, with trans-DDPto an (D/N)b of 0.053, with [Pt(dien)Cl]+ to an (D/N)b of 0.07, and with UV light by irradiating on ice with 10,000Joules/m 2 at 254 nm with a germicidal lamp. The [Pt(dien)Cl]+ and UV light treated probes were constructed by Pieter Pil (thesis, 1993). The bandshift was performed (Whitehead and Lippard, 1995) and run on a 7.5% non-denaturing polyacrylamide gel. Cytotoxicity assays Yeast cells were grown to saturation in 20 mL of YPD media (Ausubel et al., 1994) for approximately 64 hours at 30°C. Portions containing 2x10 7 cells of 99 each strain were centrifuged to remove the media and resuspended in 1 mL of SD media, pH 6.5 (Ausubel et al., 1994) plus 0 to 1 mM cisplatin. The cells were incubated in an Eppendorf tube with gentle rocking for 2 hours at 30°C. The medium containing cisplatin was removed by pelleting the cells, which then were resuspended in SD medium, diluted, and plated at 20 to 200 cells per plate. Three identical YPD plates were made for each level of platination. The plates were grown for 3 days in a 30°C incubator. Colonies on the plates were counted and the percent survival at the various concentrations was calculated relative to controls treated identically except for the lack of cisplatin. Each strain was assayed in three to five separate experiments and results from a representative experiment are shown in the figures. The error bars in the percent survival plots show a 2a level derived from colony counts on the three identical plates and do not represent multiple experiments. The data were evaluated by fitting a line to the log of the percent survival. The ln(% survival) was used because, when a least squares fit was attempted to percent survival data, points below 1% survival were insufficiently weighted. The slope of the line corresponds to k in the expression % survival=exp(-k[cisplatin]) used to fit the data. The reported values for k are an average of three to five separate experiments. Variations to this procedure are detailed below and in the Results section. The same medium was always used for growing cells and for plating the cells. Experiments where the cells were grown in media without dextrose were treated in SD media using the appropriate sugars instead of dextrose. Constructionof Ixrl expressionplasmids pYY (pYes2-Ixrl) and pCY (pCD43-Ixrl) were constructed by placing the IXR1 gene downstream from the GALl promoter (Fig. 2.3, Table II). pCD43 has a CEN origin and is present at 1-2 copies per cell. pYes2 has a 2g origin of replication and is present at 1-50 copies per cell; this plasmid is lost more readily 100 than pCD43 but produces a higher level of expression. The IXR1gene was cut out of pSB4 with AccI and SnaBI,and the piece was isolated by agarose gel electrophoresis. pSL301 was digested with EcoRV and SacI, and the vector fragment was isolated. The two fragments were ligated together to form pSL301Ixrl, with the IXR1gene in the polylinker. The large BamHI-SacIfragment of pCD43 was ligated to the BamHI-SacIfragment of pSL301-Ixrl containing IXR1 to form pCY. Similarly, pSL301-IXR1and pYes2 were digested with BamHI and XhoI and the appropriate fragments were isolated and ligated together to form pYY. pMM1 has IXR1 expressed by the Met promoter (Fig 2.3, Table II). The Met promoter was cut out of pMet with XbaI and EcoRV and isolated on an agarose gel. pYY (pYes-Ixrl) was cut with BamHI which was filled in with Klenow. The linear plasmid was then cut with SpeI. This procedure removed the Gal promoter from pYY. The Met promoter was then ligated to this vector. The resultant plasmids were analyzed for the correct size and restriction enzyme cleavage patterns, which confirmed that pMet had been inserted into the correct location. Cytotoxicityassays using Ixrl expressionplasmids Cytotoxicity assays were performed by growing BWG and BWGAixrl cells with either the control plasmid pCD43 or the expression plasmid pCY. The cells were grown to exponential phase in SCAUmedia (2% lactate, 3% glycerol) (Ausubel et al., 1994),and induced by adding 2% galactose. The cells were treated with cisplatin in SD (2% galactose) media (Ausubel et al., 1994). The cells were never permitted to enter late log phase, where small daughter cells cause the cell population to become heterogeneous. The cell density and growth rate of the cells were also monitored, and the different strains used in the cytotoxicity assays were all brought to the same state. Unless this operation was performed, 101 the results were highly variable. Cells were plated onto SCAU(2% galactose) plates. Anaerobic cytotoxicity assays All solutions used were degassed by bubbling argon through them for 0.5 hr for 5 mL volumes to 1 hr for larger volumes. Cells were grown by inoculating the media aerobically into 16 mm glass screw cap tubes, then degassing the cells plus media with a sterile cannula through a sterile septum. The tubes were pumped into the wet box so that the screw cap could be put on the tube; parafilm was then wrapped around the cap. The cells were grown in a shaking incubator at 30°C for three days. The ability of this system to keep the media oxygen-free was tested by using oxygen sensitive probes (BBLGas Pak disposable anaerobic indicator). The cisplatin treatment was performed in an anaerobic chamber (wet box). The cells were treated as stated above, except that the platinations were performed on a rocker in the wet box, at room temperature, about 25°C. The cells were centrifuged with a microcentrifuge in the wet box. They were plated as detailed above, except that all procedures were carried out in the wet box. Prior to being brought into the box, the plates were treated overnight in the BBLGas pak oxygen removal system; the removal of the oxygen was confirmed with oxygen sensitive probes (BBLGas Pak disposable anaerobic indicator). The plates were pumped into the box still in the BBLGas pak apparatus (Becton, Dickinson, Inc.), which is basically a large jar that can hold the appropriate atmosphere. After the cells were put on the plates, they were transferred back into the BBLGas pak apparatus, removed from the box, and grown for three days at 30°C. After those three days of anaerobic growth, they were removed and grown aerobically so that the colonies could be easily counted. The oxygen indicators were always present while the plates were growing, and did not change color until the plates were removed from the apparatus. 102 RESULTS CytotoxicitydifferencebetweenIXR1 and ixrl strains The difference in cisplatin cytotoxicity between IXR1 and ixrl was present in two different strains of yeast, both of which are significantly different from the original IXR1strain. JM43 and its related mutants were constructed originally by the laboratory of M. Cumsky, U.C. Irvine. These cells differed from the IXR1 cells in genotype and they grew significantly more rapidly. The JM43 strain was not as sensitive to cisplatin as the IXR1 strain, as can be seen from the smaller k value (Table III). The relative sensitivities of strains to cisplatin was quantified as detailed in the materials and methods section; the exponential slope of the equation %Survival = exp(-k[Cisplatin]) was found. The slopes corresponding to two strains were compared, because it is incorrect to compare the relative sensitivities at a specific cisplatin concentration (S. Tannenbaum, personal communication). The slope can be easily converted into LD50 values, or any other similar measure (LD50 = ln(0.5)/k). The JM43Aixrl strain was significantly less sensitive to cisplatin than the JM43strain (Fig. 2.4). The difference between these two strains was even greater than that for the IXR1and ixrl strains; the ratio of the slopes was as high as 6.5, whereas the ratio for the IXR1and ixrl strains only went as high as 2.1 (Table III). The other strain of yeast examined, BWG1-7A,was obtained from the laboratory of L. Guarante, M.I.T.. These cells have a different genotype than the IXR1 or JM43 strains; they grew at about the same rate as the IXR1 cells. The BWG strain was more apt to lose its mitochondria when grown on YPD plates, resulting in small colonies that could not respire. The ixrl mutant of BWG, BWGAixrl, was constructed by interrupting the IXR1gene with LEU2. The interruption of IXR1 was confirmed by Southwestern and Southern blots (Fig. 2.5). The Southwestern blot showed that no Ixrl was present. The Southern blot 103 verified that the IXR1 gene had an insert of the appropriate size. The BWG strain was significantly more sensitive to cisplatin than the other two strains (Table III). The BWGAixrl strain was less sensitive to cisplatin than the BWG strain by 1.65 fold (Fig. 2.6, Table III). This difference was approximately the same as that in the IXR1strain. The results with the BWG and JM43strains confirmed the difference between IXR1 and ixrl strains in two different backgrounds of yeast. These results indicate that the difference in cisplatin sensitivity between the IXR1 and ixrl strains was not due to an unrelated mutation that may have occurred when constructing the ixrl strain. Ixrl binding to damagedDNA A bandshift assay demonstrated that Ixrl bound specifically to cisplatin treated DNA (Fig. 2.7). Ixrl did not bind to DNA treated with trans-DDP, [Pt(dien)C1]+ , which forms monofunctional adducts, or UV light. Roxl, an HMG domain protein Roxl is an unusual HMG domain protein because there are five amino acids in the middle of the domain, dividing it into two separate pieces that are homologous to other HMG domains (Fig. 2.1b). A JM43Aroxl strain was obtained and treated with cisplatin (Fig. 2.8). There was no significant difference between JM43 and JM43Aroxl (Fig. 2.8, Table III). The unusual structure and the unexpected behavior of this HMG domain protein led us to obtain a Roxl expression vector and determine whether it bound to cisplatin-DNA adducts. Up to this time, all HMG domain proteins that had been analyzed had been found to bind to cisplatin. Results from the Lippard laboratory (N. L. Raju, unpublished data) and the Cumsky laboratory (J.Lambert, personal communication) indicate that Roxl does not bind to cisplatin-DNA adducts. Furthermore, no band of the correct molecular weight is visible in Southwestern blots performed on yeast cell extracts of ixrl strains (Fig. 2.5, for example). These 104 results indicate that Roxl does not actually bind to cisplatin-DNA adducts, and thus, no difference in cisplatin sensitivity could be expected. Roxl is currently the only HMG domain protein known not to bind to cisplatin-DNA adducts. Abf2, an HMG domain protein An abf2mutant was constructed in the IXR1strain by interrupting ABF2 with TRP1. This mutant was characterized by Southwestern blotting (Fig. 2.9). Since this protein is so much smaller than Ixrl, a higher percentage SDS-PAGE gel was run and the Ixrl bands do not resolve well at the top of the gel, so they were not included in the figure. The two abf2strains tested were both missing the same band, indicating that the band is Abf2 and that Abf2 does indeed bind cisplatin-DNA adducts. Unfortunately, when cisplatin cytotoxicity assays were attempted, it became clear that abf2cells did not grow as well as ABF2 cells, a result previously noted in the literature (Diffley and Stillman, 1992). The exact state of growth of cells makes a large difference in their cisplatin sensitivity. ABF2 and abf2 cells could not be compared because they could not be grown similarly enough that any results would be valid. Ixrl overexpressionstudies Ixrl was expressed in yeast cells to demonstrate further that it is responsible for the cisplatin cytotoxicity difference between IXR1 and ixrl strains. It is also possible that if enough Ixrl could be expressed in an IXR1 cell, the cell would become even more sensitive to cisplatin. There are several ways of expressing proteins in yeast using a number of types of vectors. One common system uses the galactose-inducible promoter GALl. pCY was constructed by inserting IXR1 in front of the GALl promoter of the plasmid pCD43 (Table II). Expression off this plasmid was generated by growing the cells in media lacking dextrose, and then adding galactose to induce expression. When the cells were induced in exponential growth, expression of Ixrl was strong 1 hour after 105 induction (Fig. 2.10a). Cisplatin cytotoxicity assays are usually performed when the cells have been grown to saturation or reach the post-diauxic phase. Galactose-induced Ixrl expression did not occur in cells that were at saturation, either in cells induced after they were at saturation (Fig. 2.10 B), or in cells that were continually induced through late exponential phase. Therefore, the cytotoxicity assays performed with this plasmid had to be carried out with cells in exponential growth. Cisplatin cytotoxicity assays were performed on exponential stage BWG and BWGAixrl cells with either the control plasmid pCD43 or the expression plasmid pCY. Since the cells were in exponential phase, the difference between BWG and BWGAixrl was substantially diminished (Fig. 2.11). The expression of Ixrl from the pCY plasmid did indeed cause the cells to become more sensitive to cisplatin, both in the BWGAixrl strain and in the BWG strain. This result supports the hypothesis that it is indeed Ixrl which causes the difference between IXR1 and ixrl strains. Other expression systems were investigated since the GAL promoter did not express protein in cells grown past the exponential phase. Proteins can be expressed by using the genomic promoter. This strategy was attempted for Ixrl and for a mutant form of Ixrl, Ixrl-1, which contains the HMG-domain (Fig. 2.1a). Expression of Ixrl or Ixrl-1 from a yeast plasmid containing the gene with its own promoter occurred in cells in exponential phase, but not once the cells had reached saturation. Therefore, this system would not function any better than the GAL system. A newer promoter called the Met promoter can be induced by growing the cells in media lacking methionine. This promoter was chosen because cells that have been grown to saturation have exhausted the dextrose in the media, and may be exhausting other components as well. The vector was constructed by placing the Met promoter upstream from the Ixrl 106 gene. Cells were grown on SCAUraAMet(dextrose) media to preserve the plasmid and to express Ixrl off the promoter. The cells do not need exogenous methionine to grow. Ixrl expression was present in cells grown to saturation (Fig. 2.12). JM43 and JM43Aixrl were grown with either the control plasmid pYes2 or the expression plasmid pMM and treated with cisplatin (Fig. 2.13). There was a strong difference between the JM43+pYes2 and JM43Aixrl+pYes2 strains (slope ratio of 2.7, Table IV). The JM43Aixrl+pMM strain was still less sensitive than JM43+pYes2,but it was substantially more sensitive than the JM43Aixrl+pYes2 strain. This result indicates that Ixrl can make cells more sensitive to cisplatin. There was no difference between the two JM43strains, probably because the level of Ixrl expression was not sufficiently high. In the Southwestern (Fig. 2.12), the difference between the JM43 strains is not nearly as high as the difference between the two JM43Aixrl strains. Unfortunately, there is no method for raising the levels of expression from this promoter, and this method has already proven itself better than other more common methods such as the GAL promoter. Cytotoxicityassayson Ixrl mutants There are several strains of yeast isolated by the Cumsky laboratory that contain mutant forms of Ixrl. These mutants act like ixrl strains in that they express CoxVb in the presence of oxygen. The best characterized is Ixrl-1 (Fig. 2.1a), which contains most of the sequence of Ixrl, including the HMG domains, but is lacking the C-terminal tail. Ixrl-1 is in a JM43Acox5abackground. When Ixrl-1 was tested for cisplatin sensitivity, it was found to be substantially more sensitive to cisplatin than JM43Acox5a(Fig. 2.14a) The ratio of slopes k(Ixrl-1) / k(Acox5a) = 2.8 + 0.6, with the values ranging from 2.0 to 3.4. Ixrl-1 was also more sensitive than JM43 itself (Fig. 2.14a, Table III) by about 1.3 fold. This result led us to wonder if there was something about the Ixrl-1 protein that caused it to 107 make cells more sensitive to cisplatin. The Ixrl-1 strain, however, is a cox5a mutant, so it cannot be strictly compared to the wild-type strain. The increased sensitivity could have been due to the cox5amutation. Since there was no strain with Ixrl-1 in a wild-type background, and attempts to express Ixrl-1 from a plasmid in saturated cells failed (see above), CoxVa was expressed from a plasmid in the Ixrl-1 cells. CoxVa, expressed from its genomic promoter, may be more stable in cells than Ixrl, and thus more easily expressed. Four strains, JM43+pCD43,JM43Aixrl+pCD43, Ixrl-1+pCD43, and Ixrl-1+pCox5a were grown to saturation in SCAUra (dextrose) media (for plasmid descriptions, see Table II). The difference in cisplatin cytotoxicity between JM43+pCD43 and JM43Aixrl+pCD43 was significant (Fig. 2.15, Table V), but the two Ixrl-1 strains were just as sensitive as the JM43+pCD43 strain. This result indicates that the Ixrl-1 protein does not cause cells to become more sensitive to cisplatin. The increased sensitivity of the Ixrl-1 strain was dependent on the media conditions; the previous experiments were done in YPD media. The Ixrl-1 mutant protein does not cause the cells to become less sensitive to cisplatin even though strains with that protein express CoxVb. These experiments demonstrate that it is the HMG domain of Ixrl that is crucial to the cisplatin sensitivity of the strain, not the function of the protein for suppressing CoxVb expression. Another Ixrl mutant, Ixrl-9 was also briefly investigated. This mutant has not been sequenced yet; it was tested primarily to see if there were any interesting results that might make it worth sequencing. Cisplatin cytotoxicity assays revealed no significant difference between Ixrl-9 and the most related strain, BMH200Acox5a,or the parent strain BMH200 (Fig. 2.14b). Since Ixrl-9 does not suppress CoxVb expression, that function cannot be related to the cisplatin cytotoxicity difference between IXR1 and ixrl strains. 108 Cytotoxicity assays on cox5a strains CoxVa is the isoform of cytochrome c oxidase subunit V that is used under aerobic conditions. It is required for aerobic respiration if CoxVb is repressed by both Roxl and Ixrl. The cisplatin sensitivity of the JM43Acox5astrain fell between that of the JM43 strain and the JM43Aixrl strain (Fig. 2.14a and Table III). This phenomenon was significantly less pronounced in the BMH200 background (Fig. 2.14b). The difference in cisplatin cytotoxicity between COX5a and cox5astrains probably arises because these assays were performed at saturation, where the cells were required to respire aerobically. A cox5acell cannot aerobically respire and thus cannot pass through the diauxic shift, which means that the cell population does not increase to as high a level as in the COX5a strains. A JM43Acox5aAixrlstrain treated with cisplatin was more sensitive than the JM43Acox5amutant (Fig. 2.16). The two forms of cisplatin desensitization were not additive, instead, they were subtractive. A strain called F::5 was also analyzed in order to determine whether it displayed any interesting differences in cisplatin cytotoxicity. F::5is Acox5aAixrl,with both JM43 and JM45 parents. JM45 is exactly the same as JM43, except that it is the other mating type, and it responds to cisplatin as JM43 does. JM43Acox5aAixrlcells grow very slowly on YPGE media, which contain only non-fermentable sugars. If the cells are grown on those plates for about 1 week, fast-growing colonies arise at a rate far greater than the background mutation rate and these form the F::5 strain. The difference seems to be due to a cellular adaptive response, not a gene mutation (J. Lambert, personal communication). The F::5 strain was just as sensitive to cisplatin as JM43 itself (Fig. 2.16, Table III). These data, taken as a whole, indicate the complexity of the cellular response to cisplatin and the need to make sure that cell lines being compared 109 are in all other respects identical. cox5na strains do not respire aerobically in an efficient manner, and they have a different cisplatin sensitivity because the assay requires cells to grow until they respire aerobically. Any small differences in cell growth can have a large effect on measured cisplatin cytotoxicity. Anaerobic cytotoxicity assays Since Ixrl regulates the expression of a protein used only under hypoxic or anaerobic conditions, cytotoxicity assays were performed under the latter conditions. Cells and plates grown without oxygen were monitored with oxygen indicator strips. The cisplatin treatments themselves were performed in an anaerobic chamber at room temperature. The difference in cisplatin sensitivity between the JM43 and JM43Aixrl cells was still present (Fig. 2.17, Table VI). The difference was a bit less pronounced than in the aerobically grown cells, with a slope ratio of 2.4 instead of 3.9, but this result is probably more an indication of differences in cell growth conditions than anything else. This result indicates that the increased expression of CoxVb in ixrl cells does not cause the cisplatin cytotoxicity difference, and that the latter is not function of oxygen metabolism. Cytotoxicity assayconditions Both the results with the cox5astrains and the fact that cells need to be grown to saturation for a large cisplatin cytotoxicity difference to be observed inspired a series of experiments examining the cytotoxicity assay under a variety of conditions. The platination media did not seem to make much difference; SD media with dextrose, galactose, or no sugars at all were all used. SC media (SD plus amino acids) have also been used successfully, although the added amino acids caused the cells to become less sensitive to cisplatin. IXR1 cells were still more sensitive than ixrl cells when cisplatin treatment was lengthened to 4 hours. Cells treated for 4 hours were, of course, more sensitive to cisplatin than ones treated for two hours. The only change that seemed to affect the difference 110 in cytotoxicity strongly was the state of the cells at the time of platination, which depended on the media and on how long they were grown. For each different type of media and plasmid reported in the above experiments, it was necessary to determine how long the cells took to grow to saturation. Some experiments examining the effect of different media upon the cisplatin cytotoxicity difference were performed in hopes that they would shed some light on the reason the cells needed to be grown to saturation for the difference to be seen. One possibility is that the dextrose supply was exhausted, and thus the cells were forced to respire aerobically. Cells were grown on YPD with 10% dextrose instead of 2% so that the dextrose would not be exhausted when the cells reached saturation. The IXR1and ixrl cells grown on YPD+10% dextrose no longer showed the difference in cisplatin cytotoxicity (Fig. 2.18). This result was confirmed in the JM43 background (Fig. 2.19a). When the JM43 cells were permitted to grow a bit longer, exhausting more of the dextrose, the difference began to return (Fig. 2.19b). If the only reason that cells need to be grown to saturation is to exhaust the dextrose, then cells grown on media lacking dextrose should show the difference between IXR1 and ixrl without being grown to saturation. YPGE contains glycerol and ethanol, both of which are non-fermentable carbon sources and thus force the yeast cells to respire. When the IXR1and ixrl cells were grown to mid-exponential phase on YPGEmedia, the difference in cisplatin cytotoxicity was not present (Fig. 2.20a). When the same cells were grown to saturation, the difference returned, and was even greater than the difference when the cells were grown on YPD media (Fig. 2.20b, Table VI). The sensitivity of the strains to cisplatin also changed; cells grown to saturation were far less sensitive than those in exponential phase. These results indicate that the cells need to be dense enough before the cisplatin cytotoxicity difference appears. 111 It is possible that the expression of Ixrl changes as cells grow to saturation. If the expression level of Ixrl were to increase in cells at saturation the cytotoxicity difference would naturally be larger. Aliquots of cells were removed as the cells grew to saturation, and Southwestern blots were performed on these cells. The blots showed no increase in Ixrl expression at all as the cells reach saturation; if anything, the level of Ixrl decreased. Thus, the need to grow the cells to saturation for the cytotoxicity difference to become sufficiently large cannot be explained by an increase in the level of Ixrl. It is possible that Ixrl was modified in some way that raised its binding capacity for cisplatin-DNA adducts; this potential alteration did not dramatically change its electrophoretic mobility. DISCUSSION The HMG domainsof Ixrl cause the differencein cisplatinsensitivity The difference in cisplatin sensitivity between IXR1and ixrl strains was examined in more depth because this result was the first indication that HMG domain proteins actually affect cisplatin cytotoxicity. Experiments were performed in order to determine whether it is the HMG domains of Ixrl or the function of the protein that causes the difference. First, the difference in sensitivity was confirmed in two other strains of yeast, in order to be sure the effect was not caused by some unrelated mutation. Ixrl was overexpressed in ixrl strains to demonstrate that the difference in cisplatin sensitivity is due to the missing Ixrl protein. In spite of difficulties encountered in expressing protein in cells that have been grown to saturation, it was shown that JM43Aixrl plus overexpressed Ixrl is more sensitive to cisplatin than the JM43Aixrl plus control plasmid strain. These results indicate that the difference in cytotoxicity between IXR1 and ixrl strains is caused by the lack of the Ixrl protein. 112 Several experiments were performed that demonstrate that increased expression of CoxVb in the ixrl strain was not the cause of the decrease in sensitivity to cisplatin. Two strains with mutant Ixrl proteins were examined, Ixrl-1 and Ixrl-9. Both of these strains express CoxVb, so if CoxVb expression affected cisplatin cytotoxicity, these strains would be less sensitive than the corresponding wild-type strains. Neither Ixrl-1 or Ixrl-9 was less sensitive to cisplatin, indicating that the change in CoxVb expression does not affect cisplatin cytotoxicity. Roxl is also a transcriptional repressor of CoxVb expression; CoxVb is expressed when either Ixrl or Roxl is missing. JM43Aroxl was as sensitive to cisplatin as JM43 (Fig. 2.8). Finally, the cytotoxicity assay was performed under anaerobic conditions. CoxVb is expressed under such conditions because the Roxl repression is alleviated. The JM43Aixrl strain was still less sensitive than the JM43 strain. This result indicates that no protein that is expressed differently in anaerobic cells is responsible for the cisplatin cytotoxicity difference. These results conclusively demonstrate that the increased CoxVb expression in the ixrl strains is not causing the difference in cisplatin cytotoxicity. There are several experiments that demonstrate that the missing HMG domains cause the difference in cisplatin cytotoxicity. Ixrl binds to cisplatin DNA adducts, as can be seen in any of the Southwestern blots, or Fig. 2.7. Its binding has been quantitated and demonstrated by footprint analysis by J. Whitehead (Whitehead and Lippard, 1995). As demonstrated in Fig. 2.7, Ixrl can bind to cisplatin-DNA adducts, but not to trans-DDP, [Pt(dien)Cl]+ , or UV adducts. IXR1and ixrl strains were equally sensitive to trans-DDPand UV light damage (data not shown) (Brown et al., 1993). A homolog of cisplatin which forms similar bifunctional DNA adducts, [Pt(en)C121,also shows the cytotoxicity difference (data not shown). If the mere act of damaging the DNA were sufficient to cause the differential cytotoxicity, then the ixrl strain should have 113 been less sensitive than the IXR1strain to either trans-DDPor UV light. Only damaging agents that cause adducts to which HMG domain proteins bind cause ixrl strains to be less sensitive than IXRI strains. Furthermore, mutant Ixrl proteins that still bind cisplatin-DNA adducts did not affect cellular cisplatin sensitivity. The Ixrl-1 strain is not less sensitive than its corresponding wild-type strain, JM43 (Fig. 2.14, 2.15). The Ixrl-1 protein is missing the end of the protein which contains a long stretch of glutamine residues (Fig. 2.1a), and is thought to be related to protein-protein interactions (Latchman, 1991). Since the HMG domains are still intact, Ixrl-1 can still bind the cisplatin-DNA adducts. Therefore it is the absence of the HMG domains, not the absence of a putative protein-protein interaction domain, that causes the decrease in cisplatin cytotoxicity in the ixrl strain. The binding of the HMG domains to the cisplatinDNA adduct is most likely the cause of the difference in cisplatin cytotoxicity. Exactly how the binding causes the cytotoxicity difference is explored later in this thesis. Different cellular conditions cause different responses Many experiments have been performed that indicate the complex nature of the effect of different conditions on the IXR1 /ixrl cisplatin cytotoxicity difference. Cisplatin cytotoxicity assays only show a strong difference between IXR1 and ixrl strains when the cells have been grown to saturation. The initial cytotoxicity experiments were all performed in YPD media. The difference was not present if the cells were grown in YPD media with 10% dextrose instead of 2% dextrose. This result indicated that the difference was repressed by glucose. Perhaps the cells need to respire aerobically or ferment alternative sugar sources in order for the difference to appear, because there are many genes that are repressed by glucose. Cytotoxicity assays were performed on cells grown in YPGE,which only contains non-fermentable carbon sources. Exponential phase 114 cells grown on YPGEdid not show a difference in cisplatin cytotoxicity between the IXR1 and ixrl cells, indicating that alleviation of dextrose inhibition was not the only reason cells had to be grown to saturation. When the YPGE cells were grown to saturation, the difference was substantially larger than in the YPD cells, supporting the theory that dextrose does inhibit the cytotoxicity difference. There was no rise in Ixrl expression in saturated cells that could explain these results. Cells that have been grown to saturation, or post-diauxic phase, are different from exponential cells in several ways. Post-diauxic phase cells are, by definition, growing substantially more slowly. Several studies have been performed on cells in the post-diauxic phase or in the stationary phase. Unfortunately, because the difference is not well defined, papers sometimes refer to post-diauxic phase as stationary phase leading to confusion about which phase to assign a given alteration in cellular function (Werner-Washburne et al., 1993). Cyclic AMP concentrations are lower in post-diauxic shift cells, and the mRNA levels drop by 50% (Werner-Washburne et al., 1993). The chromatin folds up more tightly in a TOP1 dependent fashion (Wemer-Washburne et al., 1993). The diauxic shift activates transcription of several proteins, including CYC7 (Pillar and Bradshaw, 1991), several heat shock proteins, several proteolysis proteins including ubiquitin-conjugating proteins, and, of course, proteins involved in aerobic respiration such as alcohol dehydrogenase (ADH2) (Wemer-Washburne et al., 1993). CYC1, the other isoform of cytochrome c, is down-regulated in the stationary phase, and perhaps in the post-diauxic phase (Pillar and Bradshaw, 1991). In some cases, the diauxic shift is caused by nitrogen, sulfur or carbon starvation (Drebot et al., 1990a), and the Ras pathway is involved in these cases (Werner-Washburne et al., 1993). The transition from stationary or post-diauxic phase cells to exponential growth is also of interest, since the cisplatin-treated 115 cells undergo this shift on the plates in order to form colonies. Histones H2A and H2B are made during the transition (Drebot et al., 1990b),and a zinc finger protein, GCS1, is involved in regulating the transition (Ireland et al., 1994). It is clear in the literature that not only are these phenomena complicated, but they have not been fully investigated yet. Therefore, it seems unlikely that we can understand the reason why cells need to be grown to saturation in order for the cisplatin cytotoxicity difference between IXR1 and ixrl cells to appear before other researchers define the system more completely. CONCLUSIONS In conclusion, the differential sensitivity of IXR1 and ixrl strains is due to the HMG domains of Ixrl, not to its ability to repress COX5b expression. The reason that Ixrl binding to cisplatin-DNA adducts affects cisplatin sensitivity is investigated more in subsequent chapters. 116 REFERENCES Allen, L.A., X.J.Zhao, W. Caughey and R.O. Poyton (1995)Isoforms of yeast cytochrome c oxidase subunit V affect the binuclear reaction center and alter the kinetics of interaction with the isoforms of yeast cytochrome c. J. Biol. Chem. 270, 110-118. Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith and K. Struhl, Eds. (1994).Current protocols in molecular biology. Wiley Interscience. Balasubramanian, B., C.V. Lowry and R.S. Zitomer (1993) The Roxl repressor of the Saccharomyces cerevisiaehypoxic genes is a specific DNA-binding protein with a high-mobility-group motif. Mol. Cell. Biol. 13, 6071-6078. Brown, S.J.,P.J. Kellett and S.J.Lippard (1993)Ixrl, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science 261, 603-605. de Winde, J.H. and L.A. Grivell (1993)Regulation of mitochondrial biogenesis: Transcriptional regulation and signal transduction in yeast. Prog Nucl Acids Res and Mol Biol 46, 54-91. Diffley, J.F.X.and B. Stillman (1992)DNA binding properties of an HMG1related protein from yeast mitochondria. J. Biol.Chem. 267, 3368-3374. Drebot, M.A., C.A. Barnes, R.A. Singer and G.C. Johnston (1990a) Genetic assessment of stationary phase for cells of the yeast Saccharomyces cerevisiae.J. Bacteriology 172, 3584-3589. Drebot, M.A., L.M. Veinot-Drebot, R.A. Singer and G.C. Johnston (1990b) Induction of yeast histone genes by stimulation of stationary-phase cells. Mol. Cell. Biol. 10, 6356-6361. Hodge, M.R., G. Kim, K. Singh and M.G. Cumsky (1989)Inverse regulation of the yeast COX5 genes by oxygen and heme. Mol. Cell. Biol. 9, 1958-1964. Ireland, L.S.,G.C. Johnston, M.A. Drebot, N. Dhillon, A.J. DeMaggio, M.F. Hoekstra and R.A. Singer (1994)A member of a novel family of yeast 'Zn-finger' proteins mediates the transition from stationary phase to cell proliferation. EMBO J. 13, 3812-3821. Lambert, J.R., V.W. Bilanchone and M.G. Cumsky (1994) The ORD1 gene encodes a transcription factor involved in oxygen regulation and is identical to IXR1,a gene that confers cisplatin sensitivity to Saccharomycescerevisiae.Proc. Natl. Acad. Sci. (U.S.A.) 91, 7345-7349. Latchman, D. (1991).Eukaryotic transcription factors. Academic Press. 117 Laz, T.M., D.F. Pietras and F. Sherman (1984) Differential regulation of the duplicated isocytochrome c genes in yeast. Proc. Natl. Acad. Sci. (U.S.A.) 81, 4475-4479. Lowry, C.V., M.E. Cerdan and R.S. Zitomer (1990)A hypoxic consensus operator and a constitutive activation region regulate the ANB1 gene of Saccharomyces cerevisiae. Mol. Cell. Biol. 10, 5921-5926. Lowry, C.V. and R.S. Zitomer (1988)ROX1encodes a heme-induced repression factor regulating ANB1 and CYC7 of Saccharomyces cerevisiae. Mol. Cell. Biol. 8, 4651-4658. Megraw, T.V. and C.-B. Chae (1993)Functional complementarity between the HMG1-like yeast mitochondrial histone HM and the bacterial histone-like protein HU. J. Biol. Chem. 268, 12758-12763. Pil, P.M. and S.J. Lippard (1992) Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 256, 234-237. Pillar, T.M. and R.E. Bradshaw (1991)Heat shock and stationary phase induce transcription of the Saccharomycescerevisiaeiso-2 cytochrome c gene. Curr. Genet. 20, 185-188. Trietel, M.A. and M. Carlson (1995)Repression by SSN6-TUP1is directed by MIG1, a repressor/activator protein. Proc. Natl. Acad. Sci. (U.S.A.) 92, 3132-3136. Wang, G.L. and G.L. Semenza (1993)Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J. Biol. Chem. 268, 21513-21518. Waterland, R.A., A. Basu, B. Chance and R.O. Poyton (1991) The isoforms of yeast cytochrome c oxidase subunit V alter the in vivo properties of the holoenzyme. J. Biol. Chem. 266, 4180-4186. Werner-Washburne, M., E. Braun, G.C. Johnston and R.A. Singer (1993) Stationary phase in the yeast Saccharomycescerevisiae.Microbiological Reviews 57, 383-401. Whitehead, J.P. and S.J.Lippard (1995)Purification of the yeast protein, Ixrl(Ordl), and characterization of its specific binding to a cisplatin intrastrand d(GpG) cross-link in DNA. in preparation Williams, F.E. and R.J. Trumbly (1990) Characterization of TUP1, a mediator of glucose repression in Saccharomyces cerevisiae.Mol. Cell. Biol. 10, 6500-6511. 118 Zhang, M., L.S. Rosenblum-Vos, C.V. Lowry, K.A. Boakye and R.S. Zitomer (1991) A yeast protein with homology to the f3-subunit of G proteins is involved in control of heme-regulated and catabolite-repressed genes. Gene 97, 153-161. Zitomer, R.S. and C.V. Lowry (1992)Regulation of gene expression by oxygen in Saccharomyces cerevisiae. Microbiological Reviews 56, 1-11. 119 Table I Saccharomyces cerevisiae strains Strain Genotype IXR1 MATa, ura3-52, ade2, trpl-1, Iys2-201, his3-200, leu2-3,112 ixrl IXR1 ixrl::LEU2 IXRlAabf2 IXR1 abf2::TRP1 JM43 MATa, his4-580, trpl-289, leu2-3,112, ura3-52 JM45 JM43 MATa JM43Aixrl JM43 ixrl::LEU2 JM43Aroxl JM43 rox::LEU2 JM43Acox5a JM43 cox5a::URA3 Ixrl-1 JM43 cox5a::URA3, ixrl-l JM43Acox5aAixrl JM43 cox5a::URA3, ixrl::LEU2 F::5 JM43 cox5a::URA3,ixrl::LEU2,grows quickly on YPGE BMH200 MATa, ade2, ura3-52 BMH281 BHM200 Acox5a Ixrl-9 BMH281 ixrl-9 BWG BWG1-7A ura3, leu2, his4, adel BWGAixrl BWG ixrl::LEU2 120 Table II Plasmids used in cytotoxicity experiments Plasmid Description pYes2 yeast GAL expression plasmid with no protein after the promoter, 2g origin Often used as a control plasmid pCD43 yeast GAL expression plasmid with no protein after the promoter, CEN origin Often used as a control plasmid pYY pYes2-Ixrl, plasmid pYes2 with IXR1 after the promoter pCY pCD43-Ixrl, plasmid pCD43 with IXR1 after the promoter pSL301 E. coli plasmid with a large polylinker pSL301-Ixrl IXR1 in the pSL301 polylinker pMM1 yeast expression plasmid with Met promoter linked to IXR1 pCox5a yeast Cox5a expression plasmid, uses the Cox5a genomic promoter 121 Table III Cytotoxicity assay results WT Strain Slope (k) Mutant k(WT)/k(mutant) range of ratios JM43 43 + 1.0 Aixrl 3.9 + 2 2.0 - 6.5 Aroxl 1.1 + 0.2 0.78 - 1.2 Acox5a 2.0 ± 0.3 1.7 - 2.3 Ixrl-1 0.76 ± 0.1 0.66 - 0.84 Acox5aAixrl 1.4 ± 0.01 1.4 F::5 1.0 + 0.08 1.0 - 1.1 BWG 27.9 + 9.5 Aixrl 1.65 + 0.22 1.5 - 2.0 IXR1 7.9 + 1.6 Aixrl 1.5 + 0.2 1.3 - 2.1 Table IV Ixrl overexpression cytotoxicity assay Strain Slope (k) JM43+pYes2 11.4 ± 1.5 JM43Aixrl+pYes2 k(J+pYes2)/k(other) range of ratios 4.2 + 0.4 2.7 + 0.3 2.4 - 2.9 JM43+pMM 11.5 ± 2.0 1.0 + 0.09 0.9 - 1.1 JM43Aixrl+pMM 8.0 ± 1.2 1.4 + 0.05 1.4 - 1.5 122 Table V Ixrl-1 cytotoxicity assay Strain Slope (k) JM43+pCD43 11.7 + 0.9 JM43Aixrl+pCD43 4.0 + 0.9 Ixrl-l+pCD43 10.9 ± 1.0 Ixrl-l+pCox5a 10.8 + 1.2 Table VI Different growth conditions Condition WT strain Slope (k) k(WT)/k(Aixrl) range of ratios Anaerobic JM43 9.1 2.4 0.8 1.7 - 3.2 YPGE saturation IXR1 2.0 + 0.1 3.2 + 1.1 2.2 - 4.4 2.4 123 124 Figure 2.1. Ixrl domains. A. Domains of Ixrl and the mutant protein Ixrl-l. B. Comparison of Roxl HMG domain to an ordinary HMG domain. 125 A. HMG domains Ixrl Ixrl-1 ig- - : ..... i I i... :" ::': -- .. .........- I -----1.. ....-, B. HMG domain Roxl .......: go~. Normal lg ::.... .... ''... "":.:.:........ i .. .ii Ixxxxx7: 4 5 amino acid spacer i 126 Figure 2.2. Natural functions of Ixrl and related proteins. Ixrl represses the transcription of CoxVb. CoxVa and CoxVb are both regulated by oxygen and glucose levels. Expression of CoxVa is activated by oxygen through heme and HAP2/3/4 and repressed by glucose through SSN6, TUP1 and HAP2/3/4. Expression of CoxVb is repressed by oxygen through heme, SSN6, TUP1, and Roxl, and repressed by glucose through MIG1, SSN6 and TUP1. 127 *- heme / SSN6&TUP1 SSN6&TUP1 / HAP2/3/4 A .. ... :ion :ose Roxl .pression CoxVa 02 repression CoxVb glucose rep repression MIGI&SSN6&TUP1 Ixrl Glucose 128 Figure 2.3. Ixrl expression plasmids. 129 BamHI / EcoRV SacI IXR1 I I I I 'I XhoI I I I I I I ' pSL301-Ixrl BamHI I Gal pmtr IXR1 I - I *pCY I -SacI pCY V CEN originBamHI I Gal pmtr II I I If g m I URA3 IXR1 I XhoI pYY L I k I I I I I origin URA3 2g origin URA3 I Met pmtr IXR1 - I I ~L XhoI pMM1 ii · I ! Im origin 2g origin URA3 I · ~~~~~ 130 Figure 2.4. Cytotoxicity assays performed on JM43 and JM43Aixrl using standard conditions. 131 .9. 100 10 cl ?i 0.1 0 0 JM43 JM43Aixrl - I error 0.1 - II 0 0.2 0.4 I I I 0.6 0.8 1 [Cisplatin] mM I 1.2 132 Figure 2.5. Confirmation of construction of BWGAixrl strain. A) Southwestern blot on BWG (IXR1) and putative BWGAixrl (ixrl) strain. B) Southern blot of genomic DNA from those strains digested with SacI and probed with a fragment from Ixrl present in the normal and interrupted genes. 133 I ,--1 ITVD1I E-Ixrl Degraded } P. -_ r Ixrl x . -0 = ,., --' A. Southwestern Blot == *-ixrl 4.6--Abf2 sf t . -- IXR1 B. Southern Blot 135 136 Figure 2.6. Cytotoxicity assays performed on BWG and BWGAixrl using standard conditions. 137 100 10 ._' cf 0.1 0.01 0 0.1 0.2 0.3 0.4 [Cisplatin] mM 0.5 0.6 0.7 138 Figure 2.7. Ixrl binds cisplatin damaged DNA but not other forms of damaged DNA. Bandshift assay using Ixrl. Pairs of lanes contain DNA without protein and DNA with Ixrl protein. From left to right, the pairs of lanes contain undamaged DNA, cisplatin damaged DNA, trans-DDPdamaged DNA, ultraviolet light damaged DNA, and Pt(dien)Cl+ damaged DNA. 139 141 142 Figure 2.8. Cytotoxicity assays performed on JM43Aroxl, JM43, and JM43Aixrl using standard conditions. 143 100 10 C ·, 1 0.1 0 0.2 0.4 0.6 0.8 [Cisplatin] mM 1 1.2 144 Figure 2.9. Southwestern blot of abf2strains. 145 ABF2 interruption 30 I V Abf2, 20 kD- 21.5 rp jim. m~ ____ 14.3 147 148 Figure 2.10. Southwestern blots of overexpression of Ixrl by using the GALl promoter. A. Induction profile of BWG+pCYcells. 2% galactose was added to the cells at time 0 and aliquots were collected at the indicated times. The same weight of cells were used in each lane. B. Induction of Ixrl expression when the cells were grown to saturation. Lane 1 contains BWG cells with the control plasmid pCD43. Lane 2 contains BWG with the Ixrl expression plasmid pCY. The cells were induced for 2 hours with 2% galactose. 149 B. A. Induction Induction in log phase Induction time (hrs) at saturation BWG BWG IpCDI Ixrl pCY I 151 152 Figure 2.11. Cytotoxicity assays performed on BWG and BWGAixrl cells with the control plasmid pCD43 and the Ixrl overexpression plasmid pCY. Cells treated with cisplatin in exponential phase after 1 hour of induction by 2% galactose. 153 100 10 ;> 1 cn 8o 0.1 0.01 0 0.1 0.2 0.3 0.4 [Cisplatin] mM 0.5 0.6 0.7 154 Figure 2.12. Ixrl overexpression from the Met promoter. Southwestern showing the levels of overexpression obtained from the pMM Ixrl overexpression plasmid. 155 JM43 JM43 JM43 JM43 Aixrl Aixrl +pMM +pMM <-- Ixrl Degraded Ixrl <- Abf2 157 158 Figure 2.13. Cytotoxicity assays performed on JM43 and JM43Aixrl with the control plasmid pYes2 and the Ixrl overexpression plasmid pMM. The cells were treated with cisplatin after being grown to saturation in SCAUraAMet media. 159 100 10 .> cn 0-- 1 0.1 0 0.1 0.2 0.3 0.4 [Cisplatin] mM 0.5 0.6 0.7 160 Figure 2.14. Cytotoxicity assays performed on mutant Ixrl and cox5astrains. A. Assay on JM43, JM43Aixrl, JM43Acox5a,and Ixrl-l using standard conditions. B. Assay on BMH200, BMH200Acox5a,and Ixrl-9 using standard conditions. 161 A. a 1UU 10 .c d 1 0.1 0.01 0 0.2 0.4 0.6 0.8 1.2 1 [Cisplatin] mM 12 100 . 10 (> 0. 1 0.1 0 0.2 0.4 0.6 0.8 [Cisplatin] mM 1 1.2 162 Figure 2.15. Cytotoxicity assays performed on Ixrl-1 strains. Assay was performed on JM43,JM43Aixrl, and Ixrl-1 with the control plasmid pCD43 and on Ixrl-1 with the CoxVa expression plasmid pCox5a. Cells were grown to saturation on SCAUramedia. 163 100 10 C1 1 Qn 0.1 0.01 0 0.1 0.2 0.3 0.4 [Cisplatin] mM 0.5 0.6 0.7 164 Figure 2.16. Cytotoxicity assays performed on JM45, F::5,JM43Acox5a,and JM43Acox5aAixrlusing standard conditions. 165 100 10 cQ 0 1 0.1 0 0.2 0.4 0.6 0.8 [Cisplatin] mM 1 1.2 166 Figure 2.17. Cytotoxicity assays performed on JM43 and JM43Aixrl using anaerobic conditions. Cells were grown on YPD without oxygen, and the cytotoxicity assay was performed using anaerobic conditions. 167 100 10 -4 1 cr cn 0.1 0.01 0.001 0) 0.2 0.4 0.6 0.8 [Cisplatin] mM 1 1.2 168 Figure 2.18. Cytotoxicity assays performed on IXR1and ixrl grown on YPD and YPD with 10% dextrose. 169 100 --- 4 mb 10 ::I V) 1 0.1 0 0.2 0.4 0.6 0.8 [Cisplatin] mM 1 1.2 170 Figure 2.19. Cytotoxicity assays performed on JM43 and JM43Aixrl grown on YPD with 10% dextrose. The cell in B. were grown longer than those in A. 171 A. 100 4 10 1c 0.1 0 0.2 0.4 0.6 0.8 1 1.2 0.6 0.7 [Cisplatin] mM B. ~~~~~~~~~~ ~~~~~~~~~~~~~~~~~~~~~~ AA 100 10 > 1 cn 0.1 0.01 0 0.1 0.2 0.3 0.4 [Cisplatin] mM 0.5 172 Figure 2.20. Cytotoxicity assays performed on IXR1and ixrl grown in YPGE. A. Cells were treated with cisplatin in exponential phase. B. Cells were treated with cisplatin after they were grown to saturation. 173 A. 100 10 (c oe 1 0.1 0 0.2 0.4 0.6 0.8 1 1.2 [Cisplatin] mM B. 100 10 -4 ;- 80 1 0.1 0 0.5 1 1.5 2 [Cisplatin] mM 2.5 3 3.5 174 175 CHAPTER 3 The HMG domain protein Ixrl shields cisplatin-DNA adducts from excision repair in vivo 176 INTRODUCTION Ixrl is an HMG domain protein from Saccliaromyces cerevisiae(Brown et al., 1993). Also known as Ordl, it regulates the expression of cytochrome c oxidase subunit 5b, which is used in aerobic respiration when oxygen levels are low (Lambert et al., 1994). A yeast strain in which the Ixrl gene had been deleted was less sensitive to cisplatin than the corresponding wild-type strain (Brown et al., 1993). This result showed that Ixrl can modulate cisplatin cytotoxicity. Since there was no significant difference between the IXR1and ixrl strains when they were treated with ultraviolet light (Brown et al., 1993),the difference in cisplatin cytotoxicity was not due to some intrinsic alteration in the cells. This result is supported by the results detailed in the preceding chapter. It was also demonstrated in chapter 2 that the difference in cisplatin cytotoxicity was due to the HMG domains of Ixrl, not the natural function of Ixrl. The cause of the difference in cisplatin cytotoxicity is investigated further in this chapter. There are several ways Ixrl could alter cisplatin cytotoxicity. Ixrl could affect the formation of cisplatin-DNA adducts, either by assisting the binding reaction or by regulating the uptake, export, or availability of the drug. Ixrl could also be titrated or "hijacked" away from its natural binding site by cisplatin-DNA adducts, a possibility demonstrated by in vitro studies of another HMG domain protein, hUBF (Treiber et al., 1994). Such behavior could either cause faulty regulation of transcription at the natural binding site or result in improper transcription at the site of the cisplatin-DNA adduct. A third possibility is that Ixrl might affect the repair of cisplatin-DNA adducts. Ixrl is not a repair protein, since removing it increased the resistance of the yeast cells to cisplatin. It probably does not regulate the transcription of repair genes, since deleting Ixrl had no effect on the sensitivity of yeast cells to ultraviolet light (Brown et al., 1993). Ixrl could block the repair of the cisplatin-DNA adducts by 177 preventing the excision complex from recognizing the cisplatin-DNA adduct (Fig. 3.1, or, in less detail, Fig. 1.8). Relatively high levels of HMG domain proteins block the excision repair of cisplatin d(GpG) cross-links in mammalian cell extracts (Huang et al., 1994). In this mechanism, removing Ixrl would cause the 1,2-intrastrand cross-links to be repaired more readily, which would increase the resistance of the yeast cells to cisplatin. If repair shielding could be demonstrated in yeast, it would have important implications for humans, since the excision repair system of S. cerevisiaeis highly homologous to that of human cells (Friedberg, 1991a; Cleaver, 1994). Changes in the level of HMG domain proteins may account for the acquired resistance found in many ovarian carcinoma patients. Many of the yeast repair proteins (Rad) have mammalian counterparts in the xeroderma pigmentosum (XP) cell complementing proteins or in the excision repair crosscomplementing (ERCC)proteins (Cleaver, 1994). Cisplatin-DNA adducts are repaired by the excision repair system in both human and yeast cell extracts (Hansson and Wood, 1989;Wang et al., 1993). Most laboratories study excision repair by using UV-irradiated DNA. Very little work has been carried out to examine the sensitivity of yeast excision repair mutants to cisplatin (Brendel and Ruhland, 1984;Hannan et al., 1984;Wilborn and Brendel, 1989). Currently, functions are being assigned to both yeast and mammalian repair gene products and specific interactions among repair proteins have been identified (Fig. 3.1). The human protein corresponding to Radl4 (Bankmann et al., 1992),XP-A complementing factor, binds to DNA damaged with cisplatin and with UV light (Jones and Wood, 1993). Radl4 itself binds to UV-damaged DNA (Guzder et al., 1993). XP-A interacts with the rodent counterparts of the Radl-RadlO complex, ERCC1 and ERCC4 (XP-F)(Li et al., 1994;Park and Sancar, 1994). Another large complex identified contains Rad2, Rad4, Rad3, Rad25, Ssll, 178 Tfbl, and possibly Rad23 (Feaver et al., 1993;Bardwell et al., 1994a; Bardwell et al., 1994c). Rad3, Ssll, and Tfbl are part of RNA polymerase II transcription initiation factor b, the yeast homologue of TFIIH (Gileadi et al., 1992; Feaver et al., 1993; Wang et al., 1994). Rad2 is a structure-specific endonuclease (Habraken et al., 1993; Harrington and Lieber, 1994), which is capable of degrading circular single-stranded, but not double-stranded, DNA (dsDNA) (Habraken et al., 1993). It specifically cleaves a branched DNA structure and is thought to cut on the 3' side of the adduct (Harrington and Lieber, 1994),within a few nucleotides of the Ixrl binding site (Huang et al., 1992). XP-G (Rad2) is required for the 3' incision whereas ERCC-1 (RadlO) is not (O'Donovan et al., 1994). Cell extracts lacking XP-G do not have 5' incision activity either, suggesting that the 3' cut is made first (O'Donovan et al., 1994). Radl and RadlO form a complex that acts as a ssDNA endonuclease; it binds ssDNA preferentially but shows no preference for damaged DNA (Sung et al., 1993;Tomkinson et al., 1993;Tomkinson et al., 1994). Thus, Radl and RadlO cleave DNA, but other proteins are involved in adduct recognition and duplex unwinding to form the single-stranded substrate. The Radl-RadlO complex is responsible for the excision at the 5' side of the adduct (Bardwell et al., 1994b),which is approximately two turns of helix upstream of the cisplatin binding site (Huang et al., 1992). In the present study we have evaluated the repair blockage hypothesis by constructing yeast strains in which both IXR1 and an excision repair gene are interrupted. If repair shielding occurs, the differential cisplatin sensitivity of the IXR1 and ixrl strains should substantially diminish when a component of the excision complex involved in damage recognition is removed (Fig. 3.1). Specifically, we constructed double mutants of the IXR1 gene and the excision repair genes RADI, RAD2, RAD4, RAD10, and RAD14. These genes are homologous to the mammalian genes encoding XP-F/ERCC4, XP-G/ERCC5, XP- 179 C, ERCC1, and XP-A, respectively. Other repair-related genes were also interrupted, including Rad6, which is involved in error-prone repair, Rad9, which regulates DNA-damage induced cell-cycle arrest, and Rad52, which is involved in double-strand break repair. MATERIALS AND METHODS Yeast Strains and plasmids Yeast strains used to construct the rad mutants were IXR1: MATa, ura3-52, ade2, trpl-1, lys2A201, his3-200, leu2-3,112 and ixrl: MATa, ura3-52, ade2, trpl-1, lys2A201, his3-200, ixrl::LEU2 (Brown et al., 1993). The Cumsky laboratory kindly supplied their IXR1 (JM43) and ixrl (JM43Aixrl)strains (Lambert et al., 1994); JM43: Matoc, his4-580, trpl-289, leu2-3,112, ura3-52. Plasmids used for gene interruption are in Table I. The following plasmids were used for RAD expression: pG12-RAD1 1 , pWS502 (Rad2) 2 , pR67 (Rad6) 2 , pG12-RAD10 2 , pR14.9 (Rad14)3 , and pTB301 (Rad52) 3 . Constructionofrad strains The various RAD genes were disrupted by transforming both the IXR1 and the ixrl strains with plasmid fragments containing the RAD gene interrupted by a selectable marker (Table I) (Ausubel et al., 1994). Cells with the rad gene disruptions were selected by growing the transformed cells on synthetic media lacking a necessary component such that only the presence of the interrupting gene permitted cell growth. The sensitivity of the resultant colonies to ultraviolet light was examined in a streak test to confirm interruption of the RAD gene (Naumovski and Friedberg, 1984). rad9 strains are not as sensitive to ultraviolet light as excision repair mutations, so a higher UV dose was required to see the difference between rad9 and RAD9. Since interruption of the RAD52 gene does 1 Plasmids obtained from E. Friedberg. 2 Plasmids obtained from L. Prakash. 180 not sensitize the cells to UV light, the putative rad52strains were tested by examining their sensitivity to methyl methanesulfonate (MMS) (Prakash and Prakash, 1977). Expression or lack of expression of Ixrl was monitored by Southwestern blot analysis (Brown et al., 1993), and several of the strains were also checked by expressing the deleted gene from a plasmid. In particular, the rad2, rad6, rad14, rad52, IXR1 radl, and IXR1 randO strains were no longer UV- sensitive following expression of the appropriate RAD gene from a plasmid. Cytotoxicity assays Yeast cells were grown to saturation in 20 mL of YPD media (Ausubel et al., 1994) for approximately 64 hours at 30°C. All strains grew to similar densities except for the rad6and rad52strains, which saturated at approximately one half of the density of the other strains. Portions containing 2x107 cells of each strain were centrifuged to remove the media and resuspended in 1 mL of SD media, pH 6.5 (Ausubel et al., 1994)plus 0 to 1 mM cisplatin. The cells were incubated in an Eppendorf tube with gentle rocking for 2 hours at 30°C. The medium containing cisplatin was removed by pelleting the cells, which were resuspended in SD medium, diluted, and plated at 20 to 200 cells per plate. Three identical YPD plates were made for each level of platination. The plates were grown for 3 days in a 30°C incubator. Colonies on the plates were counted and the percent survival at the various concentrations was calculated relative to controls treated identically except for the lack of cisplatin. The IXR1 RAD and ixrl RAD strains were treated with only three different cisplatin concentrations because their differential sensitivity has already been investigated (Brown et al., 1993). Each strain was assayed in three to five separate experiments and results from a representative experiment are shown in the figures. The error bars in the percent survival plots show a 2a level derived from colony counts on the three identical plates and do not represent multiple experiments. The data were evaluated by 181 fitting a line to the log of the percent survival. The log(% survival) was used because, when a least squares fit was attempted to percent survival data, points below 1% survival were insufficiently weighted. The slope of the line corresponds to k in the expression survival=exp(-k[cisplatin]) used to fit the data. The reported values for k are an average of three to five separate experiments, except for k for the RAD strains, which corresponds to the average of 18 experiments. All experiments were performed with RAD IXR1 and RAD ixrl strains grown and treated identically to the rad strains. RESULTS Construction of rad IXR1 and rad ixrl yeast strains The genes for Radl, Rad2, Rad4, Rad6, Rad9, RadlO, Radl4, and Rad52 were interrupted by transforming IXR1and ixrl strains with plasmids containing an interrupted copy of the RAD gene in question. The removal of repair activity was checked by assaying the sensitivity of the cells to DNA damaging agents (Fig. 3.2). The rad strains were significantly more sensitive to ultraviolet light or MMS. Several of the strains were also checked by expressing the interrupted gene from a plasmid. Cisplatincytotoxicity in IXR1 and ixrl strains The cytotoxicity of cisplatin in various yeast strains was measured by treating cells with varying amounts of the drug for 2 hours. As found previously (Brown et al., 1993), removing the Ixrl protein by interrupting its gene caused the yeast cells to be less sensitive to cisplatin (Fig. 3.3). This result was repeated in two other pairs of IXR1 and ixrl strains with different backgrounds. In one pair of strains, constructed in a different laboratory (Lambert et al., 1994), the ixrl strain was 6 times more resistant to cisplatin treatment (Fig. 2.4), demonstrating that the differential cisplatin cytotoxicity between IXR1 and ixrl strains is not dependent on a specific strain of yeast. 182 Excision repair mlrtants All excision repair mutants were substantially more sensitive to cisplatin than either IXR1 or ixrl (Figs. 3.3, 3.4, and 3.5). The rad IXR1 and rad ixrl strains were compared in order to determine whether the differential sensitivity of IXR1 and ixrl strains was related to excision repair. Interrupting the RAD2, RAD4, or RAD14 genes caused ixrl strains to be nearly as sensitive to cisplatin as IXR1 strains (Fig. 3.3). Thus, the difference in sensitivity between the RAD IXR1 and RAD ixrl strains results from modulation of the actions of the Rad2, Rad4, and Radl4 proteins by Ixrl, indicating that Ixrl blocks the access of Rad2, Rad4, and Radl4 to cisplatin adducts. When the cisplatin cytotoxicity of rad IXR1 and rad ixrl strains was compared for radl and radiO,the ixrl strains were still less sensitive to cisplatin than the IXR1 strains (Fig. 3.5). This result suggests that Radl and RadlO are functionally distinct from Rad2, Rad4, and Radl4, as measured by this assay. As discussed below, this finding is in accord with recent studies performed in vitro, which assign specific functions to some of these proteins. Differences in cytotoxicity were quantitated by fitting % survival = exp(-k[cisplatin]) to the data and examining the slopes (k-values) (Table II). The results indicate that all 5 excision repair mutants were approximately 5-8 times more sensitive to cisplatin than wild type cells. The ratio of slopes for the IXR1 compared to the ixrl strains was 1.1 for the rad4 and radl4 strains, and 1.2 for the rad2 strain, significantly less than the average value of 1.5 for the repair proficient cells. The ratio is greater than 1.0 because excision repair is not the only repair process which removes cisplatin adducts. Deletion of genes involved in either double-strand break repair (Fig. 3.6) or error-prone repair (Fig. 3.7) also caused the cells to be more sensitive to cisplatin. Comparison of the range of k-value ratios obtained in the various experiments performed clearly indicates that the 183 difference between RAD and rad2,rad4,and radl4 strains is significant because they do not overlap. When the average ratios of the various strains are compared, that for RAD is greater than that for any of the excision repair strains. The Student t-test, applied by using the Fisher-Behrens problem, demonstrated the IXRl/ixrl ratios for rad2,rad4,and radl4 to be significantly different from the corresponding ratio in the RAD lines at the 95% confidence level. The radl and radiOratios were not significantly different from the ratio in wild type cells. Double-strandbreak repairmutant Rad52 is involved in homologous recombination and the repair of doublestrand breaks, MMS-DNA adducts, and ionizing-radiation-DNA adducts (Prakash and Prakash, 1977). The rad52strain was three-fold more sensitive to cisplatin treatment than the RAD52 strain (Fig. 3.6 and Table II). This result is reasonable since cisplatin forms interstrand cross-links that would have to be repaired by a system that can treat both strands. The sensitivity of the rad52 strain to cisplatin fell in between those of the excision repair mutants and that of the wild-type strain, consistent with the lower frequency of interstrand compared to intrastrand cross-link formation (Bruhn et al., 1990). The rad52ixrl strain was liesssensitive to cisplatin than the rad52IXR1 strain, indicating that the difference between IXR1 and ixrl does not involve Rad52. The k-value ratio of the IXR1 to the ixrl strains is slightly higher for the rad52strains, probably because the ability to remove interstrand adducts has been diminished. Under these circumstances, intrastrand adduct repair will be more important to cell survival, and the effect of Ixrl on cisplatin cytotoxicity correspondingly greater. Ixrl apparently had no effect on double-strand break repair, which was expected since this protein probably does not bind specifically to interstrand adducts. 184 Error-pronerepairmutant Rad6 is part of the error-prone repair pathway, which is distinct from the excision repair pathway (Friedberg, 1991b). Cisplatin cytotoxicity was determined for rad6 IXR1 and rad6 ixrl strains (Fig. 3.7, Table II). Both rad6 strains are very sensitive to cisplatin, more so than the excision repair deficient strains. The rad6 IXR1 strain is more sensitive to cisplatin than the rad6 ixrl strain, indicating that Rad6 does not effect the underlying differential cytotoxicity of RAD IXR1 and RAD ixrl. Checkpointmutant Treatment of yeast with DNA damaging agents arrests the cell cycle in either the G1/S or the G2/M transition, but not in rad9strains (Schiestl et al., 1989; Siede and Friedberg, 1990; Weinert et al., 1994). When Rad9 is removed, the cells can no longer check to see whether the DNA is damaged before proceeding to the next stage in the cell cycle. rad9mutants are less sensitive to UV light than excision repair mutants (Siede et al., 1993). The rad9 IXR1 and rad9 ixrl mutants were studied in order to determine whether Rad9 had any affect on cisplatin cytotoxicity or could mediate the difference between IXR1 and ixrl strains. Cisplatin cytotoxicity assays showed no difference between the RAD9 and rad9 strains (Fig. 3.8 and Table II). On the other hand, rad9 ixrl was less sensitive to cisplatin than rad9IXR. These results indicate that the difference between IXR1 and ixr strains is unaffected by deletion of Rad9 and that this protein does not mediate the response of yeast cells to cisplatin. DISCUSSION Ixrl affects excision repair The antitumor activity of cisplatin might be mediated by HMG domain proteins, which bind specifically to cisplatin-DNA 1,2-intrastrand cross-links. Deletion of Ixrl, a yeast HMG domain protein with similar binding 185 characteristics, 3 caused the cells to be as much as 2.1-fold less sensitive to cisplatin (Brown et al., 1993 and Table II). In the present work we have measured this effect in a different yeast background where the difference was six-fold (Fig. 3.4). One problem with cisplatin is that a number of cancers have either natural or acquired resistance to cisplatin treatment. A 2.3-fold difference in repair capability can lead to clinically relevant cisplatin resistance in human tumors (Ali-Osman et al., 1994). In this context, the differences observed in the yeast cells are sufficiently significant to warrant further investigation into their origins. Since less platinum was bound to DNA isolated from the ixrl strain following cisplatin treatment, it was suggested that the difference in sensitivity was related to the repair of the cisplatin-DNA adduct (Brown et al., 1993). There were several alternative possibilities, however; for example, reduced uptake of cisplatin into the ixrl cells would also have produced the observed results. Here we demonstrate that the difference in cisplatin cytotoxicity between the IXR1 and ixrl strains involves Rad2, Rad4, and Radl4, since interrupting the genes encoding any of these three proteins diminishes the difference between IXR1 and ixrl strains. All three proteins are required for excision repair, so it is likely that Ixrl blocks the excision repair of cisplatin-DNA adducts. Increased excision repair of cisplatin-DNA adducts in the RAD ixrl strain thus accounts for :itsgreater survival. Although the differences in cisplatin sensitivity that distinguish the rad2,rad4,and radl4 strains from the RAD strain are not large, they are quite reproducible and statistically significant at the 95% confidence level (Table II; note that the ranges are not overlapping). This finding is supported by recent in vitro excision repair assays using human cell extracts. Addition of relatively high levels of HMG1 to the extracts blocked repair of the cisplatin 1,2-d(GpG) intrastrand cross-link by the human excinuclease, but did 3 Whitehead, JP and SJL, manuscript in preparation. 186 not affect the repair of adducts to which HMG1 does not bind, specifically, the cisplatin 1,3-d(GpTpG) intrastrand cross-link (Huang et al., 1994). The present results show that HMG domain proteins can block removal of cisplatin-DNA adducts by the excision repair proteins in vivo. The results for the rad6and rad52strains demonstrate that the increased sensitivity to cisplatin of the radstrains is not masking differences between IXR1 and ixrl strains. The rad6 strains are substantially more sensitive than the excision repair deficient strains, yet the differences between the rad6 IXR1 and rad6 ixrl strains is still evident. Thus, the results for the rad2,rad4,and radl4 strains cannot be explained solely by theorizing that the difference between the IXR1 and ixrl strains disappears because these strains are more sensitive to cisplatin than the RAD strains. Although Radl and RadlO are also required for excision repair, interrupting their genes does not affect the difference between IXR1 and ixrl strains. The radl ixrl and radiOixrl strains are more resistant to cisplatin than their IXR1 counterparts; there is a measurably smaller difference between the IXR1 and ixrl strains in rad2,rad4,or radl4 strains (Table II). Even though all five of these Rad proteins are involved in excision repair (Cleaver, 1994), they are not equally capable of mediating the difference between the IXR1 and ixrl strains. We suggest that the difference in the results for the radl and radiOstrains, compared with those for the rad2,rad4,and rad14strains, arises because they act at different stages in the repair pathway (Fig. 3.1). The functions of the Rad proteins, elucidated by experiments carried out in vitro, and described in the introduction, support the present in vivo data. To elaborate, excision of cisplatin 1,2-intrastrand cross-links occurs in at least three steps, which currently appear to be performed by different proteins. The initial step involves adduct recognition and is the step that Ixrl would block by binding to the adduct. 187 Subsequently, the DNA is unwound and cleaved at both the 5' and 3' ends, and the damaged strand is removed. The proteins deleted in the present study function at different stages in this process. Radl4 recognizes DNA damage, whereas Rad2 and RadI-RadlO cleave DNA but have no specific affinity for damaged DNA. Rad4 has not been sufficiently studied to determine its activity. As discussed above, in vitro data indicate that Rad2 cleaves the DNA first. Until the DNA is cleaved, all steps in the excision repair pathway are reversible (Fig. 3.1). Since the RadI-RadlO complex acts after the first cut is made by Rad2, any disruption by Ixrl in Radl4 binding to the adduct will not affect the ability of Radl-RadlO to make the second incision. The ability of the cells to respond differentially to cisplatin when different members of the excision repair family of proteins are deleted indicates that, in vivo, there must be some factor that partially compensates for the loss of a particular protein. Such an activity is absent in cell extracts used to study excision repair, where deletion of a gene product results in complete inability to remove cisplatin 1,2-intrastrand cross-links (Huang et al., 1994). Such a hypothesis is supported by studies performed in mammalian cells having severely reduced excision repair (Venema et al., 1991;Evans et al., 1993;Zhen et al., 1993). A reduced level of excision repair would probably not be apparent in cell extract studies even if it were present, because the assays are inefficient and unable to detect repair that is 10-fold diminished. Comparisonto previouscisplatinyeaststudies Very little work has been done with cisplatin and yeast cells. CisplatinDNA adduct repair was defective in yeast cell extracts lacking Radl, Rad2, or RadlO (Wang et al., 1993). Only a few studies have been performed where whole yeast cells were treated with cisplatin. radl, rad2,rad3,rad52,and double mutant radl rad2 strains were more sensitive to cisplatin than wild-type yeast (Brendel 188 and Ruhland, 1984;Hannan et al., 1984;Wilborn and Brendel, 1989). The present results are generally in agreement with these previous experiments, but the conditions used by other workers were sufficiently different such that quantitative comparisons are not possible. The cisplatin sensitivities of the excision repair mutant strains compare well with those for cells treated with UV light. The sensitivity of rad9 strains to ultraviolet light falls midway between the sensitivity of RAD and radl strains (Siede and Friedberg, 1990);in the cisplatin cytotoxicity assay, the rad9 and RAD strains were equally sensitive to cisplatin. Double-strandbreakrepairmutant The results with the double-strand break repair protein, Rad52, provide further evidence that excision repair is responsible for the difference between the IXR1 and ixrl strains. Although rad52strains are more sensitive to cisplatin than RAD52 strains, rad52 ixrl remains less sensitive than rad52IXR1. Presumably, Rad52 helps repair interstrand cross-links, which are not recognized by HMG domain proteins, such as Ixrl. rad52is approximately three-fold more sensitive to cisplatin treatment than RAD52. Interstrand cross-links comprise ~ 4% of the total cisplatin adducts, whereas 1,2-intrastrand cross-links represent - 90% of the population (Lepre and Lippard, 1990). When the sensitivities of the different yeast strains are corrected for the number and types of adducts formed, it is apparent that interstrand cisplatin cross-links are more toxic than intrastrand cross-links. Our data indicate that Ixrl does not block repair of all types of cisplatin-DNA adducts, probably because Ixrl does not bind interstrand crosslinks. Error-pronerepairmutant Rad6 is involved in several pathways, including error-prone DNA repair (Friedberg, 1991b). It is a ubiquitin-conjugating enzyme, an activity required for its ability to function in repair (Sung et al., 1990). Although the rad6 strains are 189 20-fold more sensitive to cisplatin, the difference between the rad6 IXR1 and rad6 ixrl strains is not significantly different from that of the RAD strains. Ixrl does not seem to block the action of Rad6, which seems reasonable since it should only interfere with proteins which act at or after the damage recognition step. Rad6 may effect error-prone repair by modifying other proteins that actually perform the repair steps. Cell-cycle checkpoint mutant Rad9 induces cell cycle arrest at the G1/S border when cells are damaged with ultraviolet light and at the G2/M border when cells are damaged with ionizing radiation (Siede and Friedberg, 1990;Siede et al., 1993;Weinert et al., 1994). Cisplatin arrests the cell cycle at the G2/M border or in the S phase in mammalian cells (Sorenson and Eastman, 1988b;Sorenson and Eastman, 1988a; Sorenson et al., 1990;Inoue et al., 1992). Since there is not a large difference between the rad9 and RAD strains, the cytotoxicity assay makes it seem unlikely that Rad9 affects cisplatin cytotoxicity significantly. Thus, Rad9 is probably not involved in cisplatin-induced cell cycle arrest. CONCLUSIONS The ability of the HMG domain protein Ixrl to sensitize yeast to cisplatin has been linked to excision repair. The Ixrl protein probably shields the cisplatin-DNA 1,2-intrastrand cross-links from the repair complex. This hypothesis is explored further in the next chapter by examining the level of cisplatin-DNA adducts on the DNA of the various strains. If HMG domain proteins are blocking repair in tumor cells, then some tumors might adjust the activity of the HMG domain proteins to become more resistant to cisplatin therapy. It should be possible to design cisplatin analogs to circumvent this resistance; if the analog-DNA adduct bound HMG domain proteins more tightly than the cisplatin-DNA adduct, then the analog-DNA adduct would not be 190 repaired as quickly. The analog would be a more effective drug against the resistant tumors, and possibly against normal tumors of other origin. 191 REFERENCES Ali-Osman, F., M.S. Berger, A. Rairkar and D.E. Stein (1994) Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases axand 3,and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy. J. Cellular Biochem. 54, 11-19. Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith and K. Struhl, Eds. (1994).Current Protocols in Molecular Biology. U.S.A., Current Protocols, John Wiley & Sons, Inc. Bankmann, M., ,. Prakash and S. Prakash (1992)Yeast RAD14 and human xeroderma pigmentosum group A DNA-repair genes encode homologous proteins. Nature (London) 355, 555-558. Bardwell, A.J., L. Bardwell, N. Iyer, J.Q. Svejstrup, W.J. Feaver, R.D. Kornberg and E.C. Friedberg (1994a) Yeast nucleotide excision repair proteins Rad2 and Rad4 interact with RNA polymerase II basal transcription factor b (TFIIH). Mol. Cell. Biol. 14, 3569-3576. Bardwell, A.J., L. Bardwell, A.E. Tomkinson and E.C. Friedberg (1994b) Specific cleavage of model recombination and repair intermediates by the yeast RadlRadlO DNA endonuclease. Science 265, 2082-2085. Bardwell, L., A.J. Bardwell, W.J. Feaver, J.Q. Svejstrup, R.D. Kornberg and E.C. Friedberg (1994c)Yeast RAD3 protein binds directly to both SSL2 and SSL1 proteins: implications for the structure and function of transcription/repair factor b. Proc. Natl. Acad. Sci. (U.S.A.) 91, 3926-3930. Brendel, M. and A. Ruhland (1984)Relationships between functionality and genetic toxicology of selected DNA-damaging agents. Mutation Res. 133,51-85. Brown, S.J.,P.J. Kellett and S.J. Lippard (1993)Ixrl, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science 261, 603-605. Bruhn, S.L.,J.H. Toney and S.J. Lippard (1990)Biological processing of DNA modified by platinum compounds. Progress in Inorganic Chemistry 38, 477-516. Cleaver, J.E. (1994) It was a very good year for DNA repair. Cell 76, 1-4. Evans, M.K., J.H. Robbins, M.B.Ganges, R.E. Tarone, R.S. Nairn and V.A. Bohr (1993)Gene-specific DNA repair in Xeroderma pigmentosum complementation groups A, C, D, and F. J. Biol. Chem. 268, 4839-4847. 192 Feaver, W.J., J.Q. Svejstrup, L. Bardwell, A.J. Bardwell, S. Buratowski, K.D. Gulyas, T.F. Donahue, E.C. Friedberg and R.D. Kornberg (1993)Dual roles of a multiprotein complex from S. cerevisiaein transcription and DNA repair. Cell 75, 1379-1387. Fleer, R., C.M. Nicolet, G.A. Pure and E.C. Friedberg (1987) RAD4 gene of molecular cloning and partial characterization of a gene Saccharomycescerezvisiae: that is inactivated in Escherichia coli. Mol. Cell. Biol. 7, 1180-1192. Friedberg, E.C. (1991a) Eukaryotic DNA repair: Glimpses through the yeast Saccharomyces cerevisiae.Bioessays 13, 295-302. Friedberg, E.C. (1991b)Yeast genes involved in DNA-repair processes: new looks on old faces. Molecular Microbiology 5, 2303-2310. Gileadi, O., W.J. Feaver and R.D. Kornberg (1992) Cloning of a subunit of yeast RNA Polymerase II Transcription factor b and CTD kinase. Science 257, 13891392. Guzder, S.N., P. Sung, L. Prakash and S. Prakash (1993)Yeast DNA-repair gene RAD14 encodes a zinc metalloprotein with affinity for ultraviolet-damaged DNA. Proc. Natl. Acad. Sci. (U.S.A.) 90, 5433-5437. Habraken, Y., P. Sung, L. Prakash and S. Prakash (1993)Yeast excision repair gene RAD2 encodes a single-stranded DNA endonuclease. Nature (London) 366, 365-368. Hannan, M.A., S.G. Zimmer and J. Hazle (1984)Mechanisms of cisplatin-induced cytotoxicity and genotoxicity in yeast. Mutation Res. 127, 23-30. Hansson, J. and R.D. Wood (1989)Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum(II). Nucleic Acids Res. 17, 8073-8091. Harrington, J.J.and M.R. Lieber (1994)Functional domains within FEN-1 and RAD2 define a family of structure-specific endonucleases: implications for nucleotide excision repair. Genes Dev. 8, 1344-1355. Huang, J.-C., D.B. Zamble, J.T. Reardon, S.J. Lippard and A. Sancar (1994) HMG- domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin. Proc. Natl. Acad. Sci. (U.S.A.) 91, 10394-10398. Huang, J.C., D.L. Svoboda, J.T. Reardon and A. Sancar (1992)Human nucleotide excision nuclease removes thymine dimers from DNA by incising the 22nd phosphodiester bond 5' and the 6th phosphodiester bond 3' to the photodimer. Proc. Natl. Acad. Sci. (U.S.A.) 89, 3664-3668. 193 Inoue, S., S. Mizuno, M. Ito and T. Ohnuma (1992) Flow cytometric analyses of the characteristics of tumor cells treated with two platinum compounds: 1,1cyclobutanedicarboxylato(2-aminomethylpyrrolidine)-platinum(II) and cisplatin. Jpn. J. Cancer Res. 83, 1231-1240. Jones, C.J. and R.D. Wood (1993)Preferential binding of the Xeroderma pigmentosum Group A complementing protein to damaged DNA. Biochemistry 32, 12096-12104. Lambert, J.R., V.W. Bilanchone and M.G. Cumsky (1994)The ORD1 gene encodes a transcription factor involved in oxygen regulation and is identical to IXR1, a gene that confers cisplatin sensitivity to Saccharomycescerevisiae.Proc. Natl. Acad. Sci. (U.S.A.) 91, 7345-7349. Lepre, C.A. and S.J.Lippard (1990).Interaction of platinum antitumor compounds with DNA. Nucleic Acids and Molecular Biology Eds. F. Eckstein and D. M. J. Lilley. Heidelberg, Springer-Verlag. Li, L., S.J. Elledge, C.A. Peterson, E.S. Bales and R.J. Legerski (1994) Specific association between the human DNA repair proteins XPA and ERCC1. Proc. Natl. Acad. Sci. (U.S.A.) 91, 5012-5016. Naumovski, L. and E.C. Friedberg (1984) Saccharomyces cerevisiaeRAD2 gene: isolation, subcloning, and partial characterization. Mol. Cell. Biol. 4, 290-295. O'Donovan, A., A.A. Davies, J.G. Moggs, S.C. West and R.D. Wood (1994) XPG endonuclease makes the 3' incision in human DNA nucleotide excision repair. Nature (London) 371, 432-435. Park, C.H. and A. Sancar (1994)Formation of a ternary complex by human XPA, ERCC1, and ERCC4(XPF) excision repair proteins. Proc. Natl. Acad. Sci. (U.S.A.) 91, 5017-5021. Prakash, L. and S. Prakash (1977)Isolation and characterization of MMS-sensitive mutants of Saccharomyces cerevisiae. Genetics 86, 33-55. Schiestl, R.H., P. Reynolds, S. Prakash and L. Prakash (1989)Cloning and sequence analysis of the SaccharomycescerevisiaeRAD9 gene and further evidence that its product is required for cell cycle arrest induced by DNA damage. Mol. Cell. Biol. 9, 1882-1896. Siede, W., A.S. Friedberg and E.C. Friedberg (1993) RAD9-dependant G1 arrest defines a second checkpoint for damaged DNA in the cell cycle of Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. (U.S.A.) 90, 7985-7989. 194 Siede, W. and E.C. Friedberg (1990)Influence of DNA repair deficiencies on the UV sensitivity of yeast cells in different cell cycle stages. Mutation Res. 245, 287292. Sorenson, C.M., M.A. Barry and A. Eastman (1990)Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst. 82, 749-754. Sorenson, C.M. and A. Eastman (1988a) Influence of cis- diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res. 48, 6703-6707. Sorenson, C.M. and A. Eastman (1988b) Mechanism of cis- diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res. 48, 4484-4488. Sung, P., S. Prakash and L. Prakash (1990) Mutation of cysteine-88 in the SaccharomycescerevisiaeRAD6 protein abolishes its ubiquitin-conjugating activity and its various biological functions. Proc. Natl. Acad. Sci. (U.S.A.) 87, 2695-2699. Sung, P., P. Reynolds, L. Prakash and S. Prakash (1993)Purification and characterization of the SaccharomycescerevisiaeRAD1/RAD10 endonuclease. J. Biol. Chem. 268, 26391-26399. Tomkinson, A.E., A.J. Bardwell, L. Bardwell, N.J. Tappe and E.C. Friedberg (1993)Yeast DNA repair and recombination proteins Radl and RadlO constitute a single-stranded-DNA endonuclease. Nature (London) 362, 860-862. Tomkinson, A.E., A.J. Bardwell, N. Tappe, W. Ramos and E.C. Friedberg (1994) Purification of Radl protein from Saccharomycescerevisiaeand further characterization of the Radl/RadlO endonuclease complex. Biochemistry 33, 5305-5311. Treiber, D.K., X. Zhai, H.M. Jantzen and J.M. Essigmann (1994)Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc. Natl. Acad. Sci. (U.S.A.) 91, 5672-5676. Venema, J., A. van Hoffen, V. Karcagi, A.T. Natarajan, A.A. van Zeeland and L.H.F. Mullenders (1991)Xeroderma pigmentosum complementation group C cells remove pyrimidine dimers selectively from the transcribed strand of active genes. Mol. Cell. Biol. 11, 4128-4134. Wang, Z., J.Q. Svejstrup, W.J. Feaver, X. Wu, R.D. Kornberg and E.C. Friedberg (1994)Transcription factor b (TFIIH) is required during nucleotide-excision repair in yeast. Nature (London) 368, 74-76. 195 Wang, Z., X. Wu and E.C. Friedberg (1993) Nucleotide-excision repair of DNA in cell-free extracts of the yeast Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. (U.S.A.) 90, 4907-4911. Weinert, T.A., G.L. Kiser and L.H. Hartwell (1994) Mitotic checkpoint genes in budding yeast and the dependence of mitosis on DNA replication and repair. Genes Dev. 8, 652-665. Weiss, W.A. and E.C. Friedberg (1985)Molecular cloning and characterization of the yeast RADO1 gene and expression of RAD10 protein in E. coli. EMBO J. 4, 1575-1582. Wilborn, F. and M. Brendel (1989)Formation and stability of interstrand crosslinks induced by cis- and trans-diamminedichloroplatinum(II) in the DNA of Saccharomyces cerevisiae strains differing in repair capacity. Curr. Genet. 16, 331338. Zhen, W., M.K. Evans, C.M. Haggerty and V.A. Bohr (1993) Deficient gene specific repair of cisplatin-induced lesions in Xeroderma pigmentosum and Fanconi's anemia cell lines. Carcinogenesis 14, 919-924. 196 Table I Plasmids used in construction of radstains Gene Plasmid Interrupting gene Restriction enzymes used to cut plasmid RAD1 pWS15101 URA3 PvuII RAD2 pWS5201 TRP1 SalI RAD4 pNF416 2 URA3 SphI, XmnI, isolate 4.2 kB RAD6 pR6.71 3 URA3 BamHI RAD9 pTWO39-URA3 4 URA3 BglII, SalI RAD10 pBRWS-RAD10 5 URA3 BglII, partial SalI RAD14 pBRWS-RAD14 1 HIS3 SpeI, EcoRV RAD52 pSM22 6 URA3 BamHI 1 E. Friedberg, 4 unpublished. (Siede et al., 1993). 5 2 (Fleer et al., 1987). 3 L. Prakash, (Weiss and Friedberg, 1985). 6 D. unpublished. Schild, unpublished. 197 Table II Quantitation of cisplatin cytotoxicity in yeasta Strain IXR1 IXR1 / ixrl range RAD 7.9+1.6 1.5±0.2 1.3-2.1 ad2 49+7 1.2+0.06 1.09-1.24 rad4 42+12 1.1+0.09 0.93-1.16 43+14 1.1+0.13 0.94-1.26 radil 66+7 1.3+0.02 1.30-1.34 ladlO 53+5 1.5+0.16 1.3-1.7 rad6 202+50 1.4+0.05 1.40-1.50 rad9 9.4+0.5 1.5+0.06 1.48-1.60 rad52 20+6 2.2+0.3 1.9-2.6 ad14 a Values reported in the table are the slopes (k) of cytotoxicity plots such as those in Figs. 3-8, where % survival=exp(-k[Pt]) and [Pt] is the concentration of cisplatin in the medium. The Student t-test, applied using the FisherBehrens problem, demonstrated that the IXR1 /ixrl ratios for rad2,rad4, and radl4 were significantly different at the 95% confidence level than that for RAD. The ratios for radl and radi0 were not significantly different. 198 Figure 3.1. Model for excision repair of cisplatin-DNA adducts. The numbered proteins are the Rad proteins. S1 stands for Ssll, and T1 stands for Tfbl. The details of the figure are explained in the text. 199 - - ad14 recognize: Ixrl binds - - I I adduct Le - 3' ad3 *Rad2 cle .Ll-- 11f - : A - -. C J.'L-- -1 ULC O IUC UI LI1C I DNA polymerase & ligase Radl/10 cuts at the 5' side t adduct *Rad3 may help unwind the duplex/ * RT,"1 /1 n hind" / " """'f L '" "" . ' 201 202 Figure 3.2. A. Ultraviolet light sensitivity of various yeast strains. Strains were streaked onto YPD agar and 80% of the plate was exposed to ultraviolet light. Strains which were rad did not survive this operation. B. Sensitivity of rad52 strains to MMS. The plate on the left was YPD only, the plate on the right was YPD + 0.017%MMS. rad52strains are highly sensitive to MMS damage. 203 A ixrl rat rad2 rad rad B IXI RA d52 IXIr I IX :rl 152 rad 0d52 IXI ad52 ntrol RA rad, no MMS ontrol MMS treated 205 206 Figure 3.3. Cisplatin cytotoxicity assays performed on the excision repair deficient strains RAD IXR1, RAD ixrl, rad2 IXR1 and rad2 ixrl. RAD IXR1 and RAD ixrl strains were also treated in the same experiment; those lines were left out since they were similar to those in Fig. 2A. 207 100 10 (d 1 0 0.1 0.01 0 0.2 0.4 0.6 0.8 [Cisplatin] mM 1 1.2 208 Figure 3.4. Cisplatin cytotoxicity assays performed on the excision repair deficient strains rad4 IXR1, radl4 IXR1, rad4 ixrl, and radl4 ixrl. RAD IXR1 and RAD ixrl strains were also treated in the same experiment; those lines were left out since they were similar to those in Fig. 2A. 209 100 10 (n 1 0--- 0.1 0.01 0 0.05 0.1 0.15 [Cisplatin] mM 0.2 0.25 0.3 210 Figure 3.5. Cisplatin cytotoxicity assays performed on the excision repair deficient strains radl IXR1, radIOIXR1, radl ixrl and radi0 ixrl . RAD IXR1 and RAD ixrl strains were also treated in the same experiment; those lines were left out since they were similar to those in Fig. 2A. 211 100 10 1 0.1 0.01 0.001 0 0.05 0.1 [Cisplatin] mM 0.15 0.2 212 Figure 3.6. Cisplatin cytotoxicity assays performed on RAD IXR1 and the double strand break repair deficient lines rad52IXR1 and rad52ixrl. The RAD ixrl strain was also treated in the same experiment; that line was left out of the figure since it was similar to that in Fig. 2A. 213 100 10 1 . 0.1 0.01 0.001 0 0.2 0.4 0.6 0.8 [Cisplatin] mM 1 1.2 214 Figure 3.7. Cisplatin cytotoxicity assays performed on the error-prone repair deficient strains rad6 IXR1, and rad6 ixrl. RAD IXR1 and RAD ixrl strains were also treated in the same experiment; those lines were left out since they were similar to those in Fig. 2A. 215 100 10 cfn C> 1 0.1 0 0.01 0.02 0.03 0.04 0.05 [Cisplatin] mM 0.06 0.07 0.08 216 Figure 3.8. Cisplatin cytotoxicity assays performed on RAD IXR1, RAD ixrl, and the cell cycle checkpoint deficient lines rad9IXR1 and rad9 ixrl. 217 1)0 10 c ~> 1 01 0.01 0.001 0 0.2 0.4 0.6 0.8 [Cisplatin] mM 1.2 218 219 CHAPTER 4 Repair of cisplatin-DNA adducts 220 INTRODUCTION The processing of cisplatin-DNA adducts by repair proteins affects the cytotoxicity of the drug. In the previous chapter, the hypothesis that Ixrl partially blocks excision repair proteins from repairing cisplatin-DNA adducts was supported by cytotoxicity assays involving various rad mutants. If this hypothesis is correct, there should be fewer cisplatin-DNA adducts in the ixrl cells because more DNA repair occurs in those cells. In this chapter, the level of cisplatin-DNA adducts was determined both for genomic DNA and for a transcribed gene. Other experiments were performed to investigate the processing of cisplatin-DNA adducts in various systems. The cleavage of cisplatin and trans-DDP DNA adducts by bacterial restriction enzymes was investigated. The repair of cisplatin and trans-DDPadducts by mammalian cell extracts was studied. These experiments support the theory that trans-DDP-DNA adducts are repaired more readily than cisplatin-DNA adducts. The level of platinum adducts was measured to determine whether the difference between IXR1 and ixrl strains was really due to differential repair. Platinum levels were checked on the genomic DNA by atomic absorption. These experiments give the level of platinum on global DNA. Excision repair of cisplatin adducts often occurs faster on genes that are being transcribed (May et al., 1993;Zhen et al., 1993). Therefore, the platinum adduct levels were also investigated on a highly transcribed gene, specifically, phosphoglycerate kinase (PGK) (Hitzeman et al., 1982). The platinum levels were determined by using quantitative polymerase chain reaction (PCR) (Grimaldi et al., 1994). CisplatinDNA adducts block Taq polymerase (Comess et al., 1992),which means that DNA with cisplatin adducts is not amplified. The level of adducts can be 221 estimated from the amount of product obtained from cisplatin-treated DNA compared to control DNA. Restriction enzyme digestion can be used as a simple model for the ability of platinum adducts to inhibit protein function. The activity of restriction enzymes is easy to measure, and restriction enzymes bind to small regions of DNA. BamHI activity, for example, is blocked by cisplatin-DNA adducts (Ushay et al., 1981), as are other restriction enzymes such as EcoRI and SalI (Balcarova et al., 1992; Brabec and Balcarova, 1993). The studies presented here investigate BamHI and EcoRI, as well as several other restriction enzymes. Further experiments were done on a site-specifically platinated construct that contains a trans-DDP-DNA adduct within a XhoI restriction site. The presence of cisplatin- and trans-DDP-DNA adducts was monitored by restriction enzyme digestion. Since adducts block some restriction enzymes well, it is possible to watch the removal of the adducts in mammalian cell extracts by measuring enzymatic cleavage of the DNA. This assay was developed to confirm that trans-DDP-DNA adducts are repaired more readily than cisplatinDNA adducts. Two different sorts of repair assays indicated that such was the case (Ciccarelli et al., 1985;Heiger-Bernays et al., 1990). It was hoped that this new assay would be more sensitive than the other assays. MATERIALS AND METHODS Determiningcisplatin-DNA adduct levels Saccharomycescerevisiaestrains and growth media are defined in chapters 2 and 3. Atomic Absorption experiments to measure platinum adduct levels in cells Yeast cells were grown to saturation in 100 mL of synthetic complete media at 30°C for 4-5 days. SC was used instead of YPD media because, when the cells were grown in the latter media, they turned red due to the absence of 222 the Ade2 protein. This red-brown color would have been carried with the DNA through most if not all of the isolation procedure; high levels of impurities prevent the furnace from effectively vaporizing the platinum and thus lead to anomalous platinum levels. One mL portions of IXR1and ixrl cells were used in a cisplatin cytotoxicity assay. The difference in cisplatin sensitivity between IXR1 and ixrl was not as pronounced as for cells grown in YPD, but was still reproducibly present. Cells were pelleted in sterile flasks and resuspended in cisplatin-containing SC media. Fresh media were used since the pH value decreased while the cells were growing. The cells were shaken in media containing cisplatin for 4 hours. The amount of cisplatin used was adjusted to correspond to approximately the same percentage of cells killed for each of the strains. Thus, the radl, rad2,rad4,radlO,and rad14strains were treated with 33 pRMcisplatin whereas the rad52strains were treated with 83 gM cisplatin and the rad9 and RAD strains with 167 gM cisplatin. The DNA was isolated by making spheroplasts, breaking them open, precipitating most of the protein with KOAc, and subsequently precipitating the DNA (Philippsen et al., 1991). The pellet was resuspended in 10 mL of TE (10 mM Tris pH 8.0, 1 mM EDTA) buffer. The RNA present in the sample was digested by treating the sample with RNAce-itTM (Stratagene) for 16-24 hours at 37°C. The DNA was then treated with Proteinase K (Sigma) for 16 hours at 37°C to digest any remaining protein. The sample was extracted once with phenol/chloroform/isoamyl alcohol (25:24:1).The DNA was precipitated with NH4OAc and ethanol. The pellet was resuspended in 1 mL of TE buffer and a 10 L portion was run on an agarose gel to confirm that the RNA was completely digested. The sample volume was reduced to approximately 500 jtL in vacuo and then extracted with phenol/chloroform/ isoamyl alcohol until no further precipitate was visible at the interface of the phases. The DNA was again precipitated with NH4OAc and ethanol; the pellet 223 was redissolved in 500 gL of TE buffer. Samples were dialyzed against several changes of 0.1 M NH4OAc over a 48 hour period. Excess NH4OAc was removed by dialysis into distilled, deionized H20 with several changes over a 24 hour period. The concentration of DNA was quantitated by measuring the A260. Equal amounts of DNA for the IXR1and ixrl strains were dried down and resuspended in 70 [tL of water. The DNA was digested with DNAse I (Boehringer Mannheim). The digestion solution was made 1 mM in MgCl2 since the DNAse I requires magnesium ion; the level of magnesium was kept low since higher quantities of magnesium caused false platinum readings. The total reaction volume was 100 AL. A 1 L portion of DNAse I (10 mg/mL) was added three times during the course of a 3 day incubation at 37°C. A 10 gL portion of the sample was run on an agarose gel to confirm that the digestion was complete. Atomic absorption analysis was performed on these samples with a Varian AA1475 and a GTA95 graphite tube atomizer, as described previously (Ciccarelli et al., 1985). The bound drug/nucleotide ratios, (D/N)b, were the average of values from three to four experiments. Polymerase chain reaction basedassay Cisplatin-DNA adducts block polymerases, including Taq polymerase, so the extent of cisplatin damage can be measured by monitoring the quantity of product from a polymerase chain reaction (PCR) assay. Cells were grown and treated with cisplatin for these assays as they were for cytotoxicity assays (chapters 2, 3), except that a 5 mL volume was employed. Cells were pelleted, washed once with water, repelleted in an Eppendorf tube, and stored at -80°C until the DNA was extracted. The cells were resuspended in 0.2 mL of buffer (1% SDS, 2% Triton X-100, 100 mM NaCl, 10 mM Tris pH 8.0, 1 mM EDTA). The cells were broken by 3 minutes of vortexing after 0.2 mL phenol/CHC13/isoamyl alcohol, and 0.3 g acid-washed beads (Sigma, 425-600microns) were added. The 224 aqueous layer was increased by adding 0.2 mL TE. The tubes were centrifuged for 5 minutes and the aqueous layer was transferred to a new tube. The DNA was precipitated with 1 mL of EtOH. The pellet was resuspended in 0.4 mL of TE plus 1 gL of RNAce ItTM (Stratagene) and was incubated overnight at 37°C. Proteinase K was then added and the DNA was incubated for 2-16 hrs at 37°C. The DNA was extracted three times with phenol/CHC13/isoamyl alcohol and ethanol precipitated. The pellet was again resuspended in TE and RNAce It, and incubated overnight. The DNA was extracted two times with phenol/CHC13/ isoamyl alcohol and once with CHC13/isoamyl alcohol to remove all remaining protein. The DNA was ethanol precipitated and resuspended in 0.6 mL H 20. The concentration of the DNA was determined by measuring the A260 value of an 0.5 mL aliquot of that solution. The remaining solution was diluted if necessary to permit pipetting 10 ng of DNA for use in the PCR reactions. Cells for investigating the time dependence of the removal of cisplatinDNA adducts were grown in YPD media with 1 gCi of tritiated adenine or uracil per flask (20 mL) of YPD media. The cells were treated with cisplatin as described above. The cells were then pelleted and resuspended in five times as much YPD media, which sufficiently diluted the cells so that they would eventually grow. Aliquots of cells were taken at the times indicated in the individual experiments. Cells were pelleted and stored in the -80 until DNA was prepared as detailed above. The level of tritium in the DNA was measured with a Beckman scintillation counter where 0.5 mL of DNA was added to 5 mL of Hydrofluor scintillation fluid. This procedure yields disintegrations per minute (dpm)/gg of DNA. The method for carrying out the PCR reactions was derived from Grimaldi et al. (1994). PCR reactions were performed in 100 gL with 10 ng DNA, 1.2 mM each dNTP, 0.5 mM MgCl2, 0.5 M KCl, 0.1 M Tris pH8.3, 50 pmol of each oligo, 2 225 ~tCi dCTP (NEN), and 2 units Taq polymerase (GIBCO). The oligos used were 5'CACGAATT(GAGCTCTTTGGCTGAT-3' and 5'-CCCTTGCCAGCCAGCTGGAATACC-3' which amplify a 432 bp segment to give a 480 bp piece of DNA. The reactions were carried out in a 96 well dish with oil overlays on each sample. The samples were incubated for 2 minutes at 94°C, cycled through 20 cycles of 1 min. at 94°C, 1 min. at 60°C, 1 min. at 72'C, and finally incubated for 4 min. at 72°C. Reactions with 5 ng and 10 ng of control DNA were always performed to be sure that the PCR was still solely dependent on DNA. A 30 gL aliquot of the reaction was mixed with formamide loading dye and run on a 4.5% polyacrylamide gel. The gel was dried and analyzed using a phosphorimager (Molecular Dynamics). The lesions/strand ratio was calculated by assuming a Poisson distribution of adducts, so lesions/strand = -ln (PCR product/PCR product of undamaged DNA). PCR experiments were also performed on plasmid DNA damaged with cisplatin. The plasmid used, pDEC (pDEC006),and the oligos skpl3 and skpl4 were the gift of Dave Coufal and Sonja Komar-Panicucci. These oligos amplify a 473 bp section of DNA to make a 513 bp piece of DNA. The plasmid was treated with cisplatin and the adduct levels were determined by atomic absorption analysis. The 1.00gL PCR reactions were performed with 3 pg DNA, 10 gL 10OxPCR buffer (GIBCO),0.273 gg primers, 0.2 mM each dNTP, 1.5 mM MgCl2, 2 iuCidCTP (NEN), and 2 units Taq polymerase (GIBCO). The samples were incubated for 3 min. at 94°C, 28 cycles of 45 sec. at 94°C, 30 sec. at 57°C, and 1.5 min. at 72°C, and finally 45 sec. at 94°C, 30 sec at 57°C, and 10 min. at 72°C. ]Products were analyzed as described above. 226 Restriction enzyme cleavage of cisplatin and trans-DDP treated DNA. Platinationof DNA The virus M13mpl8 DNA was treated with trans-DDPat 0.075 Pt/nucleotide 37'C (Ushay et al., 1981). Aliquots were taken at 30 min, 1, 2, 4, 6, 10, and 24 hrs, and the reaction was stopped by adding NaCl to 0.2 M. M13mp18 DNA was also treated with trans-DDPat 1.5 Pt/nucleotide. pUC19 plasmid DNA was treated similarly with cisplatin and trans-DDPat (D/N)formal=l Pt/nucleotide and at 0.075 Pt/nucleotide. Excess platinum was removed from the DNA by applying the DNA to G-50 sephadex quick-spin columns (Boehringer Mannheim) or by repeated ethanol precipitation of the DNA. Restriction enzyme digestion Restriction enzyme digestion was performed such that unplatinated samples were completely cleaved. All restriction enzymes were supplied by New England BioLabs, and the digestions were performed in their suggested buffer. After digestion, samples were run on an 0.8% agarose plus ethidium bromide gel (Sambrook et al., 1989). Constructionof a circularpieceof DNA containinga site-specifictrans-DDPd(GAG) adduct The construction was done using the gapped-duplex protocol (Naser et al., 1988). First, a 12 base pair sequence, CCTCGAGTCTCC,was inserted into the HindII restriction site of M13mp18, and the construct was confirmed by sequencing. This construct was called M13mpl8-Xhol2C because the inserted oligonucleotide had a site for the XhoI restriction enzyme. Single stranded DNA was made from M13mpl8-Xhol2C. Double stranded M13mp18 was made and cleaved with HindII. When the linear M13mpl8 DNA was denatured and slowly renatured in the presence of a great excess of the single-stranded M13mp18Xhol2C DNA, gapped duplexes were formed. Unadducted CCTCGAGTCTCC 227 and trans-DDP treated CCTCGAGTCTCCwere ligated into the gap. Any remaining M13mpl8 was linearized by digesting with HindII; the closed-circular DNA was isolated by agarose gel electrophoresis and subsequent electroelution in an Amicon centrilutor. The trans-DDP treated CCTCGAGTCTCColigonucleotide was obtained from Chris Lepre. It was examined by atomic absorption analysis and by complete enzymatic degradation of the oligonucleotide (Bellon and Lippard, 1990). RepairAssay Preparationof substrate pUC19 plasmid was treated with cisplatin or trans-DDPto an (D/N)b of approximately, 0.006, and then digested with Sma I for 1 hour, which cut about one half of the pUC19 circles. The remaining closed-circular DNA was purified by 2 successive 5% to 20% sucrose gradient centrifugation steps which were each spun at 2°C in the ultracentrifuge in a SW27 rotor for 27 hrs at 24000 rpm. The fractions from the gradient were analyzed by agarose gel electrophoresis. Fractions containing closed-circular DNA were pooled and ethanol precipitated. Restriction enzyme based repair assay in cell extracts Repair reactions were run with 0.2 gg pUC19 DNA, 200 gg HeLa cell extract, 45 mM Hepes (pH 7.8), 60 mM KCl, 7.5 mM MgCl2, 0.9 mM DTT, 0.4 mM EDTA, 2 mM ATP, 20 jiM each dGTP, dCTP, dTTP, and dATP, 40 mM creatine phosphate, 1 gg creatine phosphokinase, 3.4% glycerol, and 18 gg BSA for 6-24 hrs. at 30°C. The pUC19 was recovered by digestion of the above mixture with RNAse and proteinase K in the presence of 0.5% SDS. The mixture was then phenol extracted to remove proteins and ethanol precipitated. The DNA was resuspended in TE, digested with Nde I and Sma I, and radiolabelled by filling in the Nde I produced overhanging ends with the Klenow fragment of DNA 228 polymerase I. Sucrose loading buffer (40%) was then added and the DNA was loaded onto a 1.8% agarose gel. The gel was run at 100 volts, dried, and put onto the phosphorimager for quantitation of the bands. RESULTS Levels of cisplatin-DNA adducts on yeast genomic DNA The amount of cisplatin covalently bound to the yeast genomic DNA was measured. For these experiments, cells were grown to saturation in synthetic complete media and treated with cisplatin for four hours. After platinum treatment, the cells were harvested and the DNA was isolated. The experimental conditions differed from those in the cytotoxicity assays because the cells never grew in fresh media following cisplatin treatment. There was a significant difference between the IXR1and ixrl strains (Table I). This result supports the repair blockage hypothesis. The difference in cisplatin-DNA adduct level between IXR1 and ixrl strains is not present in the radl, rad2,rad4,or rad10strains, further supporting the hypothesis (Table I). It was not clear if a difference was present in the radl4 strains. The difference was present in the rad52 strains indicating that, as found in the cytotoxicity assay, Rad52 is not part of the cause of the difference. The rad9 strains showed no particular difference, which is not in agreement with previous cytotoxicity results. Overall, the results examining the level cisplatin-DNA adducts on globally platinated DNA in excision repair deficient strains indicate that the repair shielding hypothesis is valid. Levels of cisplatin-DNA adducts on a transcriptionally active yeast gene Cisplatin-DNA adduct levels on part of a gene that is highly expressed were investigated. Actively transcribed genes are thought to be repaired more readily than other types of DNA (May et al., 1993;Zhen et al., 1993). The gene for phosphoglycerate kinase (PGK) was chosen since it is well studied (Hitzeman 229 et al., 1982). Quantitative PCR was exploited to give information about the adducts. Taq polymerase is blocked by cisplatin-DNA adducts, so if a piece of DNA has an adduct, it will not be amplified by PCR. The adduct levels can be obtained by comparing the amount of product obtained in control, unplatinated DNA PCR reactions to the product for the cisplatin treated DNA reactions. Adducts are assumed have a Poisson distribution, which means that the lesions per strand = -I:n(Product(damaged)/Product(undamaged)). (Drug/nucleotide)bound ((D/N)b) ratios can be calculated by dividing the lesions per strand by the length of the product, 480 bases. This calculation assumes that product cannot be produced from DNA when there is an adduct between the furthest ends of the primer hybridization sites. Initial experiments were carried out with a plasmid, pDEC, which has a 513 bp PCR product. This plasmid was treated with three different levels of cisplatin. The resulting PCR experiment gave (D/N)b ratios that were between 1.2 and 2.5 fold higher than (D/N)b ratios obtained from atomic absorption readings. More extensive studies of the accuracy of PCR based (D/N)b ratios are present in the literature(Jennerwein and Eastman, 1991). The results confirm that quantitative PCR is a reasonably accurate technique for determining the amount of platinum bound per nucleotide. Cells were grown and treated with cisplatin exactly as for the cytotoxicity assays, except that the volume and number of cells were increased 5 fold. DNA was extracted from these cells and the proteins and RNA were removed from the DNA preparation. The PCR conditions were established on unplatinated DNA by varying [DNA], [MgC12], [dNTP], and the number of cycles. The conditions were adjusted so that the PCR reaction was always dependent solely on the substrate DNA. This aspect was examined in every PCR reaction by amplifying 5 ng of unplatinated DNA and comparing the amount of product to that of the 10 230 ng sample. The PCR products were analyzed on a 4.5% polyacrylamide gel, which was dried and the bands were quantified on a phosphorimager. The 480 bp product was the only product of the reaction (Fig. 4.1). The lower diffuse band was due to the primers themselves becoming radiolabelled. The time dependence of cisplatin-DNA adduct removal was investigated by treating cells with the drug and then letting them recover from treatment by growing in fresh media for various times. The level of DNA synthesis that is not related to repair was calculated by using cells grown in media containing tritiated uracil or adenine. The recovery was performed in normal media, where new DNA synthesis diluted out the amount of tritium per glgof DNA. The calculated level of cisplatin-DNA adducts was adjusted to take into account only the tritiated DNA present in the original cells. Cisplatin adduct level and removal studies were performed on the IXR1, ixrl, radl4 IXR1, radl4 ixrl, JM43, and JM43Aixrl strains. The cisplatin-DNA adduct levels rose with the level of cisplatin treatment in both the IXR1 and ixrl cells (Fig. 4.2). There was no significant difference in cisplatin adduct level between the IXR1 and ixrl strains. The (D/N)b values for the strains at the same platination levels used in the atomic absorption experiments was 1.6x10-3 adducts/nucleotide, and hence the level determined by the PCR technique for the transcribed gnee was an order of magnitude less than the level for bulk DNA from the atomic absorption experiment. This result indicates that the PGK gene is repaired more rapidly than the rest of the DNA. The rate of cisplatin adduct removal experiment also showed no significant difference between the IXR1 and ixrl strains (Fig. 4.3). The small difference observed in Fig. 4.3 was not reproducible; also, since the slopes are essentially the same, the rate of repair is also the same. The IXR1and ixrl cells did not grow significantly during the 6 hour experiment, according to the level of tritium in the DNA. The cells did 231 grow significantly when the cells were grown for 24 hours; the DNA in these samples was almost entirely newly synthesized. Repair was nearly complete at 6 hours for both strains. These results indicate that removing Ixrl does not cause any difference in the repair of cisplatin-DNA adducts in the highly transcribed PGK gene. The radl4 strains were much more sensitive to cisplatin in the cytotoxicity assays (Chapter 3) and the cisplatin-DNA adduct levels are correspondingly higher at the same platination levels. At 33 gM cisplatin, the (D/N)b was 1.1x10-3 adducts/nucleotide, again an order of magnitude lower than that from the atomic absorption experiment (Fig. 4.4). Again, this result is consistent with the possibility that the PGK gene is repaired more readily than the rest of the DNA. One interesting and reproducible aspect of this experiment was that the amount of PCR product increased at low platination levels in the ixrl strain. This increase caused the apparent number of adducts per strand to become negative (Fig..4.4). This phenomenon was sometimes encountered with the IXR1 strain as well. Cisplatin adducts are known to unwind DNA which may make it easier for the primers to anneal to the genomic DNA. When the primers can anneal more readily, more product can be formed from the same amount of substrate. The repair rate in the radl4 strains was also examined (Fig. 4.5). This experiment showed that the radl4 strains do indeed remove cisplatin-DNA adducts. The rate at which this occurred was not reproducible; two experiments are shown in Fig. 4.5 to show the range of results obtained. Full repair of the adducts took eight hours for these strains. The strains did not grow significantly during those eight hours. There was no significant difference in the repair of cisplatin-DNA adducts in the radl4 ixrl strain. Interestingly, repair was observed; the radl4 strains should be deficient in global excision repair, so some other form of repair must be occurring. 232 The results with the JM43 and JM43Aixrl strains were similar to those for the IXR1 and ixrl strains. No difference in adduct level was noted between JM43 and JM43Aixrl (Fig. 4.6). This result again implies that the lack of ixrl does not affect the repair of the PGK gene. The cisplatin repair rates in these strains were similar when DNA replication was not accounted for (Fig. 4.7a). These cells grew substantially during the experiment, however, as can be seen in Fig. 4.7b. This growth level was high enough to account for all of the increase in PCR product (Fig. 4.7c). The adduct levels on the original DNA appear to actually increase significantly with time. It is possible that repair of the cisplatin-DNA adducts in these strains involved large pieces of DNA, which would mean that a significant part of the new DNA synthesis was part of the repair event. If such were the case, not all the decrease in tritium signal should be used to adjust the adduct levels because the majority of the tritium signal is no longer due to cell growth. Alternatively, this result would also be explained if repair occurred in the time between platination and recovery. Repair that occurs before the time 0 point is naturally not seen in this experiment; if a significant amount of the repair occurs when the DNA is treated with cisplatin, then that would explain the low rate of repair in this experiment. Since the JM43 strains both grow significantly faster than any of the other strains tested, it is quite likely that they are repairing their DNA more quickly. Restrictionenzyme cleavageof cisplatin-and trans-DDP-DNA adducts There are several publications which discuss how cisplatin and trans-DDP form adducts on DNA which block restriction enzyme cleavage (for example, Ushay et al., 1981;Balcarova et al., 1992). A series of experiments was performed to define how well some restriction enzymes were blocked by such damage on the DNA. DNA was treated with the same concentration of cisplatin or transDDP for varying times. The cleavage of several restriction enzymes was checked 233 for the minimum times needed to cleave fully unplatinated DNA, since if DNA is over-digested, nonspecific or star activity can occur, which also cleaves the DNA. Digestion was measured by running digested DNA on agarose gels and monitoring the conversion of the closed-circular plasmid band to nicked and linear forms. Both pUC'19and M13mp18 DNA were used in these experiments. M13mp18 treated with trans-DDPwas cleaved with SacI. SacI digestion is fully inhibited by DNA damaged at a (D/N)b between 0.12 and 0.17 (Fig. 4.8). Cisplatin and trans-DDP damaged pUC19 were cleaved with BamHI, SmaI, PstI, and EcoRI. Two of these experiments are shown in Figs. 4.9 and 4.10, and the data are summarized in Table II. Higher levels of cisplatin cause all three of the plasmid bands to migrate faster on the gel. The nicked and linear bands merge, as has been shown separately (data not shown); this phenomena has also been noted in the literature (Ushay et al., 1981). This result is probably due to the adducts bending the DNA and altering its mobility in the gel. It is clear from Table II that different restriction enzymes cleave damaged DNA to different extents. The different extents of cleavage may be because, at lower levels of platination, the damage is not actually within the restriction enzyme site. A sitespecifically platinated construct was made as shown in Fig. 4.11. This construct contains a trans-DDP-DNA adduct in the XhoI site, CTCGAG. The oligonucleotide was characterized in several ways. It was shown to be free of detectable impurities by running HPLC columns that separate unplatinated and platinated oligonucleotides. The oligo itself was digested to completion to demonstrate that all of the G bases are bound to the platinum; no G peak was visible in the HPLC trace, whereas a peak for Pt-d(G)2 was present. The platination level of the oligonucleotide was also checked by atomic absorption 234 analysis, and the oligo was found to be fully platinated. The presence of the adduct on the final construct was also determined. Replication blockage experiments demonstrate that polymerases are blocked by platinum adducts; it has been found that different adducts are blocked to different extents. If one assumes complete blockage of the polymerase, then one can determine how many adducts are present on the DNA. The trans-DDP-M13-Xhol2C construct was characterized in a replication-blockage experiment (Comess, 1991). The polymerase was blocked in at least 75% of the strands at the site of platination, indicating that at least 75% of the DNA circles had platinum attached. The actual number of circles with platinum attached is probably higher than this since in similar experiments, the cisplatin d(GCG) 1,3-intrastrand adduct only blocked replication by about 75% (Comess, 1991). The adduct probably does not rearrange into interstrand adducts since it was never heated (Locker et al., 1995). These experiments demonstrate that the trans-DDPd(GAG) adduct was present both on the oligonucleotide and on the final trans-DDP-M13-Xhol2C construct. trans-DDP-M13-Xhol2C was cleaved fairly efficiently by XhoI, even though the adduct was in the XhoI site. This result was observed for several different preparations of trans-DDP-M13-Xhol2C (data not shown). In Fig. 4.12, it is clear that the closed circular trans-DDP-M13-Xhol2C construct was converted to nicked and linear pieces. The XhoI enzyme did not convert this construct to linear DNA as readily as it linearized the unplatinated construct (lanes 4 and 5). The trans-DDP-M13-Xhol2Cconstruct was treated with cyanide to remove the platinum adduct. The resulting unplatinated construct was cleaved more readily than trans-DDP-M13-Xhol2C (lanes 6 and 7); this particular preparation did not have much closed circular DNA, however, other experiments showed complete cleavage of such DNA when far more was present. There was more linear product in both of the constructs without a platinum adduct. XhoI 235 cleaved the DNA with the platinum adduct, but it could not make a doublestranded cut as easily. The platinum adduct does not block the binding and nicking activity of the XhoI enzyme, even when the adduct is present in the binding site. Restriction enzyme based DNA adduct repair assay A repair assay can be used that takes advantage of the ability of platinumDNA adducts to block cleavage by some restriction enzymes. Certain restriction enzymes, such as SmaI, are blocked by relatively low quantities of platinum adducts. The repair of the adducts can be examined with the restriction enzymes since when adducts are removed, the restriction enzyme can cut the DNA. A substrate for such a repair assay was created by treating pUC19 DNA with cisplatin or trans-DDP. The treated plasmid was cut with SmaI to linearize any DNA that SmaI could cut naturally, and the closed circular portion was isolated. The DNA was run on two sucrose gradients to purify further the closed circular form so that the assay only measured actual repair events. Any nicks present in the DNA can act as initiation points for polymerases which might remove the adducts by displacing the damaged strand. The presence or absence of the adducts was verified by digesting the plasmids with SmaI and NdeI (Fig. 4.13). NdeI does not have a potential platination site in its recognition site and is not particularly sensitive to platinum adducts, so it can be used to help generate a small, readily visible piece of DNA. The SmaI+NdeI digest releases a small piece of DNA in unplatinated constructs (Fig. 4.13, lane 4). Cisplatin and trans-DDP treated plasmids do not form this small piece of DNA (Fig. 4.13, lanes 2 and 3). The untreated, cisplatin treated, and trans-DDP treated plasmids were used in a repair assay, where they were treated with HeLa cell extract and then assayed for release of the small piece of DNA (Fig. 4.14). The presence of the small piece of DNA indicates that there were an insufficient number of adducts 236 present on the DNA to block the SmaI restriction enzyme. The small piece of DNA is present in the untreated plasmid lane (Fig. 4.14, lane 1, at product arrow). There is no significant amount of product in the cisplatin treated plasmid lane (Fig. 4.14, lane 2), which implies that the cisplatin-DNA adducts are not readily repaired in this assay. The product band is present in the trans-DDP treated plasmid lane (Fig. 4.14, lane 3), which means that the trans-DDPadducts are repaired enough to permit SmaI cleavage of the DNA. The trans-DDP damaged plasmid was repaired more strongly than the cisplatin damaged plasmid. DISCUSSION Platinum levels on yeast DNA--generalDNA The repair shielding hypothesis was supported by experiments examining the amount of platinum adducts on yeast genomic DNA. The level of platinum adducts on the DNA was quantified in various IXR1 and ixrl strains by atomic absorption analysis. The repair shielding hypothesis predicts that the adduct levels will be lower in the ixrl strains because the adducts are removed more readily by the excision repair system. When the adduct levels were measured in IXR1 and ixrl by atomic absorption, the ixrl DNA clearly had less platinum attached (Table I, RAD strain). This result was previously reported by S. Brown (Brown et al., 1993). This result was further investigated by examining the excision repair deficient strains radl, rad2,rad4,radlO,and radl4. If the decrease in cisplatin adduct levels in the ixrl strain is due to the shielding of excision repair, then inactivating the excision repair pathway should remove the difference in adduct levels between ixrl and IXR1 strains. The repair deficient strains were treated with much lower levels of cisplatin so that the number of dead cells was not significantly greater in the rad strains. Dead cells can lead to abnormally high levels of adducts since they no longer repair their DNA. At 237 these lower levels of platination, rad strains had about the same number of adducts as RAD strains (Table I). Since cisplatin-DNA adducts are removed by excision repair, the rad strains cannot repair the cisplatin-DNA adducts as readily so more adducts were accumulated, for example, compare rad2 to RAD (Table I), taking into account the higher levels of cisplatin used to treat the RAD strains. The excision repair deficient strains did not show any difference in platinum adduct levels between rad ixrl and radIXR1 strains, which supports the repair shielding hypothesis. The difference between RAD IXR1 and ixrl strains present in the atomic absorption experiment disappeared in the radl, rad2,rad4, and radlOstrains. Therefore, the decreased level of adducts in the ixrl strain was dependent upon active excision repair, indicating that Ixrl shields the adduct from excision repair in the IXR1strain. In the cytotoxicity assays of radl and radlO,the rad ixrl strains were still less sensitive than the rad IXR1 strains (Chapter 3), although the strains were not different in the atomic absorption assay. The cytotoxicity assay was more sensitive and more reproducible than the platinum level experiments, so small differences are more apparent. The results of the atomic absorption experiments with the rad14strain are unclear; while the average (D/N)b of the two strains were significantly different, the standard deviation on those numbers was large enough to cause them to overlap. It is likely that further experiments would demonstrate that there is no significant difference between these two strains. Therefore, no real conclusion can be made about the presence of a difference between the radl4 IXR1 and rad14ixrl strains. Overall, these results support the repair shielding hypothesis because the difference in platination levels between the IXR1and ixrl cells was dependent upon excision repair. 238 Platinum levels on actively transcribed DNA in yeast DNA repair occurs more rapidly in the actively transcribed gene PGK than in the rest of the DNA. Adduct levels were measured in the highly transcribed PGK gene by quantitative PCR. In all four strains tested using both PCR and atomic absorption analysis, the adduct levels were an order of magnitude lower in the PCR experiments. There were fewer adducts present on the PGK gene than on the remainder of the DNA. This result could be due to either increased repair or decreased adduct formation. The adduct formation is unlikely to be decreased selectively in the PGK gene, since cisplatin-DNA adducts should form more readily in actively transcribed regions of DNA since they are not wound up as chromatin. Increased repair of cisplatin-DNA adducts in actively transcribed genes has been demonstrated in mammalian cells (May et al., 1993). This phenomenon is also present in mammalian and yeast cells for UV adducts (Bohr, 1991;Verhage et al., 1994). These results are the first demonstration that gene-specific repair occurs in yeast cells with cisplatin adducts. Ixrl apparently does not block repair of cisplatin adducts in the actively transcribed PGK gene. There was no difference in adduct levels between IXR1 and ixrl strains in the PGK gene. This result was observed in both the IXR1and JM43 strains. Interrupting RAD14 caused the adduct levels to increase on the PGK gene because excision repair was disabled. It takes about 5 fold less cisplatin to give the radl4 strains the same amount of adducts as the IXR1 strains. This result implies that the PGK gene was repaired at least in part by excision repair in the IXR1 strain. Since the adduct levels in the IXR1 and ixrl strains were the same, Ixrl cannot be affecting the repair of this gene. Therefore, Ixrl does not block cisplatin-DNA adduct repair in the PGK gene, probably because it is highly repaired due to active transcription. 239 The rate of cisplatin-DNA adduct repair was investigated in the highly -transcribed gene PGK. There was no significant difference in the rate of the repair of this gene between IXR1 and ixrl cells in two different yeast backgrounds, which supports the above conclusion that Ixrl does not block cisplatin-DNA adduct repair in the PGK gene. There is a significant amount of repair of this gene occurring during the platination step since it has much lower levels of adducts than the rest of the DNA. The JM43, IXR1,and rad14 strains all had different repair rates. In the IXR1cells, the repair of the cisplatin adducts was 50% complete in 1-2 hours, and finished within 6 hours of removal of the cisplatin from the media. The rate of cisplatin repair in the JM43cells was not clear since they grew so rapidly that, when the repair levels were adjusted for DNA synthesis, no repair was apparent. The difference between the JM43result and that for the IXR1cells was probably because JM43 cells grow significantly faster than the IXR1cells. Since radl4 cells are deficient in excision repair, one would expect the repair to occur more slowly than in the wild-type IXR1cells., As monitored by PCR, the rate of repair in the radl4 cells was not reproducible from experiment to experiment, but in some cases, it was about 2 times slower than that for the IXR1cells (Fig. 4.5). It is possible that there are other forms of repair that are used in the actively transcribed regions which repair the adducts in the rad14cells. These repair mechanisms are not as efficient as excision repair, since more adducts build up in radl4 cells. They are, however, sufficient to help repair the gene. This result is reasonable because other forms of repair do exist, excision repair is simply the most studied. These results indicate that repair occurs in the PGK.gene in both wild-type and radl4 strains. Platinum levels on yeast DNA--Other types of repair The platinum adduct levels in the rad52and rad9 strains were also measured by atomic absorption spectroscopy. The results with the double- 240 strand break repair deficient rad52strains are similar to those for the same strains in the cytotoxicity assay. Interruption of RAD52 caused the cells both to become more sensitive to cisplatin (Chapter 3) and to accumulate higher levels of adducts ( Table I). Therefore, Rad52 is involved in the cellular response to cisplatin. It participates in double-strand break repair and recombination, and is probably involved in the repair of cisplatin interstrand cross-links (Chapter 3). The rad52 ixrl strain was less sensitive to cisplatin and fewer adducts were present on its DNA than for the rad52 IXR1 strain (Chapter 3; Table I). Rad52 is therefore not part of the mechanism by which Ixrl affects cisplatin cytotoxicity. Ixrl does not block the type of repair that Rad52 assists. This result is reasonable since Ixrl does not bind to interstrand cross-links. Rad52 repairs cisplatin-DNA adducts, probably interstrand adducts, but is not blocked by Ixrl. The results with the checkpoint mutant, rad9,are substantially different from those obtained in the cytotoxicity assay experiments. There was very little difference between the rad9and RAD strains in the cytotoxicity assay, which made it seem unlikely that Rad9 affected cisplatin cytotoxicity significantly. The level of cisplatin bound to the DNA in the rad9 resting cells, however, was substantially higher than that for RAD cells (Table I). This result may indicate that Rad9 does have some role in signaling the cell to remove cisplatin adducts from DNA. It is possible that, in resting cells, Rad9 is necessary for cisplatinDNA adduct repair whereas it is not required for cells that proceed more swiftly through the GO phase of the cell cycle. Comparison to mammalian and E. coli cell adduct levels The levels of cisplatin bound to wild-type yeast DNA were about two orders of magnitude higher than equally toxic levels in human or Escherichiacoli cells (Razaka et al., 1986; Bouayandi et al., 1993; Mamenta et al., 1994). Apparently, yeast can survive higher levels of cisplatin adducts, at least in their 241 resting state. The dose of cisplatin needed to kill yeast cells was also higher than that for human or E. coli cells (Razaka et al., 1986; Bouayandi et al., 1993; Mamenta et al., 1994). Presumably, yeast repair many of these adducts when they start replicating. The adduct levels were an order of magnitude lower in genes that are actively transcribed, which indicates that many of the extra adducts are present in regions of the DNA where they will not block RNA polymerases. RestrictionEnzyme digestionof platinum-treatedDNA Restriction endonucleases bind DNA prior to cleaving and thus model other DNA binding proteins. If a platinum-DNA adduct can disrupt cleavage by a restriction enzyme, it might also disrupt the activity of a transcription factor or polymerase. Experiments were performed to investigate whether platinumDNA adducts affect all restriction enzymes. Cisplatin and trans-DDPDNA adducts have been shown to block restriction enzyme digestion in the literature (Ushay et al., 1981; Balcarova et al., 1992; Brabec and Balcarova, 1993, and references therein). Contrary to these results, a trans-DDP-d(GAG) adduct in the XhoI recognition site did not block XhoI from nicking and cleaving the DNA. The activity of XhoI was not completely blocked by the trans-DDPadduct, even though other restriction enzymes were blocked by other site-specific platinum adducts (Naser et al., 1988;Comess et al., 1992). These results indicate that different restriction enzymes are affected differently by platinum-DNA adducts. This result was not found in previous publications. Several other restriction enzymes were also investigated. BamHI, SmaI, and PstI digestions were all blocked at approximately the same relatively low adduct levels following treatment by cisplatin or trans-DDP(Table II). SacI, which recognizes the inverse of the XhoI site, required many more trans-DDP adducts to block its cleavage than were required for repression of BamHI 242 activity. Inhibition of EcoRI required more cisplatin or trans-DDPadducts than BamHI or SmaI or PstI. These differences may be because the adducts present in and around the recognition sites were different types. The quantity of adducts blocking BamHI, SmaI and PstI was sufficiently low that there is only an adduct in the recognition site of about one in six plasmids. This result means that the distortions caused by adducts in the surrounding DNA must affect the cleavage of these enzymes. The difference cannot be solely due to the presence of d(GG) sites in some sites and not in others, because trans-DDPdoes not bind to d(GG) sites, yet the same difference was observed. The higher levels of platinum required to inhibit SacI and EcoRI reflect approximately one adduct within the recognition site in about 75% of the plasmids. Apparently, the adducts must be much closer to the recognition site to disturb cleavage by these enzymes. The different restriction enzymes probably contact the DNA in different manners and with different specificities. EcoRI is known to make 12 hydrogen bonds with its recognition sequence, including one to the N7 of the guanine in its recognition sequence, which is where any adducts in the recognition sequence would bind (McClarin et al., 1986). BamHI contacts the DNA in both the major and minor grooves, and has a similar crystal structure to that of EcoRI (Newman et al., 1994; Kang et al., 1995). SmaI contacts not only both the N7 of the guanines and the phosphate backbone within the site but also the three adjacent bases on each side (Withers and Dunbar, 1995). Clearly, the additional contacts of SmaI will make it less tolerant to the distortion of the DNA duplex caused by platinum adducts. These experiments show that different restriction enzymes are affected differently by adducts, implying that generalizations about adducts blocking the binding of whole groups of proteins are not valid. Several other publications measured the inhibition of restriction enzymes by platinum adducts. The data for BamHI presented here is similar to 243 that from one such publication (Ushay et al., 1981). A different group has published two papers studying EcoRI, BamHI, and SalI (Balcarova et al., 1992; Brabec and Balcarova, 1993). Both studies were performed on the same piece of DNA and it was platinated in the same manner; in all respects, the experiments were identical. Yet the results were significantly different, since the second paper reported that the inhibition of BamHI, EcoRI and Sall required cisplatin adduct levels that were an order of magnitude lower than in the first paper. Even though the two papers have several of the same authors, there is no reference to the first paper in the second. Both papers report that BamHI and EcoRI were inhibited by similar levels of cisplatin, which does not agree with the present results. The papers do not indicate the flanking sequences of the restriction enzyme sites, nor do they use a standard plasmid, so comparisons of the flanking sequence are not possible. The difference between the current data and these past results cannot be explained since they give no explanation for their extremely different results, making it unclear which adduct levels should be used in comparisons to the present data. Restriction enzyme based repair assay A platinum adduct repair assay was developed and used to demonstrate that trans-DDP DNA adducts were repaired more readily than cisplatin-DNA adducts in HeLa cell extracts. The inhibition of restriction enzyme cleavage by platinum-DNA adducts can be used as a probe for the presence of adducts. An assay for the repair of those adducts was designed around platinum treated probes that are not cleaved by SmaI. If repair occurs, the SmaI cleaves the DNA, giving rise to a small fragment of DNA. The trans-DDPtreated probe was partially repaired when it was incubated in HeLa cell extracts. The cisplatin treated probe was not noticeably repaired. Therefore, the trans-DDPadducts were repaired more easily than the cisplatin adducts in cell extracts. trans-DDP 244 adducts do not seem to be repaired more readily than cisplatin adducts by excision repair in mammalian cells as measured by transcription reactivation experiments (Mello et al., 1995). Increased repair in mammalian cell extracts has been seen with two other assays as well; the reason for the discrepancy between these experiments is unknown (Heiger-Bernays et al., 1990; Mello et al., 1995). The more proficient repair of the trans-DDP-DNA adducts may be because HMG domain proteins do not bind to these adducts, and thus do not block their repair. The HMG domain proteins present in the HeLa cell extract may block the repair of the cisplatin adducts but not the repair of the trans-DDPadducts. Another possible explanation is that the trans-DDPadducts may be more easily recognized by the repair proteins, since trans-DDPadducts distort the DNA in a different manner from cisplatin adducts. Whatever the correct explanation is, trans-DDP adducts are repaired more readily than cisplatin adducts in cell extracts. CONCLUSIONS The data in this chapter support the hypothesis that Ixrl shields cisplatinDNA adducts from excision repair. They also demonstrate that cisplatin-DNA adducts are repaired more readily from actively transcribed genes in S. cerevisiae. In another set of experiments, it was shown that a restriction enzyme, XhoI, could still cleave DNA even with a trans-DDPadduct in its recognition site. This result and the results with the other restriction enzymes indicate that the inhibition of cleavage by platinum adducts is not a universal phenomenon. It is thus likely that other DNA processing proteins exist which platinum adducts do not inhibit. It is important that generalizations about inhibition of proteins are not made too broadly, since proteins seem to be able to adapt to DNA damage. Finally, it was demonstrated that trans-DDP-DNA adducts are repaired more readily than cisplatin-DNA adducts in mammalian cell extracts. Overall, these 245 data support the conclusion that the repair of cisplatin-DNA adducts is a key element of its cytotoxicity. 246 REFERENCES Balcarova, Z., J. Mrazek, V. Kleinwachter and V. Brabec (1992) Cleavage by restriction enzymes of DNA modified with the antitumour drug cisdiamminedichloroplatinum(II). Gen. Physiol. Biophys. 11, 579-588. Bellon, S.F. and S.J. Lippard (1990)Bending studies of DNA site-specifically modified by cisplatin, trans-diamminedichloroplatinum(II) and cis[Pt(NH 3 ) 2 (N3-cytosine)Cl]+. Biophysical Chemistry 35, 179-188. Bohr, V. (1991) Gene specific DNA repair. Carcinogenesis 12, 1983-1992. Bouayandi, K., G. Villani and B. Salles (1993) Resistance to cisplatin in an E. coli B/r NalR mutant. Mutation Res. 294, 77-87. Brabec, V. and Z. Balcarova (1993)Restriction-enzyme cleavage of DNA modified by platinum(II) complexes. Eur J Biochem 216, 183-187. Brown, S.J.,P.J. Kellett and S.J. Lippard (1993)Ixrl, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science 261, 603-605. Ciccarelli, R.B., M.J. Solomon, A. Varshavsky and S.J. Lippard (1985) In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry 24, 7533-7540. Comess, K.M. (1991) M.I.T. Thesis Comess, K.M., J.N. Burstyn, J.M. Essigmann and S.J. Lippard (1992)Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-Diamminedichloroplatinum(II) DNA adducts. Biochemistry 31, 39753990. Grimaldi, K.A., J.P. Bingham, R.L. Souhami and J.A. Hartley (1994)DNA damage by anticancer agents and its repair: Mapping in cells at the subgene level with quantitative polymerase chain reaction. Analyt Biochem 222,236-242. Heiger-Bernays, W.J., J.M. Essigmann and S.J. Lippard (1990) Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication. Biochemistry 29, 8461-8466. Hitzeman, R.A., F.E. Hagie, J.S. Hayflick, C.Y. Chen, P.H. Seeburg and R. Derynck (1982)The primary structure of the Saccharomyces cerevisiaegene for 3phosphoglycerate kinase. Nucleic Acids Res. 10, 7791-7808. 247 Jennerwein, M.M. and A. Eastman (1991)A polymerase chain reaction-based method to detect cisplatin adducts in specific genes. Nucleic Acids Res. 19, 62096214. Kang, Y.K., H.B. Lee, M.J. Noh, N.Y. Cho and O.J. Yoo (1995) Different effects of base analog substitutions in BamHI restriction site on recognition by BamHI endonuclease and BamHI methylase. Biochem Biophys Res Comm 206, 997-1002. Locker, D., M.. Decoville, J.C. Maurizot, M.E. Bianchi and M. Leng (1995) Interaction between cisplatin-modified DNA and the HMG boxes of HMG1: DNAse I footprinting and circular dichroism. J Mol Biol 246, 243-247. Mamenta, E.L., E.E. Poma, W.K. Kaufmann, D.A. Delmastro, H.L. Grady and S.G. Chaney (1994)Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 54, 3500-3505. May, A., R.S. Nairn, D.S. Okumoto, K. Wassermann, T. Stevnsner, J.C. Jones and V.A. Bohr (1993)Repair of individual DNA strands in the hamster dihydrofolate reductase gene after treatment with ultraviolet light, alkylating agents, and cisplatin. J. Biol. Chem. 268, 1650-1657. McClarin, J.A., C.A. Frederick, B.C. Wang, P. Greene, H.W. Boyer, J. Grable and J.M. Rosenberg (1986)Structure of the DNA-EcoRI endonuclease recognition complex at 3 A resolution. Science 234, 1526-1541. Mello, J.A., S.J. Lippard and J.M. Essigmann (1995) DNA adducts of cis- diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo. Submitted. Naser, L.J., A.L. Pinto, S.J. Lippard and J.M. Essigmann (1988)Chemical and biological studies of the major DNA adduct of cis-diamminedichloroplatinum(II), cis[Pt(NH 3 ) 2{d(GpG)} ] , built into a specific site in a viral genome. Biochemistry 27, 4357-4367. Newman, M., T. Strzelecka, L.F. Dorner, I. Schildkraut and A.K. Aggarwal (1994) Structure of restriction endonuclease BamHI and its relationship to EcoRI. Nature (London) 368, 660-664. Philippsen, P., A. Stotz and C. Scherf (1991) DNA of Saccharomyces cerevisiae. Methods in Enzymology 194, 169-182. Razaka, H., B. Salles, G. Villani and N.P. Johnson (1986) Toxicity, mutagenicity and induction of recA protein in Escherichia coli treated with cisDiamminedichloroplatinum (II) and cis-Diamminetetrachloroplatinum (IV). Chem.-Biol. Interactions 60, 207-215. 248 Sambrook, J., E.F. Fritsch and T. Maniatis (1989). Molecular cloning: a laboratory manual. USA, Cold Spring Harbor Laboratory Press. Ushay, H.M., T.D. Tullius and S.J.Lippard (1981)Inhibition of the BamHI cleavage and unwinding of pBR322 deoxyribonucleic acid by the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry 20, 3744-3748. Verhage, R., A.-M. Zeeman, N. de Groot, F. Gleig, D.D. Bang, P. van de Putte and J. Brouwer (1994) The RAD7 and RAD16 genes, which are essential for pyrimidine dimer removal from the silent mating type loci, are also required for repair of the nontranscribed strand of an active gene in Saccharomyces cerevisiae. Mol. Cell. Biol. 14, 6135-6142. Withers, B.E. and J.C. Dunbar (1995)Sequence-specific DNA recognition by SmaI endonuclease. J. Biol. Chem. 270, 6496-6504. Zhen, W., M.K. Evans, C.M. Haggerty and V.A. Bohr (1993)Deficient gene specific repair of cisplatin-induced lesions in xeroderma pigmentosum and Fanconi's anemia cell lines. Carcinogenesis 14, 919-924. 249 Table I (D/'N)b levels measured by atomic absorption Strain [Cisplatin] mMa IXR1I (x103 ) ixrl (x103 ) RAD 167 36 + 11 16 + 0 rad2 33 12 + 8 9 +3 rad4 33 13 + 3 15+ 3 radl4 33 13 + 3 6+3 radl 33 13 + 5 11 + 2 radiO 33' 15 + 5 16 + 3 rad9 167 64 + 23 85 + 23 rad52 83 58 + 24 20 + 1 a The different levels were used to treate the cells in order to equalize the number of killed cells. 250 Table II Platinum-DNA adducts block restriction enzyme activity Restriction Enzyme Cleavage site Reaction conditions (D/N)b values between which restriction enzymes were completely inhibited cis trans SacI ttcGAGCTCggt aagCTCGAGcca 37°C, 60 min. -- .12 .17 BamHI cggGGATCCtct 37°C, 40 min. .020 .028 .026 .038 gccCCTAGGaga SmaI gtaCCCGGGgat catGGGCCCcta 25°C, 10 min. .012 .020 .023 .028 PstI gacCTGCAGgca ctgGACGTCcgt 37°C, 10 min. .020 .026 .028 .038 EcoRI agtGAATTCgag tcaCTTAAGctc 37°C, 45 min. .089 .13 .19 .21 251 252 Figure 4.1. Gel of PCR product from PGK gene from yeast genomic DNA treated with various levels of cisplatin. The first two lanes contain unplatinated DNA; the first lane contains one half of the DNA of the second. This lane shows that the PCR reaction is dependent solely on the level of substrate DNA. 253 Cisplatin DNA 51 0*404* & to*4_S 480 bp primers 10 * iiiii 255 256 Figure 4.2. Analysis of PCR products from DNA extracted from IXR1and ixrl cells treated with increasing levels of cisplatin. 257 1 0.8 r. c7 U .4 Vx cn 4-A 0.6 0.4 Cbl 0.2 0 0 0.05 0.1 [Cisplatin] mM 0.15 0.2 258 Figure 4.3. Analysis of PCR products from DNA extracted from IXR1and ixrl cells treated with cisplatin and permitted to recover in fresh media for various times. 259 1.2 1 to (J u(J 0.8 0.6 0.4 0.2 0 0 1 2 3 4 Time (hrs) 5 6 7 260 Figure 4.4. Analysis of PCR products from DNA extracted from radl4 IXR1 and radl4 ixrl cells treated with increasing levels of cisplatin. 261 I,nu.u 0.5 0.4 $a 0.3 cn 0.2 0.1 O -0.1 -0.2 0 0.005 0.01 0.015 0.02 [Cisplatin] mM 0.025 0.03 0.035 262 Figure 4.5. Analysis of PCR products from DNA extracted from rad14IXR1 and radl4 ixrl cells treated with cisplatin and permitted to recover in fresh media for various times. The two graphs represent two different experiments. 263 1 .J : 1 rj u 7; 0.5 0 0 2 4 6 8 10 Time (hrs) .L 1 -' c¢/ - 0.8 0.6 cjI 0.4 0.2 0 0 2 4 6 Time (hrs) 8 10 264 Figure 4.6. Analysis of PCR products from DNA extracted from JM43 and JM43Aixrl cells treated with increasing levels of cisplatin. 265 11 2.5 2 1.5 1 0.5 TO 0 0.1 0.2 0.3 0.4 [Cisplatin] mM 0.5 0.6 0.7 266 Figure 4.7. Analysis of PCR products from DNA extracted from JM43 and JM43Aixrl cells treated with cisplatin and permitted to recover in fresh media for various times. A. Adduct level calculated without accounting for cell growth. B. Level of tritium in DNA shows tritium level decreasing as cells grow. C. Adduct level adjusted for cell growth. 267 A 1 . 1 1 0.8 c 0.6 u 0.4 0.2 0 0 1 2 3 4 5 6 7 8 Time (hrs) R2 Li. 1 ID 10 8 cr. 4 2 0 0 2 4 6 Time (hrs) 8 10 268 C. 4 "d : 3 "0 2 1 ;-4 0 2 4 6 Time (hrs) 8 10 269 270 Figure 4.8. SacI restriction enzyme digestion of trans-DDPtreated M13mp18 virus DNA. A. Lower levels of platinum adducts. Lane 0: untreated M13mp18 and digested M13mpl8 mixed to give marker lane. Lanes 1-8:M13mp18 treated with various levels of trans-DDPand digested with SacI. (D/N)b levels are 0.0012, 0.0049, 0.0094, 0.015, 0.027, 0.032, and 0.054 Pt/nucleotide for lanes 1-8, respectively. B. Higher levels of platinum adducts. Lanes 0-8 are the same except that lanes 1-8 contain trans-DDPtreated DNA with 0.023, 0.061, 0.085, 0.098, 0.13, 0.12, 0.17 Pt/nucleotide, respectively. 271 trans-DDP A. 0 1 2 3 4 5 6 7 8 partially digested nicked I linear completely digested \_ \ closed circular B. partially digested completely digested undigested undigested trans-DDP 0 1 2 3 4 5 6 7 8 273 274 Figure 4.9. SmaI restriction enzyme digestion of cisplatin and trans-DDPtreated pUC19 plasmid DNA. A. Treated pUC19 plasmid DNA run an agarose gel with no digestion. The "m" lane contains the X-HindIII DNA size marker. The "p" lane contains undamaged pUC19 plasmid DNA. The small band visible below the main closed-circular plasmid band is a marker plasmid that helps show the change in electrophoretic mobility between the various levels of platinum-treated DNA. The (D/N)b in the cisplatin treated samples are 0.0026, .00050,0.012, 0.020, 0.026, 0.034, 0.040 Pt/nucleotide for lanes 1-7, respectively. The (D/N)b in the trans-DDP treated samples are 0.0030, 0.0057, 0.011, 0.017, 0.023, 0.028, 0.038 Pt/nucleotide, for lanesl-7, respectively. B. SmaI digested pUC19 plasmid DNA. Lane markings are the same as for (A). 275 A. I trans-DDPdamaged Cisplatin damaged 1 2 3 4 5 6 7 1 2 3 4 nickedclosed circular marker plasmid" B. my 0 1 2 3 4 5 partially digested completely digested undigested. Cisplatin damaged 0 12 3 4 5 6 7 partially digested completely digested undigested trans-DDPdamaged 6 7 5 6 7 277 278 Figure 4.10. EcoRI restriction enzyme digestion of cisplatin and trans-DDP treated pUC19 plasmid DNA. A. Treated pUC19 plasmid DNA run an agarose gel with no digestion. The "m" lane contains the X-HindIIIDNA size marker. The "p" lane contains undamaged pUC19 plasmid DNA. The small band visible below the main closed-circular plasmid band is a marker plasmid that helps show the change in electrophoretic mobility between the various levels of platinum-treated DNA. The (D/N)b in the cisplatin treated samples are 0.032, 0.053, 0.089, 0.13, 0.17, 0.20, 0.26 Pt/nucleotide for lanes 1-7, respectively. The (D/N)b in the trans-DDP treated samples are 0.062, 0.092, 0.19, 0.21, 0.20, 0.26, 0.34 Pt/nucleotide, for lanesl-7, respectively. B. SmaI digested pUC19 plasmid DNA. Lane 0 contains undamaged pUC19 DNA digested with EcoRI. Other lane markings are the same as for (A). 279 A. m 7 6 5 4 3 2 1 / nicked - closed circular % marker plasmid Cisplatin damaged m p 1 2 3 4 5 6 7 nicked closed circular marker plasmid trans-DDPdamaged B. partial. m vO 1 2 34 5 6 7 digestE Cisplatin damaged completely digested undigested 1 2 3 4 partially digested completely digested undigested 5 6 7 trans-DDPdamaged 281 282 Figure 4.11. Construction of trans-DDP-M13-Xhol2C. Double stranded M13mp18 was linearized with HindII (step 1). This DNA was mixed with an excess of single-stranded M13-Xho12CDNA and denatured in formamide (step 2). The mix was then slowly renatured to give M13-Xhol2C gapped duplexes, one strand of M13mpl8, and the excess M13-Xho12Ccircles (step 3). The gapped duplexes were purified away from the single-stranded material by hydroxyapatite chromatography (step 4). The trans-DDPadducted oligonucleotide was ligated into the gapped duplex, yielding trans-DDP-M13Xhol2C (step 5). 283 GGAGCTCAGAGG (+) M13-Xhol2C single strand 1) linearize Dialysis (+) (+) 2) denature in formamide 3) renature in TE IF GGA(CTCAGAGG4) remove M13-Xho12C gapped duplex (+) ( ) _. single strand s & (-) Pure gapped duplex Ligate & 'GAGTCTCC pped duplex (+) (+) 'rrr-fArrr 284 Figure 4.12. Digestion of trans-DDP-M13-Xhol2C by XhoI. Lane 1 contains k- HindIII DNA size marker. Lanes 2 and 3 contain trans-DDP-M13-Xhol2C DNA. Lanes 4 and 5 contain un-M13-Xhol2C, which is made in the same way, except the oligonucleotide used in step 5 was not treated with trans-DDP. Lanes 6 and 7 contain trans-DDP-M13-Xhol2C DNA that was treated with cyanide to remove the platinum adduct. DNA in lanes 3, 5, and 7 were treated with XhoI restriction enzyme. 285 DNA M trans Unpt CN- XhoI digestion nicked linear closed circular 1 2 3 4 5 6 7 287 288 Figure 4.13. Test of repair assay substrates. Digestion of untreated, cisplatin treated, and trans-DDPtreated pUC19 with the restriction enzymes SmaI and NdeI and with NdeI alone. Lane 1 contains X-HindIII DNA size marker. Lane 8 contains the pBR322-MspDNA size marker. Lanes 2 and 5 contain trans-DDP treated pUC19 (T lanes). Lanes 3 and 6 contain cisplatin treated pUC19 (C lanes), and lanes 4 and 7 contain pUC19 alone (U lanes). The DNA in lanes 5-7 were treated with NdeI alone, whereas the DNA in lanes 2-4 were treated with both SmaI and NdeI. 289 digestion DNA M1 SmaI+NdeI NdeI T C U TCU M2 1 E. 1 2 3 4 small piece of DNA from SmaI+NdeI cleavage 5 6 7 8 291 292 Figure 4.14. Restriction enzyme based repair assay performed in HeLa cell extracts. Lane 1 contains untreated DNA, lane 2 contains cisplatin treated DNA, and lane 3 contains trans-DDP treated pUC19 DNA. The DNA in all three lanes was incubated with HeLa cell extracts, purified, and digested with SmaI and NdeI. Absence of platinum adducts was observed by watching for the band marked product. This gel is equivalent to the gel in Fig. 4.13, except that the DNA was treated with the HeLa cell extracts. 293 UCT plasmid-_ product-- 1 2 3 295 CHAPTER 5 HMG domain proteins binding to cisplatin-DNA adducts in vivo 296 INTRODUCTION Titration Hypothesis HMG domain proteins could affect cisplatin cytotoxicity in other ways than by shielding repair of cisplatin-DNA adducts. Many of the HMG domain proteins are transcription factors, and cisplatin treatment may disturb the transcription of the genes they regulate (Fig. 5.1) (Donahue et al., 1990). When HMG domain proteins bind to cisplatin-DNA adducts, they are no longer available to bind to their natural target sites. The affinity of HMG domain proteins for cisplatin-DNA adducts is the same as or greater than their affinity for their natural binding sites. In cells undergoing chemotherapy, there are more cisplatin-DNA adduct binding sites than natural binding sites, so the HMG domain proteins may be titrated or "hijacked" away from their natural binding sites, thus disrupting the expression of the gene(s) that the proteins regulate. This theory is supported by work with hUBF, the human upstream binding factor (Treiber et al., 1994). hUBF is a transcription factor for ribosomal RNA, which are critical for cell proliferation and survival. hUBF binds to a site- specific cisplatin-d(GpG) adduct more readily than its natural binding site. hUBF was removed from its natural binding site by physiological levels of cisplatin-DNA adducts. These studies were performed in vitro, and could not take into account any response the cell might make to the removal of hUBF from its natural binding site. For instance, the cell might raise the level of hUBF to prevent cisplatin-DNA adducts from hijacking enough hUBF to kill the cell. In the work described in this chapter, the titration or "hijacking" hypothesis was tested in vivo using Ixrl. Ixrl represses transcription of the COX5b gene (Lambert et al., 1994). Two kinds of experiments were devised. First, the COX5b promoter was inserted before the Bt-galactosidasegene on a yeast plasmid. S. cerevisiaecontaining the plasmid were treated with cisplatin 297 and the level of B-galactosidase activity was determined. If Ixrl were removed from the COX5b promoter by cisplatin-DNA adducts, then the expression of iBgalactosidase should increase. Experiments with ixrl cells containing the plasmid were run to control for inhibition of transcription by cisplatin that bound to the plasmid gene itself. ixrl cells expressed the iB-galactosidasegene well, since there was no Ixrl to inhibit transcription. The titration theory was also -testedby examining transcription from the COX5b promoter in genomic DNA. Yeast cells were treated with cisplatin, and the levels of Cox5b mRNA were analyzed by northern analysis. .HMG1 binds cisplatin-DNA adducts in vivo HMG domain proteins bind to cisplatin-DNA adducts in vitro. The binding of HMG1, Ixrl, and hUBF have all been studied in detail, and several other HMG domain proteins bind to globally platinated DNA (Pil and Lippard, 1992;Chow et al., 1994;Treiber et al., 1994;Whitehead and Lippard, 1995). DNA in vivo is quite different from that used for in vitro studies. Genomic DNA is longer and has proteins bound to it, such as histones that wind it up into smaller packages. Therefore, it is necessary to establish whether HMG1 binds to cisplatin l:reated genomic DNA. This question was first addressed by experiments performed in the Scovell laboratory (Scovell et al., 1987;Hayes and Scovell, 1991a; Hayes and Scovell, 1991b),which were repeated and expanded here. It was originally reported that HMG1 was cross-linked to the DNA by cisplatin. Since this work was performed before HMG1 was known to bind to cisplatinDNA adducts, it was of interest to determine whether the original experiments could be interpreted differently. 298 MATERIALS AND METHODS Yeast strains and plasmids The yeast strains used were JM43,JM43Aixrl, IXR1and ixrl. Their genotypes are given in Chapter 2. Plasmid pYep contains the COX5b promoter inserted before the i-galactosidase gene on a yeast plasmid (obtained from the Cumsky laboratory). All media types are described elsewhere (Ausubel et al., 1994). Testing the titration hypothesis Plasmidbasedtest A plasmid, pYep, with the COX5b promoter linked directly to the 3galactosidase gene was transformed into yeast. Freshly transformed cells were used in the assays since the P-galactosidase activity drops off after about a week. JM43 and JM43Aixrl cells containing the plasmid were inoculated into SCAUra (2% galactose) media and the cells were grown into log phase. The cells were then pelleted and resuspended in 5 mL of fresh media containing varying levels of cisplatin. The cells were incubated for 6 hours at 30°Cin culture tubes on a rotating wheel. The cells were then frozen at -80°C. The assay was adapted from that in Current Protocols in Molecular Biology (Ausubel et al., 1994). When the assay was performed, the cells were thawed, pelleted in the clinical centrifuge, and resuspended in 5 mL of Z buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, 50 mM -mercaptoethanol, pH 7.0). The OD600 (optical density) was determined. The assay was performed by bringing 10,50, 100, or 500 gl of cells to 1 mL with Z buffer; two different dilutions were used for each sample. A drop of 0.1% SDS and two drops of chloroform were added to each sample with a Pasteur pipet. The samples were then vortexed for 15 seconds to break the cells open. They were equilibrated to 30°C in a water bath for 15 minutes. The color reagent, o-nitrophenyl-p-D-galactoside (ONPG) was added to 299 each tube at 0.2 mL of a 4 mg/mL solution in 0.1 M KPO4, pH 7.0. The tubes were mixed by vortexing for 5 seconds. The reactions were permitted to run at 30°C until the solution was a medium yellow. The reaction was stopped by adding 0.5 mL of 1M Na2CO3; the reaction time was noted. The tube was centrifuged for 5 minutes in an Eppendorf centrifuge to pellet the cell debris. The OD420 of the samples was taken. The OD550 value of the samples was consistently 0, which indicates that the cell debris was completely pelleted. 1- Galactosidase activity was calculated according to the standard equation U = 1000*(OD420)/[(t)(V)(OD600)]where t=time the reaction ran (min), V=volume of cell culture used (mL). Each experiment was performed 3-5 separate times; the error bars in the figures represent the variation among these experiments at 2o. Cox5bmRNA analysis --Cisplatin treatmentand RNA preparation Yeast cells were treated with cisplatin in YPGE media for 6 hours at 30°C. The 10 ml aliquots were then pelleted and resuspended in 1 ml of cold water. The cells were transferred to sterile, RNAse free Eppendorf tubes. The tubes were centrifuged to pellet the cells. The cell pellets were quickly frozen by dropping the tubes in liquid nitrogen. They were then stored in the -80°C freezer. The next day, total RNA was prepared. The cells were thawed and resuspended in 400 tl TES buffer (10 mM Tris-Cl pH 7.5, 10 mM EDTA, 0.5% SDS, room temperature). An equal volume of acid phenol (phenol equilibrated with water, but not buffered) was added. To break open the cells, the tubes were incubated at 65°C for 30-60 minutes and were vortexed occasionally. The tubes were put on ice for 5 minutes, and then centrifuged for 5 minutes. The aqueous layer was removed, placed in a fresh Eppendorf tube, and another 400 p1 of acid phenol was added. The tubes were vortexed, left on ice for 5 minutes, and centrifuged for 5 minutes. The aqueous layer was removed to a new Eppendorf 300 tube and extracted with 400 ptLof chloroform. The aqueous layer from that extraction was put in another Eppendorf tube. The RNA was precipitated by adding 40 tl of 3 M NaOAc pH 5.3 and I ml of cold EtOH, incubating in the -80°C for 5 minutes, and centrifuging for 5 minutes. The pellet was washed once with -20°C 70% EtOH. The RNA was redissolved in 50 gl of water and the tube was heated to 65°C for 5-15 minutes to help dissolve the pellet. A260 (absorbance) and A280 readings were taken to confirm the purity and yield of the sample, and the RNA was stored at -20°C. All solutions were treated with diethyl pyrocarbonate (DEPC) and autoclaved to inactivate any contaminating RNAse. --NorthernBlotting All plastic apparatus were treated with 3% hydrogen peroxide for 10 minutes and then rinsed with DEPC-treated water. Approximately 30 gg of each sample were transferred into fresh Eppendorf tubes. The samples were dried to reduce the volume and resuspended in 6.8 gl of water. Each tube was brought to a volume of 30 gl by adding 3 gl of 5x formamide gel-running buffer (0.1 M MOPS pH 7.0, 40 mM NaOAc, 5 mM EDTA), 5.25 gl of formaldehyde, and 15 gl of formamide. The samples were incubated at 65°C for 15 minutes and 3 gll of formaldehyde gel loading buffer (50 % glycerol, 1 mM EDTA pH 8.0, 0.25% bromphenol blue, 0.25% xylene cyanol FF) was added. A 1.8% agarose gel was poured by dissolving 1.8 gm of agarose in 62.5 ml water and, after the solution had cooled, adding 17.9ml of formaldehyde and 19.7ml of 5x formaldehyde gelrunning buffer. The gel was pre-run at 70 volts for 5 minutes and the samples were loaded onto the gel. The gel was run for 3-5 hours at 50-70 volts. The RNA was transferred to nitrocellulose using the Schleicher & Schuell Turboblotter rapid downward transfer system. The device was set up as directed and the RNA was transferred for 3 hours. The membrane was rinsed in 2xSSC (20xSSC: 301 3M NaCl, 300mM Na citrate, trisodium salt pH 7.0) for 15 minutes and dried in a vacuum oven for 2 hours at 80°C. The blot was pre-hybridized and hybridized in Stratagene's QuickhybTM. The blot was placed in a sealable bag and 9 mL of QuickhybTMwere added. The blot was then incubated with gentle shaking for 20 minutes at 50°C. The blot was probed by adding 1 ml of QuickhybTMwith 710x106 cpm Cox5b probe to the bag and incubating for 1 hour at 50°C. The blot was rinsed twice in 3xSSC, 0.1% SDS for 15 minutes, gently blotted dry, and exposed to film overnight. The next day, the blot was put on the phosphorimager cassette overnight, and then the bands were quantitated. The blot was stripped by twice adding boiling O.1xSSC,0.1% SDSto the blot and shaking for 15 minutes. The blot was reprobed as above using the probe for actin. The probes used were 5'-GCACGAGGAGCGTCGTCACCGGCA-3'for actin and a 200 bp fragment of COX5b for Cox5b mRNA (Hodge et al., 1989). The probes were labeled with y-3 2 P-ATP and kinase, or with random priming with oa3 2 P-dCTP and Klenow, respectively. The graphs presented in the figures represent individual experiments. The numbers associated with the Cox5b mRNA levels were arbitrary units, and there was no numerical correspondence between different graphs since the numbers are based on the phosphorimager output. Binding of HMG-1 to DNA in platinated chicken erythrocyte nuclei --Isolation of chicken erythrocyte (c.e.) nuclei Chicken blood was purchased from Pel Freeze. The white blood cells were removed by repeated centrifugation and resuspension in isolation buffer (0.85%NaCl, 0.01% merthiolate and 6 mM Na2HPO4, pH 7.0). The blood was stored at -20°C in isolation buffer plus 25% glycerol. To isolate the nuclei, the cells were thawed and spun down in Corex tubes for 10 minutes at 5000 rpm. The supernatant and the remaining white blood cells 302 were removed, and the cells were resuspended in RSB(10 mM NaCI, 3 mM MgCl2, 0.25 M sucrose and 10 mM Tris-HCl pH 7.2) + 0.5%/o NP40 (detergent). The pellets were resuspended with a Dounce homogenizer and the B pestle. This treatment broke open the red blood cells. The nuclei were pelleted for 10 min at 5000 rpm. They were washed once more (pellet resuspended by homogenizing) in RSB + 0.5% NP40, and then 1 to 4 times in RSB alone. The washing removed excess chromosomal proteins; the progress of the washes could be partially followed by monitoring the disappearance of red hemoglobin. All the red color was gone after the second RSB + NP40 wash. --Platination of c.e. nuclei The nuclei pellets were resuspended into RSB. The tubes were pooled and the amount of DNA was determined by adding 0.9 mL of 5 M urea, 2 M NaCl to 0.1 ml of nuclei and measuring the A260 value. Cisplatin was dissolved into 10 mL of water, and then the necessary amount to give the desired ratio between DNA and platinum was added to the nuclei. Incubations were done at room temperature; unplatinated controls were also incubated at room temperature. The nuclei were spun down as before and washed once with RSB. --Micrococcal nuclease digestion The pellet was resuspended into 3 mL of RSB + 1 mM CaC12. 210 units of micrococcal nuclease were added and the tube was incubated at 37 C for 30 minutes. The nuclei were spun down as before. --HMG-1 extraction The final pellet was resuspended in extraction buffer (0.35 M NaCl, 5 mM Na2HPO4 pH 7.0); this salt treatment cracked open the nuclei. The pellet was Dounce homogenized with the B pestle 5-8 times to disrupt the DNA. The DNA was then pelleted by centrifugation for 15 minutes at 10000rpm. The supernatant was carefully removed and the proteins were precipitated by adding 303 0.5 volumes of 100% trichloroacetic acid. The precipitating mixture was incubated on ice for 15-45 minutes and then spun for 15 minutes at 15000 rpm. The sample appeared as a small film on the sides of the tubes and was washed once in acetone-HCl and once in acetone. The pellet was then dissolved in SDSPAGE loading buffer (100 mM Tris pH 6.8, 200 mM dithiothreitol, 4 "/ SDS, 0.2 Y. SDSbromphenol blue, and 20 % glycerol). The samples were analyzed by 12%0/ PAGE gel electrophoresis and subsequent Southwestern blotting. Southwestern blots were probed with radiolabelled cisplatin-treated DNA and unplatinated DNA (Pil and Lippard, 1992). Western blots were performed using anti-HMG1 antibody (Pil and Lippard, 1992). RESULTS Titration Hypothesisexperiments Plasmid-based assay The titration hypothesis was first tested by using a plasmid, pYep, with the Cox5b promoter in front of the 9-galactosidase gene. i-Galactosidase was easily assayed in crude cell extracts. These experiments were all performed with cells in exponential phase growth because B-galactosidase expression only occurs under these conditions. JM43 and JM43Aixrl cells were treated with various levels of cisplatin and the level of B-galactosidase activity was measured (Fig. 5.2). As expected, when no cisplatin was added, the JM43Aixrl cells produced much more B-galactosidase because there was no Ixrl to inhibit transcription from the Cox5b promoter. As cisplatin was added, the level of B-galactosidase in the JM43Aixrl cells dropped because the cisplatin bound to the pYep plasmid and blocked transcription. If the titration hypothesis were correct, the level of Bgalactosidase expression in the JM43 cells should go up when the cisplatin was added, because the adducts would titrate the Ixrl away from the Cox5b promoter. No significant increase in B-galactosidase expression was seen in Fig. 304 5.2 or in any similar experiments. This assay was performed five times using these conditions, and three times where cisplatin levels between 0 and 0.5 mM were investigated. The small peak visible in the JM43 data in Fig. 5.2 was no greater in any other experiment, and was not visible in all experiments. These data do not support the titration hypothesis. Several other treatments of the cells were also investigated, to be sure that there was no other indication of titration activity. Cells were treated with cisplatin for two hours instead of six, which made no difference. In some experiments, cells were incubated in fresh media after the cisplatin treatment to see if the cells needed time to respond to the cisplatin treatment. Neither a 16 hour (Fig. 5.3) nor a 2 hour incubation showed any increase in the levels of 13galactosidase in the JM43 strain as cisplatin was added. The JM43Aixrl strain does not lose 3-galactosidase activity with increasing cisplatin levels in the 16 hour recovery experiment, probably because the cells have repaired the cisplatin from the plasmid (Fig. 5.3). Cells were also treated with the same amount of cisplatin for various times to see whether there was any increase in the £galactosidase activity in the JM43 strain (Fig. 5.4). The results for this experiment were similar to those for the other experiments. None of these experiments supports the titration hypothesis. mRNA based assay Experiments investigating the titration hypothesis were also performed by examining the level of Cox5b mRNA. These experiments do not suffer from the drawbacks of using a plasmid based system, for example, relying on a small circle of DNA that is not necessarily processed in the same manner as genomic DNA. As in the g-galactosidase activity experiments, cells were treated with cisplatin and then broken open. Total RNA was extracted and northern blots were probed with anti-Cox5b probe. The loading was controlled in all 305 experiments by subsequently probing the blots with an actin probe. Several experiments were performed in which exponential phase cells were treated with various levels of cisplatin. The Cox5b bands from a typical northern blot are shown in Fig. 5.5a. When the cells were not treated with cisplatin, ixrl produced a higher level of Cox5b mRNA than IXR1because Ixrl was not present to inhibit transcription (Fig. 5.5a, lanes 1 and 7). These blots were quantitated on the phosphorimager. Low levels of cisplatin did not produce any appreciable increase in Cox5b mRNA in the IXR1strain (Fig. 5.5b). Higher levels of cisplatin caused the level of Cox5b mRNA to decrease in both the IXR1and ixrl strains (Fig. 5.6); there was no significant transient increase in the IXR1strain. Both of these experiments were repeated several times with no different results. Different conditions of cisplatin treatment were also investigated in this assay. In one experiment, the cells were permitted to recover for 16 hours in fresh media after the cisplatin treatment. This experiment did not yield any particularly different results from the experiments where recovery was not permitted (Fig. 5.7). A similar experiment was performed in which the cells were treated with cisplatin for 3 hours and permitted to recover for 3 hours, which did not produce any different results. Cells grown to saturation were also investigated by this method (Fig. 5.8). The mRNA levels in such cells are particularly low (Werner-Washburne et al., 1993),so more mRNA was loaded onto each blot, and the error in each lane was correspondingly greater. These blots gave no indication that the titration hypothesis is correct. One experiment was performed by using the JM43 and JM43Aixrl strains, which yielded no different results. The IXR1and ixrl cells were also treated with cisplatin for various time periods (Fig. 5.9). Again, this experiment did not show any increase in Cox5b mRNA expression in the IXR1cells with increasing levels of cisplatin treatment. None of these experiments support the titration hypothesis. 306 HMG1 binds to cisplatin-treated chicken erythrocyte DNA in chromatin Experiments were performed to determine if HMG1 bound to genomic DNA in chicken erythrocytes. Chicken blood was bought and first the red blood cells and then their nuclei were isolated. The nuclei were broken open and HMG1 was extracted with 0.35 M NaCl. The 0.35 M NaCl extraction separates soluble proteins from a DNA and protein pellet. Most proteins other than histones are present in the soluble fraction. The HMG1 band was confirmed by Southwestern and Western blots (Fig. 5.10). The HMG1 bands appear in the Southwestern blot only when probed with DNA that was treated with cisplatin (Fig. 5.10c). Histone H1 bands show up faintly in both the Southwestern blots since it does not bind specifically to cisplatin-DNA adducts (Fig. 5.10c,d). The Western blot with the anti-HMG1 antibody confirms that the band(s) in question belong to HMG1 and the two highly related proteins, HMG2 and HMG-E, which run directly below HMG1 and sometimes smear into one band with HMG1 (Fig. 5.10b). The chicken erythrocyte nuclei were treated with several concentrations of cisplatin overnight. The higher levels of cisplatin caused the HMG1 to remain with the DNA during the 0.35 M NaCl extraction and to disappear from the soluble fraction which was loaded onto the gel for the Southwestern blot (Fig. 5.11, lanes 1-4). Inspection of the histone H1 bands of a Coomassie stained gel run in parallel indicated that equal amounts of cell extracts were loaded into each lane (Fig. 5.11b). The pure HMG1 run as a standard on this gel was substantially degraded; the small upper band corresponded to the full length protein (Fig. 5.11, lane 6). The DNA-containing pellets from the 0.35 M NaCl extraction were solubilized and the DNA was purified and analyzed for platinum content by atomic absorption spectroscopy. The samples treated at 0.001, 0.01, and 0.15 (Pt/nucleotide) corresponded to actual (Drug/nucleotide)bound ratios of 1x10-4 , 307 4x10-4 , and 19x10-4 (Pt adducts/nucleotide). These experiments indicated that HMG1 was bound to either the DNA or some other component of the 0.35 M NaCl pellet. When the nuclei were treated with trans-DDP,a much smaller amount of HMG1 remained in the DNA pellet (Fig. 5.11, lane 5). In one experiment, the nuclei were treated with micrococcal nuclease after cisplatin treatment (Fig. 5.11, lanes 7 and 8). Micrococcal nuclease cleaves the DNA in the internucleosomal regions. This treatment caused the HMG1 to be present in the soluble 0.35 M NaCl fraction in the sample treated with cisplatin. This result indicates that the HMG1 which was in the 0.35 M NaCl pellet in the original experiment was associated with the DNA, not any other component of the pellet. DISCUSSION Titration Hypothesis The titration hypothesis (Fig. 5.1) theorizes that cisplatin-DNA adducts may divert HMG domain proteins such as Ixrl from their natural binding sites, thus disturbing the transcription of the genes they regulate. Ixrl inhibits transcription from the Cox5b promoter. The effect of cisplatin-DNA adducts on transcription from the Cox5b promoter was measured in a plasmid-based system and by examining Cox5b mRNA levels. Neither experiment yielded any data that suggest that Ixrl was removed from its binding site sufficiently to affect transcription from the promoter. Different levels and types of cisplatin treatment were investigated. Two different sets of yeast strains were examined. Cells were treated in exponential phase for most experiments, but some of the mRNA assays were performed with cells grown to saturation. None of the different cisplatin treatment protocols led to substantially increased expression from the Cox5b promoter in the IXR1 strains. These experiments demonstrate that the titration hypothesis is not valid for Ixrl and the Cox5b promoter in vivo. It is still possible 308 that such behavior occurs for other HMG domain proteins, like hUBF. These experiments help define the parameters for devising new cisplatin analogs; they indicate that only the blocking of the repair proteins may be crucial, not the titration of the HMG domain proteins from their native sites. HMG1 binds cisplatin-DNA addulctsin vivo HMG1 has been shown to bind to DNA in chicken erythrocyte nuclei. HMG1 is usually soluble in 0.35M NaCl extracts. When the nuclei were treated with cisplatin, the HMG1 was found in the insoluble DNA pellet. If the nuclei were treated with micrococcal nuclease, which cuts the internucleosomal region of the DNA, the HMG1 was found in the soluble fraction. Therefore, the HMG1 was associated with the internucleosomal region. This result was originally discovered in the Scovell laboratory (Hayes and Scovell, 1991a; Hayes and Scovell, 1991b). They concluded that HMG1 must be covalently crosslinked to the DNA by the cisplatin. This theory was reasonable at the time, since cisplatin was found by several laboratories to cross-link proteins to DNA (Lippard and Hoeschlele, 1979; Banjar et al., 1985; Gaczynki et al., 1990; Miller et al., 1991; Ferraro et al., 1992). Cisplatin functions well as a cross-link reagent since it is less dependent on either DNA sequence context or specific amino acids sidechains. When it was discovered that HMG1 binds to cisplatin-DNA adducts in vivo, these experiments were repeated to see if HMG1 is bound to the DNA covalently or non-covalently. The latter is certainly possible since there are other proteins in the 0.35 M NaCl DNA pellet, including the core histones (data not shown). HMG1 binds more tightly to cisplatin-treated DNA than to unplatinated DNA (Pil and Lippard, 1992), and this difference in binding may account for HMG1 staying bound to the DNA through the 0.35 M NaCl treatment. The lesser binding of HMG1 to the DNA pellet when the nuclei were treated with transDDP indicates that such may be the case. HMG1 does not bind to trans-DDP- 309 DNA adducts (Pil and Lippard, 1992). An equal amount of trans-DDPcaused much less HMG1 to be sequestered in the 0.35 M NaCl pellet. Since the platination took place over a 24 hour period, the level of crosslinking caused by trans-DDP and cisplatin should be very similar (Lepre and Lippard, 1990). In other studies, no difference was noticed in non-histone chromosomal proteins crosslinked to DNA by cisplatin and trans-DDP(Banjar et al., 1983;Banjar et al., 1984). The significant difference between cisplatin and trans-DDPfor HMG1 is probably caused by the binding affinity of HMG1 for cisplatin-DNA adducts. The HMG1 in the 0.35 M NaCl pellet is most likely partly covalently bound to the DNA, but a large part is probably non-covalently bound as well. In conclusion, HMG1 binds to DNA when it is packaged as chromatin in chicken erythrocyte nuclei. CONCLUSION The experiments in this thesis primarily examine the role of HMG domain proteins in mediating cisplatin cytotoxicity. Much of this work focused on the S. cerevisiaeHMG domain protein Ixrl. Interrupting the IXR1gene causes cells to become less sensitive to cisplatin and to have lower levels of platinum adducts on their DNA. The drop in sensitivity was shown to be related to the missing HMG domains of Ixrl, not to its function as a transcription repressor of Cox5b. The differences between the IXR1and ixrl strains were dependent on the presence of several excision repair proteins. These results mean that the excision repair proteins are involved in causing the differences between the two strains. Since Ixrl binds to cisplatin-DNA adducts, Ixrl is probably shielding the adducts from the repair machinery. Thus, the data supported the repair shielding hypothesis. Another hypothesis, the titration or "hijacking" hypothesis, was also investigated. Ixrl, however, was not titrated away from its binding site on the Cox5b gene sufficiently to affect the transcription of Cox5b. This data showed 310 that the titration hypothesis was not valid for Ixrl binding to cisplatin-DNA adducts. This thesis supports the premise that new cisplatin-related anticancer treatments could be based on maximizing the interaction between the DNA adduct and the HMG domain proteins so that the adducts are shielded as much as possible from repair. These new anticancer drugs may be more effective against tumors with acquired or intrinsic resistance to cisplatin chemotherapy. 311 REFERENCES Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith and K. Struhl, Eds. (1994). Current protocols in molecular biology. Wiley Interscience. Banjar, Z.M., L.S. Hnilica, R.C. Briggs, E. Dominguez, J.L. Stein and G.S. Stein (1985)cis-Diamminedichloroplatinum-mediated crosslinking of nuclear proteins to DNA is cell cycle specific. Arch. Biochem. Biophys. 237, 202-207. Banjar, Z.M., L.S. Hnilica, R.C. Briggs, J. Stein and G. Stein (1983) Crosslinking of chromosomal proteins to DNA in HeLa cells by UV, gamma radiation and some antitumor drugs. Biochem Biophys Res Comm 114, 767-773. Banjar, Z.M., L.S. Hnilica, R.C. Briggs, J. Stein and G. Stein (1984) cis- and trans- Diamminedichloroplatinum(II)-mediated cross-linking of chromosomal nonhistone proteins to DNA in HeLa cells. Biochemistry 23, 1921-1926. Chow, C.S.,J.P. Whitehead and S.J.Lippard (1994)HMG-domain proteins induce sharp bends in cisplatin-modified DNA. Biochemistry 33, 15124-15130. Donahue, B.A., M. Augot, S.F. Bellon, D.K. Treiber, J.F. Toney, S.J. Lippard and J.M. Essigmann (1990)Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry 29, 5872-5880. Ferraro, A., P. Grandi, M. Eufemi, F. Altieri and C. Turano (1992) Crosslinking of nuclear proteins to DNA by cis-diamminedichloroplatinum in intact cells. FEBS 307, 383-385. Gaczynki, M., J.A. Briggs, A. Wedrychowski, R. Olinski, M. Uskokovic, J.B. Lian, G.S. Stein and R.C. Briggs (1990)cis-Diamminedichloroplatinum(II) cross-linking of the human myeloid cell nuclear differentiation antigen to DNA in HL-60 cells following 1,25-dihydroxy vitamin D3-induced monocyte differentiation. Cancer Res. 50, 1183-1188. Habraken, Y., P. Sung, L. Prakash and S. Prakash (1993)Yeast excision repair gene RAD2 encodes a single-stranded DNA endonuclease. Nature (London) 366, 365-368. Hayes, J. and W.M. Scovell (1991a) cis-Diamminedichloroplatinum(II) modified chromatin and nucleosomal core particle. Biochim. Biophy. Acta 1089, 377-385. Hayes, J.J. and W.M. Scovell (1991b) cis-Diamminedichloroplatinum (II) modified chromatin and nucleosomal core particle probed with DNAse I. Biochim. Biophy. Acta 1088, 413-418. 312 Hodge, M.R., G. Kim, K. Singh and M.G. Cumsky (1989) Inverse regulation of the yeast COX5 genes by oxygen and heme. Mol. Cell. Biol. 9, 1958-1964. Lambert, J.R., V.W. Bilanchone and M.G. Cumsky (1994) The ORD1 gene encodes a transcription factor involved in oxygen regulation and is identical to IXR1, a gene that confers cisplatin sensitivity to Saccharomlyces cerevisiae.Proc. Natl. Acad. Sci. (U.S.A.) 91, 7345-7349. Lepre, C.A. and S.J.Lippard (1990).Interaction of platinum antitumor compounds with DNA. Nucleic Acids and Molecular Biology Eds. F. Eckstein and D. M. J. Lilley. Heidelberg, Springer-Verlag. Lippard, S.J. and J.D. Hoeschlele (1979)Binding of cis- and transdichlorodiammineplatinum(II) (U.S.A.) 76, 6091-6095. to the nucleosome core. Proc. Natl. Acad. Sci. Miller, C.A., M.D. Cohen and M. Costa (1991)Complexing of actin and other nuclear proteins to DNA by cis-diamminedichloroplatinum(II) and chromium compounds. Carcinogenesis 12, 269-276. Pil, P.M. and S.J. Lippard (1992) Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 256, 234-237. Scovell, W.M., N. Muirhead and L.R. Kroos (1987) cis-Diamminedichloro- platinum(II) selectively cross-links high mobility group proteins 1 and 2 to DNA in micrococcal nuclease accessible regions of chromatin. Biochem Biophys Res Comm 142, 826-835. Treiber, D.K., X. Zhai, H.M. Jantzen and J.M. Essigmann (1994)Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc. Natl. Acad. Sci. (U.S.A.) 91, 5672-5676. Werner-Washburne, M., E. Braun, G.C. Johnston and R.A. Singer (1993) Stationary phase in the yeast Saccharomycescerevisiae.Microbiological Reviews 57, 383-401. Whitehead, J.P. and S.J.Lippard (1995)Purification of the yeast protein, Ixrl(Ordl), and characterization of its specific binding to a cisplatin intrastrand d(GpG) cross-link in DNA. in preparation. 313 314 Figure 5.1. Titration hypothesis. HMG domain proteins bind to their normal binding site and activate or repress the transcription of gene X. When the cell are treated with cisplatin, the HMG domain proteins are titrated away from their natural binding sites and the transcription of gene X is not regulated properly. 315 HMG domain protein ~104 addu per cell Small number of normal. binding sites Transcription activation or repression of gene X Protein not bound to normal site so the transcription of gene X is not properly regulated 317 318 Figure 5.2. -galactosidase activity of JM43 and JM43Aixrl strains treated with cisplatin. Cells were grown to exponential phase before cisplatin treatment. 319 10)0 - o JM43 * JM43Aixrl I L7w 100 - u , a) (t m ul uc3 t= bC I '10 - I ; 1 - I 0 0.5 I I I I I 1 1.5 2 [Cisplatin] mM I I 2.5 l I 3 320 Figure 5.3. -galactosidase activity of JM43 and JM43Aixrl strains treated with cisplatin and permitted to recover in fresh media for 16 hours. Cells were grown to exponential phase before cisplatin treatment. 321 1000 o JM43 * JM43Aixrl -t~~ , 100 - ,4- tt ! uMd v) (n Md t~ tz Crl -T- 101 1 r - - I 0 0.5 I 1 I I 1.5 2 [Cisplatin] mM I 2.5 3 322 Figure 5.4. -galactosidase activity of JM43 and JM43Aixrl strains treated with cisplatin over time. Cells were grown to exponential phase before cisplatin treatment. 323 --I(UU 100 . · 10 T7 0 C 1 0.1 0 4 8 12 Time (hrs) 16 20 24 324 Figure 5.5. mRNA analysis of IXR1and ixrl strains treated with low levels of cisplatin. A. Northern blot probed for Cox5b mRNA. B. Quantification of the northern blot after loading levels were taken into account by probing for actin mRNA. Cells were grown to exponential phase before cisplatin treatment. 325 A. Cisplatin level I ixrl IXR1 V ribosomal RNA bands Cox5b mRNA two major forms I 1 2 3 4 5 6 7 8 9 101112 327 B. ,]~ ~ ~ ~ ~~oJR 87- Z C-) 6- o IXR1 - * ixrl 5- X O 432 ( 1 0 I I 0.02 0.04 I 0.06 [Cisplatin] mM I 0.08 0.1 328 Figure 5.6. mRNA analysis of IXR1and ixrl strains treated with higher levels of cisplatin. Cells were grown to exponential phase before cisplatin treatment. 329 3 2.5 2 s-0 1.5 X 0 © U 1 0.5 0 0 0.5 1 1.5 [Cisplatin] mM 2 2.5 3 330 Figure 5.7. mRNA analysis of IXR1and ixrl strains treated with cisplatin and permitted to recover in fresh media for 16 hours. Cells were grown to exponential phase before cisplatin treatment. 331 16 14 12 10 0 u 8 6 4 2 0 0.5 1 1.5 2 [Cisplatin] mM 2.5 3 332 Figure 5.8. mRNA analysis of IXR1 and ixrl strains treated with cisplatin after they were grown to saturation. 333 / 6 5 Z4 X 3 U 2 1 0 0 0.5 1 1.5 2 [Cisplatin] mM 2.5 3 334 Figure 5.9. mRNA analysis of IXR1and ixrl strains treated with cisplatin for various times. Cells were grown to exponential phase before cisplatin treatment. 335 2 1.5 < 1 Lo C 0.5 0 0 4 8 12 Time (hrs) 16 20 24 336 Figure 5.10. HMG1 is present in the 0.35 M NaCl extract of chicken erythrocyte nuclei. A. Coomassie stained gel of 0.35 M NaCi extract and pure HMG1. B. Western blot of (A) with anti-HMG-1 antibody. C. Southwestern blot of (A) probed with cisplatin treated radiolabelled DNA. D. Southwestern blot of (A) probed with untreated radiolabelled DNA. The arrows indicate the HMG1 bands. 337 A D C B &0o ,e e·*e·e 1; ?,+, i - & C> Axis~ - eel 4i 5m 46 46- is30Sif 30- ii=~ 30 21.5- 14.3- - Coomassie stain Western - - Cisplatin No cisplatin Southwestern 339 340 Figure 5.11. HMG-1 was bound to DNA in cisplatin treated chicken erythrocyte nuclei. A. Southwestern of 0.35M NaCl extracts of various chicken erythrocyte nuclei. B. Coomassie stain of histone H1 bands from gel equivalent to (A); this gel showed that equal amounts of proteins were loaded in each lane. Lane 1: untreated nuclei. Lane 2-4: nuclei treated with cisplatin at 0.15, 0.01, and 0.001 [Pt]/[nucleotide] respectively. Lane 5: nuclei treated with trans-DDPat 0.15 [Pt] / [nucleotide]. Lane 6: pure HMG1 that has degraded, the top band is full length HMG1. Lane 7: nuclei treated with micrococcal nuclease. Lane 8: nuclei treated with cisplatin at 0.15 [Pt/nucleotide] and then with micrococcal nuclease. 341 A. Micrococcal nuclease digestions HMG1 Damage ni n (D/N)f C T n1 001 -- . 0001l 0.15 - - '. 46 L " C ------- C C 0 0.15 low %~· Z. '' '11~~~~, 30 HMG1 -O A lk 6 4 Op 'q 14.3 I 5 4 3 2 1. 7 6 8 B. 30 2_3 1 m m 2 3 inZL~t~ g 4 5 6 7 8 H1bands 343 About the Author I grew up in Berkeley, California, and got my start in science at an early age from my dad the chemistry professor and my mom the physicist. Sometimes [ think I was born liking chemistry, and that liking was solidified in 7th grade when we did experimental chemistry in a self-paced course. That was definetly the most fun I had in my first 7 years of school. My AP Chemistry teacher, Ms. Beck, helped turn me into a real chemist and reminded me why I liked it so much. I graduated from Harvard with a A.B. in Chemistry and Physics, shades of both my parents, but by my senior year it was clear to me that my real love was molecular biology, especially DNA and the proteins which interacted with it. The one request my parents made for all the money they poured into my Harvard education was that I take a biology course, since I'd hated it in high school; I begged off and took biochemistry instead. After realizing that even biology was interesting, I went to work for Professor Greg Verdine in the chemistry department, doing molecular biology and molecular dynamics calculations. The experience I gained in his laboratory and on my summer job in the laboratory of Professor Sung-Ho Kim of Berkeley was invaluable when I joined Professor Steve Lippard's lab at M.I.T.. Without the experience in other laboratories that taught me that there is no one true way of doing molecular biology, the first years of my graduate school career would have been even more frustrating. The games I've played since with yeast and antitumor drugs are described in this thesis, and were fun and difficult while they lasted.